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Delivery of Vaccines and Therapeutics to Treat Infectious Diseases 
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The University of Texas at Austin, 2012 
 
Supervisor: Jennifer Maynard 
 
Efficient delivery of vaccines and therapeutic agents in vivo is a critical aspect for 
ensuring a desired immunological or biological response is achieved. This work focuses 
on developing effective delivery systems for vaccines and therapeutics to achieve 
biological potency while maintaining patient friendly administration. 
Traditional vaccines are administered via parenteral injection, which requires 
skilled personnel for administration and does not elicit strong mucosal immune 
responses. An alternative approach is to develop an oral vaccine; however, this requires 
antigens to be protected during transit through the gastrointestinal tract and be transported 
across specialized intestinal sampling cells called M cells. These M cells are extremely 
rare, making them an important target for oral vaccines. The protein invasin, from 
Yersinia psuedotuberculosis, naturally binds α5β1 integrin, a receptor found exclusively 
on M cells within the gastrointestinal tract. Therefore, we generated combinatorial 
libraries of invasin, followed by a directed evolution and high-throughput screening 
strategy to identify invasin variants with increased affinity towards α5β1 integrin. This 
process led to the creation of an invasin variant exhibiting a nine-fold decrease in EC50, 
which could be used for targeted oral vaccine systems.  
In order to test for increased vaccine efficacy due to the engineered invasin 
ligand, we developed a polymeric microparticle delivery system. These microparticles 
 vii 
were formulated to encapsulate the model antigen ovalbumin and be decorated with the 
invasin targeting ligands. To measure physiological trafficking and intestinal retention, 
novel fluorescent nanocrystals were loaded into particles conjugated to invasin. These 
nanocrystals served as a contrast agent for in vivo imaging in mice. While these particles 
were unsuccessful in generating an antibody response toward ovalbumin when 
administered to mice, a response directed to the targeting ligand itself was observed. 
These findings provide insights for further optimizing a delivery system for oral 
vaccination. 
In addition to developing an oral vaccine delivery system, we created a high 
concentration therapeutic protein formulation, suitable for low-volume subcutaneous 
administration. By adding crowding agents, we were able to generate reversible protein 
nanoclusters with low viscosity. These nanoclusters were found to revert to monomer 
upon dilution and pharmacokinetic profiles similar to solutions.      
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Chapter 1: Introduction and Background 
IMMUNE SYSTEM RECOGNITION AND ACTIVATION RELATED TO VACCINES 
Critical cellular recognition and processes must take place in order for a 
successful adaptive immune response to be implemented. One key recognition event 
takes place when a professional antigen presenting cell (APC) presents a peptide, 
representative of an immunogenic antigen, on a major histocompatibility complex 
(MHC) to a naïve T cell. The T cell then goes on to induce a cellular, humoral, or 
suppressive immune response by interacting with other cells (Figure 1). While it is 
possible to induce T cell independent humoral immunity, young children cannot 
efficiently elicit such a response and memory T cells help provide long lasting protection 
(1, 2). Once a naïve helper T cell (TH0) is properly stimulated by an APC, it can go on to 
activate B cells in the form of TH1 or TH2 cells, initiating class switching and ultimately 
produce an antibody response. TH1 responses tend to induce an acute proinflammatory 
response, but provide long lasting protection by inducing memory T cells. The TH1 
response can be characterized by antigen specific IgG2a in mice or IgG1 in humans. TH2 
responses are capable of inducing memory B cells, IgG1(murine), IgG2(human), and IgA 
responses, but may also produce unwanted IgE antibodies. Therefore, a balanced CD4+ 
TH1/TH2 response is preferred to provide a complete cellular and humoral protection 
from extracellular pathogens. Immune responses to intracellular pathogens such as 
viruses rely primarily on activation of CD8+ T cells, which recognize infected cells and 
signal them for apoptosis.  
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Figure 1.1: T-cell dependent humoral response mechanism. This image was reproduced 
with permission (3). 
Vaccines tend to focus on modulating two main processes: antigen recognition 
and co-stimulation. When vaccinating against a virus, it is important to achieve MHC 
class I presentation. The pathway leading to this type of presentation relies on the antigen 
being free in the cytosol of cells. Attenuated viruses slowly replicate inside cells leading 
to their proteins being found in the cytosol. While attenuated viruses are very capable of 
inducing complete immune responses, the safety concerns of reversion into virulent 
strains push vaccine technology towards acellular and DNA vaccines (4). For MHC class 
I presentation, acellular and DNA vaccines must release their payload in the cytosol after 
being endocytosed by APCs. Endosomal release can be achieved by incorporating a 
buffering agent with the delivered payload, which acts as a proton sponge and ultimately 
lyses endosomes (5). To protect against extracellular pathogens a humoral, or antibody 
mediated response, is needed. For induction of a humoral response via MHC class II 
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presentation, no special modifications need to be done to lyse endosomes. However, B 
cell epitopes must be preserved to allow for proper affinity maturation of antibodies. 
Another area for optimization is to increase the duration of antigen recognition. Sustained 
in vivo antigen recognition increases the strength and duration of antibody responses, 
which can supersede that of multiple booster dosing (6). This sustained recognition can 
be achieved by using attenuated replicating pathogens, DNA vaccines, and polymeric 
controlled release systems.  
Outside of antigen recognition, T cells respond to signals such as co-stimulation 
and extracellular cytokines. These signals direct T cells to either suppress or stimulate a 
protective immune response. Professional APCs are capable of displaying co-stimulatory 
molecules such as CD80, CD86, and CD40. Naive T cells recognizing these molecules, 
in association with an MHC-peptide complex, will be strongly directed to induce a 
protective immune response. Conversely, cytokines such as IL-10 and TGF-β will signal 
naïve T cells to become suppressors of antigens they recognize. Therefore, it is beneficial 
for vaccines to stimulate the expression of co-stimulatory molecules and/or suppress 
cytokines such as IL-10 and TGF-β (7). By incorporating adjuvants, immunomodulatory 
molecules, other than the antigen alone, stronger immune responses can be created. 
Although adjuvants are quite beneficial in increasing immune responses, some can lead 
to excessive inflammation raising safety concerns.  
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ORAL VACCINE DELIVERY SYSTEMS 
Traditional vaccines have been administered by intramuscular injection, with the 
exception being the oral polio vaccine (OPV). Great efforts are being made to produce 
vaccines capable of oral administration. Oral is the preferred route for any therapeutic 
due to ease of administration, which leads to increased patient compliance. Cost per dose 
is also decreased as the need for trained administration and needles is reduced. Oral 
dosage forms are also considered to be safer and have reduced purity requirements 
compared to injectables (8). With regards to vaccines, oral administration mimics natural 
pathogen exposure leading to a more complete immune response by activating both the 
mucosal and systemic immune system (9). This activation of the mucosal immune system 
leads to a secretory IgA (SIgA) response. SIgA is extremely effective at protecting the 
body by doing the following: transporting into mucosal secretions, resisting proteolytic 
degradation, being produced at high amounts (>50 mg/kg body weight), inhibiting 
pathogen adhesion and invasion, and reducing inflammatory effects of other 
immunoglobulins. Clinical studies have shown immunological memory and protection 
develop from oral infection with pathogens such as Vibrio cholera further suggesting oral 
vaccination is a suitable approach to establish long lasting immunity (10). 
Although oral vaccination appears to be capable of eliciting a more complete 
immune response, it has not dominated the market due to several critical challenges. One 
key hurdle is antigen degradation during transit through due to low pH and proteolytic 
environment in the stomach. The other major issue is that the antigens must cross through 
the gut lumen for antigen presentation. The two primary mechanisms for transit occur 
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through M cells and the less well understood transepithelium dendritic cells (DCs) (11-
14). M cells are rare cells, found in the gastrointestinal tract (GIT) of adult humans at a 
rate of 1 in every 10,000,000 epithelial cells (15). These two factors coupled together 
result in very low bioavailability for oral vaccines. Another aspect to consider is the lack 
of a safe and well-understood mucosal adjuvant. Aluminum salts are generally regarded 
as safe (GRAS) and are the primary adjuvants used with commercial human vaccines 
(16). However, aluminum salts have not proven effective when employed with mucosal 
vaccines. New mucosal vaccines are being developed and studied such as bacterial 
toxins, CpG DNA, immune stimulating complexes (ISCOMs), virus-like particles 
(VLPs), compound 48/80, etc (17-19).  
Only a handful of oral vaccines have demonstrated success in humans for targets 
such as Vibrio cholera, Salmonella typhi, rotavirus, and poliomyelitis (8). Low antigen 
presentation may be major limitation of subunit based oral vaccines. Live-attenuated 
vaccines have proven to be more effective due to their ability to replicate after crossing 
the epithelium barrier (20). This replication helps to not only increase the amount of 
antigen available for T and B cell recognition, but can also increase co-stimulation. 
However, live-attenuated vaccines possess the ability to mutate into a virulent strain. 
While strict screening of manufactured batches can help alleviate this concern, mutated 
vaccine excreted by the patients may go on to infect others. 
In order to decrease safety concerns, acellular subunit vaccines are being 
developed. While these subunit vaccines are not capable of replicating and are therefore 
believed to be safer, their efficacy has been hindered by limited delivery to 
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immunomodulatory cells and a lack of adjuvanticity (21). To overcome these hurdles, 
efforts are being made to target antigens to certain regions in the GIT, incorporate 
antigens into delivery systems for protection during GIT transit, and/or promote uptake 
(9). The oral vaccination delivery system of choice has been antigens entrapped in micro 
and nano particles composed of poly(lactic-co-glycolic acid) (PLGA). PLGA is attractive 
due to its ability to slowly hydrolyze into nontoxic molecular components making it 
biocompatible. Optimization of PLGA formulations leads to particles that slowly release 
the entrapped antigen, which is capable of acting as a booster. Single intramuscular doses 
of antigen entrapped in PLGA have induced comparable antibody titers to repeated doses 
of antigen adsorbed to alum (6, 22). Many authors have demonstrated the quality of the 
antigen can be jeopardized during formulation by exposure to oil/water interface and 
during release due to low pH. The primary quality control concerns are denaturation, 
acylation, deamidation, and the formation of irreversible aggregates (23, 24). Adjusting 
the formulation method and including excipients that stabilize and buffer can address 
many of these concerns. However, successful immunogenicity has been achieved without 
such modifications.  
MUCOSAL IMMUNE SYSTEM 
Designing more effective oral vaccines involves a solid understanding of the 
mucosal-associated lymphoid tissue (MALT). Historically, the mucosal immune system 
has not been studied in as much detail as the systemic immune system, likely due to the 
same challenges associated with mucosal vaccinations. However, the mucosa is the front 
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line for pathogen as well as innocuous antigen encounters. The gut-associate lymphoid 
tissue (GALT) contains 70% of the body’s lymphocytes and has co-evolved with 
commensal bacteria to produce balanced immune responses (25, 26). The GALT is 
composed of both organized tissue and lymphocytes scattered throughout the epithelium 
and lamina propria (connective tissue directly beneath the epithelium) depicted below. 
 
Figure 1.2: Representation of the GALT lymphatic system. This image was reproduced 
with permission (27). 
The two organized tissues most important for initiating GALT related immune 
responses are Peyer’s patches and mesenteric lymph nodes (MLNs). MLNs may play a 
critical role in bridging the mucosal and peripheral immune responses. The Peyer’s 
patches are aggregated lymphoid regions just beneath the epithelium in the lower small 
intestine. These regions are composed of germinal centers and rich amounts of TGF-β 
and IL-10. In the absence of co-stimulatory signals these cytokines tend to promote the 
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development of regulatory T cells (Tregs) or a TH2 response, producing antigen specific 
IgA. In humans, Peyer’s patches can be found in the GI tract as early as gestation all the 
way through adulthood, while reaching their peak (~250) during puberty (28, 29). They 
begin to appear in the jejunum, but are most frequently found in the ileum. Shown below 
is the luminal surface of a Peyer’s patch, which appears as a macroscopic dome 
exhibiting a reduced brush border structure. 
 
Figure 1.3: Structure of Peyer’s patch and M cell. (A) SEM image of the luminal surface 
(27); (B) Schematic of the cross section of an M cell (1). These images were reproduced 
with permission. 
The surface of Peyer’s patches, also called the follicle-associated epithelium 
(FAE), can be distinguished by the presence of microfold (M) cells. The percent of M 
cells, compared to other cells, in the FAE is reported to be species dependent: ~50% in 
rabbits, ~10% in mice, and <5% in humans (30). While frequencies greater than 50% 
have been found in the caecum of humans, the extra M cells appear to have different 
characteristics (31). M cells are different from regular epithelial cells in that they do not 
possess microvilli, lack a mucus layer, do not express MHC class II molecules, have 
fewer lysosomes, and have an invaginated pocket where lymphocytes reside (27, 32). M 
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cells act as a channel for transporting antigens, particulates, viruses, and bacteria from the 
lumen to the Peyer’s patch. The properties of the material to be transported, such as size, 
surface charge, and presence of ligands, controls the mechanism of transport by different 
processes such as phagocytosis, clathrin-mediated endocytosis, and macropinocyctosis 
(25). The endosome is then transferred to the basolateral surface where the material is 
released. The transcytosis process can occur in as little as 10 minutes (33). Once the 
transported material is acquired in the Peyer’s patch, lymphocytes are able to interact 
with the material to gain acquired immunity or tolerance.  
The importance of M cells in transcytosing material from the lumen to mucosal 
lymphocytes coupled with their scarcity illuminates the value of developing targeted 
vaccine systems. In order to target these cells, markers distinct from regular epithelial 
cells must be identified and exploited. Historically, it has been difficult to determine 
receptors specific to the apical surface of M cells, since no stable M cell line exists. 
Researchers have relied on two methods to study M cells: isolating sections of the ileum 
and an in vitro M cell model. While isolating ileal sections containing Peyer’s patches 
may be the more ideal method, it relies on live animals or humans. The isolation of 
murine Peyer’s patches led to research using lectins targeting of α-L-fucose. 
Unfortunately, it was later discovered that this receptor is not specific to M cells in 
humans. A human in vitro M cell model was first demonstrated in 1997 by culturing the 
human Caco-2 cell line in transwell plates and adding freshly isolated Peyer’s patch 
tissue from mice to the basolateral chamber (12). While this method showed conversion 
from the Caco-2 cell phenotype to the M cells, it still relied on animals for the model. 
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Since then others have modified the model by using the Raji B cell line in place of 
Peyer’s patch tissue to make the model animal free, shown below (34). This model, while 
difficult to work with, has led to increase understanding of the properties and expression 
characteristics of human M cells.  
 
Figure 1.4: Development of the in vitro M cell model. This image was reproduced with 
permission (35). 
While several markers have been discovered to be specific to apical M cell 
expression, β1 integrin stands out as a promising target as it has been verified in isolated 
human tissue (36, 37). Further studies using the in vitro M cell model has revealed the 
α5β1 heterodimer is specific to the M cell apical surface and plays a role in transcytosis 
(15). A naturally evolved bacterial ligand called invasin has been found to bind this 
receptor with a Kd of 5.0 nM and 70 n M for the mutimeric and monomeric forms, 
respectively (38). However, we believe this to be an underestimate of the affinity, which 
will be discussed later. Another receptor specific to M cells in the GI tract is ganglioside 
GM1. Cholera toxin B subunit (CTB), in its holotoxin form, has been identified as a high 
affinity ligand binding with a Kd of 0.19 nM (39). This has led to CTB be being used as 
the primary large molecule targeting ligand for oral vaccine development (39, 40). 
However, it has also been shown that the SIgA and IgG can act as endogenous 
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competitors by also binding GM1, which is ultimately reduces CTB’s effective affinity 
(41). The poor ability to express CTB coupled with the endogenous binding competitors 
makes invasin a more logical choice for a commercial oral vaccine targeting M cells. 
With the identification of molecular targets on M cells, researchers can begin to discover 
and develop ligands that target M cells with high affinity and specificity. Increased 
targeting and trancytosis have been demonstrated by controlling surface charge and/or 
receptor specific peptides (42, 43). However, the utilization of large targeting molecules, 
with increased surface area for binding, should greatly increase the efficacy by targeting 
M cells more efficiently. 
While it is desired to induce protective immunity by vaccination, it is important to 
understand the natural tendency to develop oral tolerance. The human GALT has the very 
difficult task of maintaining a homeostatic balance of tolerance and immunity to the 
myriad of antigens, viruses, and microorganisms it encounters over its 100 m2 of surface 
area (44). The gut has an estimated steady state population of 1014 commensal microbes 
(45). It is important for the GALT to maintain tolerance when appropriate to avoid 
conditions such as inflammatory bowel disease, Crohn’s disease, and food allergies. The 
mechanisms that enable the identification of pathogens in the GALT are not clear. Some 
researchers have noticed a reduced role LPS is able to play on activation of intestinal 
lymph DCs, which likely aids in suppressing inflammation to commensal bacteria (46). 
Expanding on the “hygiene hypothesis,” researchers have proposed that certain 
nonpathogenic microbial molecules, such as polysaccharide A, help balance the 
TH1/TH2 responses to minimize allergic reactions (47). The induction of acquired oral 
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tolerance is believed to occur at the T cell level. Large doses of an antigen is known to 
induce T cell anergy, while repeated low doses will initiate a regulatory T cell response 
(48, 49).  
The means by which an APC presents an antigen is believed to direct T cell 
differentiation. DCs are considered to be the primary APC involved in T cell activation 
and several different DC subsets have been identified in the GALT. Some DC subsets are 
known to be spatially distinct inside the GALT, such as between intestinal epithelial cells 
(CX3CR1+) (50). Other DCs expressing CD103 are considered steady-state migrating 
lymph DCs (L-DCs), since they traffic from the Peyer’s patch to the MLNs. 
CD4loCD172alo L-DCs are believed to maintain tolerance by carrying endocytosed 
fragments of apoptotic enterocytes to the draining lymph nodes (51). Plasmacytoid DCs 
have been implicated as playing a critical role in priming Tregs by upregulating the 
ICOS-L co-stimulatory molecule (52-54). Since different DC subsets can be found in 
different locations in the GALT, it is reasonable to hypothesize that the means in which 
an antigen is transported across the lumen may result in varied DC subsets presenting the 
antigen to T cells. This could ultimately determine whether T cells are directed towards a 
suppressive or stimulatory role. However, Milling et al. showed that different isolated L-
DC subsets were not suppressive on their own, suggesting cytokines such as TGF-β, IL-
10, and retinoic acid from other in vivo sources play an important role (51). It is known 
that several different Tregs exist in the GALT, some of which secrete TGF-β 26. The 
actions of natural Tregs and antigen specific Tregs is also not well understood, but likely 
play an important role in GALT immunomodulation. In short, in order to overcome the 
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natural propensity for tolerance, oral vaccines should possess some adjuvant activity. A 
summary of identified GALT DC subsets is listed below.  
 
Table 1.1: Summary of subsets of dendritic cells in the GALT. This table was reproduced 
with permission (55). 
INVASIN: A NATURAL LIGAND FOR α5β1 INTEGRIN 
Although M cells have evolved to help the mucosal immune system sample the 
contents of the lumen to distinguish pathogens from normal flora, pathogens such as 
Salmonella typhimurium, S. typhi, Yersinia pestis, Y. enterocolitica, Y. 
pseudotuberculosis, Enteropathogenic Escherichia coli, and Shigella flexneri are known 
to selectively target M cells for infection (56). All three Yersinia pathogens possess a 
chromosomal gene for a surface expressed protein called invasin, which has been 
identified as a means for the pathogens to bind and increase translocation through 
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intestinal M cells (57). Y. pseudotuberculosis once translocated across M cells utilizes a 
type-III secretion system to inject effector proteins that compromise immune cell 
phagocytosis and recognition (58). The targeting of M cells is believed to be due to the 
interaction between invasin and apical M cell surface expressed α5β1 integrin (57, 59, 
60). The specificity for α5β1 integrin, makes invasin an attractive targeting ligand for 
oral vaccines. The identification of invasin in 1987 by Isberg et al. has paved the way for 
research helping to understand the pathogenicity of several strains in the Yersinia genus 
(61). Unless specifically mentioned, “invasin” will refer to the variant from Y. 
pseudotuberculosis.  
The incorporation of invasin on the surface of bacteria and inert particles has been 
shown to promote internalization by non-phagocytic cells (38). The mechanism of 
internalization appears to be linked to the ability to cluster β1 integrins and induce actin 
reorganization (62). Invasin is much more effective at inducing adhesion and 
internalization than the variant from Y. enterocolitica (63). The primary difference 
between these molecules is not due to affinity variations in the binding region, but the 
presence or absence of a domain that enables self-assembly. The extracellular region of 
invasin can be broken down into 5 domains, shown below.  
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Figure 1.5: Crystal structure of the extracellular C-terminal region of invasin with 
domains defined by their amino acid range. This image was generated in Pymol using 
PDB entry 1CWV. 
The D2 domain allows for the creation of dimers and tetramers, while the D4/D5 
super domain is responsible for the binding event to certain β1 heterodimer integrins. 
Full-length invasin is 986 amino acids where the N-terminal 502 amino acids are used for 
translocation and localization to the outer membrane (62, 64). Portions of the 
extracellular region have been genetically fused to the C-terminal end of maltose binding 
protein (MBP) to produce soluble, stable, highly expressed protein (65). This has enabled 
protein-protein interactions to be studied, leading to a better understanding of critical 
sites and regions. Two cysteines, located at amino acid positions 907 and 982, have been 
shown to form a disulfide bond that is critical for receptor binding (66). Random 
mutagenesis, performed in strains harboring a mutazyme, and site-directed mutagenesis 
of invasin have revealed many residues that play a role in invasin’s ability to facilitate 
adhesion and internalization (67, 68). The solvent exposed residues that appear to be 
most important are aspartic acid residues at positions 811 and 911 (66, 67).  
Invasin has been shown to be capable of binding multiple heterodimers of β1 
integrins, such as α3β1, α4,β1, α5β1, α6β1, αvβ1 (69, 70). However, invasin does not 
bind to α2β1 or the β2 forms of integrins. While α5β1 is the only known heterodimer to 
exist on the surface of M cells, the affinity for the other heterodimers may have resulted 
from an evolutionary pressure to aid infection after M cell translocation (71, 72). 
Integrins are known to play many roles both in cellular adhesion, differentiation 
proliferation, and survival. Once across the epithelium, many different cell types have 
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exposed integrins, which may be targeted. The endogenous ligand for α5β1 integrin is 
fibronectin, which contains the famous arginine-glycine-aspartic acid (RGD) sequence, 
exploited for different pharmaceutical targeting strategies. Interestingly, even though 
invasin does not possess an RGD peptide, it binds much tighter than fibronectin (73). The 
monomeric form of invasin (D2 domain deleted) and the multimeric form bind 
approximately 10 and 100 times tighter than fibronectin, respectively (38). Selective 
amino acid mutations on the β1 chain has further supported that both fibronectin and 
invasin utilize a similar β1 interface for binding (70). The mechanism of invasin-
mediated invasion appears to be strictly due to affinity for α5β1 integrin, which initiates 
a zippering effect, shown below (38).  
 
 
Figure 1.6: Zippering effect initiated by invasin. This image was reproduced with 
permission (74). 
A positive correlation between integrin affinity and degree of internalization has 
been observed, using mAbs with varying affinities to α5β1 integrin (38). However, it has 
been shown that α5β1 integrin is able to alter its conformation from a relaxed state to a 
tensioned one (75). This has been shown to effect the affinity of fibronectin for α5β1 
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integrin. It is believed that fibronectin may bind in a two-step process, where one epitope 
(RGD) binds in the relaxed state and then upon mechanical tensioning the synergy site is 
engaged. This tensioning may be linked to the integrin clustering effect, triggering an 
intracellular signal cascade leading to engulfment of particles. It is speculated that invasin 
has a comparable binding interface used to bind α5β1 integrin, which is further supported 
by RGD competitive inhibition of invasin (73). It should be noted that the sequence 
homology between invasin and fibronectin is quite low and are not likely to have evolved 
from the same origin.  
 
Figure 1.7: Comparison of the binding surfaces of invasin and human fibronectin. 
Another interesting aspect of the invasin α5β1 interaction is the potential for 
adjuvant activity. The first evidence of invasin adjuvant activity was identified in 1993 by 
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co-immobilizing a monomeric MBP-invasin fusion with anti-CD3 on microplates and 
culturing isolated CD4+ and CD8+ human T cells (76). This study showed invasin was 
capable of mimicking co-stimulatory APC molecules by elevating cytokines such as 
interferon-γ (INF-γ) and tumor necrosis factor-α (TNF-α). Invasin was also able to 
activate CD8+ T cells to become cytotoxic effectors. By replacing invasin with different 
peptides from invasin, they were able to find the amino acids corresponding to 868-878 
from invasin, were also able to stimulate adjuvant behavior. These effects were inhibited 
by the addition of anti-α5 integrin antibody, showing the adjuvant behavior was linked to 
integrins on the T cells. Particles coated with invasin from Y. enterocolitica are also able 
to induce IL-8 secretion from cultured epithelial cells (77). This behavior has been linked 
to a signal cascade triggered by clustering β1 integrins, shown below (78). This property 
means the utilization of invasion may serve dual purposes: targeting and immune 
stimulation. Therefore, an additional adjuvant may not be required to overcome oral 
tolerance and induce a protective immune response.  
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Figure 1.8: Potential signal cascade activation stimulated by invasin. This image was 
reproduced with permission (78). 
Preliminary in vivo work testing invasin as a potential targeting molecule and 
immunomodulatory molecule has been successful. When carboxylated 0.5um fluorescent 
polystyrene particles were conjugated to invasin and orally administered to rats, 
approximately 13% of the particles were found in systemic circulation (79). This was a 
five-fold increase over controls with no enteric invasin protection mentioned. Another 
study tethered a fusion protein, consisting of c-terminal invasin and a fragment of 
ovalbumin (OVA), to carboxylated polystyrene particles (1um) and administered them by 
intraperitoneal injection (80). They were able to show a balanced TH1/TH2 response as 
well as CD8+ T cell stimulation using invasin. This supported the idea that invasin may 
have an ability to help promote cross-presentation which would not restrict its vaccine 
20  
targets to extracellular pathogens. Another study utilized live bacteria as a carrier, which 
expressed OVA, a protein to facilitate endosomal lysis, and invasin (81). These bacteria 
were orally administered and demonstrated suppressed growth of tumor cells expressing 
OVA. These examples provide promise for oral vaccines targeted by invasin.  
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Chapter 2: Engineering a Pathogenic Targeting Protein for Oral 
Vaccine Delivery 
INTRODUCTION 
Design of vaccines to induce mucosal immunity has been challenging (82), but 
are expected to confer robust protection since most infectious diseases gain entry via 
mucosal routes (4, 27, 83, 84). Oral vaccines are a promising approach due to their ease 
of administration and the option for solid dosage formulations with reduced cold-chain 
dependence. However, the only FDA approved oral vaccines have been live attenuated 
pathogens, including those for adenovirus, rotavirus, and typhoid. As live pathogens, 
these present safety concerns for their potential to revert to virulence, as observed with 
the Sabin live oral polio vaccine (85). In contrast, recent efforts have focused on 
particulate vaccines incorporating key proteins or epitopes from pathogens (86). While 
safer, these injectable formulations do not induce strong mucosal immune responses. 
Ideally, a vaccine would include recombinant subunits and be capable of inducing both 
mucosal and systemic immune responses.  
An intriguing solution is the use of orally administered polymeric particles to 
protect a subunit vaccine during gastrointestinal (GI) transit, followed by targeting to 
lymphoid tissue in the gut (87). Vaccines targeting the rare M cells along the GI tract 
have shown improved immune responses, compared to untargeted formulations (40, 42). 
These M cells, which sample antigens and particulates in the GI tract, are believed to play 
a critical role in inducing immunity (88). They transport foreign material to underlying 
dendritic cells, B and T cell lymphocytes, which in turn initiate an immune response (27, 
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89). Because these cells are very rare, ~1 in every 10,000,000 human epithelial cells, 
vaccine potency may be increased by targeting M cells through a specific ligand-receptor 
interaction (4, 15, 29, 90). A variety of ligands appear promising in terms of increased 
IgG or IgA titers, IFN-gamma production and murine survival upon challenge, including 
the NKM 16-2-4 antibody, CKS9 peptide, UEA-1 lectin, and cholera toxin B subunit (40, 
42, 71, 91-93). 
Of these receptor-ligand pairs, the α5β1 integrin is unique to the human M cell 
surface, compared to other enterocytes (32, 57, 59). This receptor is also targeted by 
certain Yersinia bacteria, which present a surface-displayed invasin protein that adheres 
to the α5β1 integrin in order to facilitate infection (36, 61, 94). Bacteria expressing 
invasin increase the number of adherent bacteria ~10 fold and internalized bacteria ~2.5 
fold in an in vitro M cell model, compared with bacteria not expressing invasin (36). 
When incubated with mouse intestinal loops, ~5 times more adherent and ~30 times more 
internalized bacteria were recovered from M cells for bacteria expressing versus not 
expressing invasin (57). Purified, adsorbed invasin is necessary and sufficient to mediate 
internalization of polystyrene beads into HEp-2 cells (62) and increases the systemic 
presence of particles 6.5-fold after oral dosing in mice (79). 
The invasin from Y. psuedotuberculosis has been well-characterized, a large (107 
kDa) protein anchored in the outer membrane by a beta-barrel transmembrane domain, 
with its five extracellular domains (D1-D5) forming an 18nm rod-like extension 
homologous to tandem type III fibronectin domains (Table 2.1) (95, 96). The domains 
D1-D4 are immunoglobulin-like while D5 is C-type lectin-like domain. The D2 domain 
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mediates self-assembly into dimers and tetramers, increasing the avidity of binding and 
efficiency of endocytosis (62, 96, 97). Receptor binding is mediated by the D4-D5 
domains, containing two critical aspartic acids residues: D911 which is required for 
binding and D811 aids binding (Table 2.1) (67, 68). The orientation of these two residues 
suggests convergent evolution with the RGD and synergy sites of fibronectin, although 
this molecule has significantly weaker affinity for integrins (96). Invasin is efficiently 
expressed in E. coli as the intact, surface displayed protein, or as soluble protein when the 
D1-D5 or D4-D5 domains are fused to the c-terminus of maltose binding protein (MBP) 
(36, 73). In addition, invasin possesses adjuvant qualities, stimulating CD4 and CD8 T 
cell proliferation and cytokine release (76, 80). In the context of vaccine design, high 
intrinsic affinity for the α5β1 integrin and high invasin surface density on vaccine 
particles are expected to enhance immune responses to an oral vaccine (25, 29, 74, 90).  
All studies to date have demonstrated a correlation between ability to target M 
cells and improve immune responses, suggesting M cell targeting/uptake has not yet been 
saturated and that higher affinity could enhance this effect. The potential for invasin to 
improve oral vaccine delivery led us to generate variants with enhanced α5β1 binding 
affinity and, presumably, enhanced M cell targeting in vivo. We first performed alanine 
scanning of eight invasin residues suspected to contribute to the binding interface, to aid 
in identification of regions to target with saturation mutagenesis. We identified four 
residues, which, when substituted with alanine for bacterial display, resulted in ~50% 
reduced binding to purified α5β1 integrin or ~50% reduction in Caco-2 cell invasion. 
Next, we constructed four site-directed saturation libraries targeting 31 residues within 
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the D4-D5 domains, followed by eukaryotic cell-based panning and FACS enrichment of 
bacterial-displayed libraries to identify affinity-enhanced invasin variants. We identified 
three mutations conferring increased affinity for α5β1, as measured by a flow cytometry-
based assay and ELISA. Two of the substitutions created a novel RGD epitope 
surrounding the essential D911 residue that appears to mimic fibronectin’s RGD epitope, 
while the third led to increased specificity and affinity towards the α5 subunit of the 
integrin complex. These results suggest invasin recognizes α5β1 in the same manner as 
fibronectin and may comprise a new targeting ligand for oral vaccines. 
Domain Residues Function Reference 
SP 1-48 Translocation across 
inner membrane 
(Fairman, 2012) 
β 128-486 Outer membrane anchor (Fairman, 2012) 
D1 503-594  (Hamburger, 1999) 
D2 595-693 Self-assembly (Dersch, 1999), (Dersch, 2000), 
(Hamburger, 1999) 
D3 694-794  (Hamburger, 1999) 
D4/D5 795-986 Binding region (Leong, 1991), (Hamburger, 1999) 
Table 2.1: Important regions of invasin from Y. psuedotuberculosis 
RESULTS AND DISCUSSION 
Identification of four novel residues with reduced invasin-integrin binding upon 
alanine substitution 
Y. psuedotuberculosis invasin is a 107kDa adhesion protein embedded in the 
bacterial outer membrane with five extracellular domains extending outwards (96). The 
integrin binding interface is restricted to the terminal two extracellular domains (D4-D5), 
as determined by the ability of progressively truncated invasin variants to adhere to and 
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invade HEp-2 cells (65, 98). Subsequently, several key residues within the D4-D5 region 
were identified as key mediators of the binding interaction. Using a mutator E. coli strain 
to randomly introduce mutations into the invasin gene, followed by selection of clones no 
longer able to bind HEp-2 cells, the residues C907 and C982 were found to form a 
critical disulfide bond and the region spanning residues 903-913 was implicated in 
binding (68). A library of invasin variants, targeting the 903-913 region with mutagenic 
oligonucleotides, identified residue D911 as essential for integrin binding. Motivated by 
this result, all the aspartic acid and lysine residues in the D4D5 region were 
systematically substituted with alanine to identify additional key residues (67). The 
residue D811 was identified as an important residue, but less essential than D911. 
Finally, residues flanking D811 were substituted with alanine prior to analysis as soluble 
MBP fusion protein. Here, the F808A substitution was found to have a moderate effect in 
integrin binding, similar to that observed with the to D811A substitution. 
Given this prior identification of several residues important for integrin binding, 
we chose construct targeted, saturation mutagenesis libraries, in which several adjacent 
residues are randomized to all other amino acid residues. This approach restricts the 
number of possible amino acid combinations present in each library, such that every 
protein variant can be analyzed. In addition to the D911 and D811 residues, we sought to 
identify additional residues on the invasin surface directly engaging α5β1 integrin to 
define regions likely to result in productive libraries. Due to their large size, restricted 
mobility, and ability to mediate electrostatic, hydrophobic, and hydrogen bonding 
interactions, solvent exposed tyrosine residues often contribute significantly to the 
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binding free energy of protein-protein interactions (99). Inspection of the invasin crystal 
structure revealed five solvent-exposed tyrosines in the D4-D5 region (Y860, Y863, 
Y878, Y885, and Y976), four of which had not been previously assessed for integrin 
binding activity (Figure 2.1A). The Y878 residue was previously implicated, as a 
decameric invasin peptide containing this residue engaged the α5β1 integrin on T cells 
(76).  
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Figure 2.1: Integrin binding activity of purified invasin and D911A variant. (A) Structure 
of D4/D5 domains of invasin with residues color-coordinated based on relative 
importance to integrin binding or cell uptake. Green: minimal role; orange: moderate 
role; red: critical role. The single critical disulfide bond is shown in purple. The 
backbones for residues substituted in libraries are shown in cyan. From PDB entry 
1CWV. (B) To display invasin on the surface of E. coli cells, the plasmid pTAK020 was 
constructed by inserting the complete invasin gene into the arabinose inducible pBAD30 
plasmid. The entire 986 amino acid residue (107 kDa) protein is expressed, including the 
native translocation signal peptide (SP), outer membrane insertion region (β Domain), 
and five external domains (D1-D5). To produce soluble invasin, DNA encoding domains 
1-5 (amino acid residues 503-986) or the minimal integrin binding domains 4 and 5 
(residues 795-986) were introduced into the pMAL-c5x plasmid, for cytoplasmic 
expression as a c-terminal fusion to the MalE gene (encoding maltose binding protein, 
MBP) to create the MBP-D1D5 (93 kDa) and MBP-D4D5 (62 kDa) constructs, 
respectively. (C) ELISA demonstrating the impact of the D911A () substitution on 
binding of MBP-D4D5 to immobilized α5β1 integrin, using anti-MBP for detection. For 
reference, the wild-type invasin sequence is shown for the multimeric MBP-D1D5 () 
and monomeric MBP-D4D5 () constructs. 
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This work utilized expression of the invasin gene in three different genetic 
constructs, consisting of bacterial surface display and soluble expression of the D1-D5 or 
D4-D5 domains as a fusion protein to MBP (Figure 2.1B). Using PCR-based 
mutagenesis, we introduced alanine residues to sequentially replace each of these five 
native tyrosines. We also generated alanine substitutions at residues previously found to 
contribute to binding, D811, D911, and the R883 residue which was postulated in 
Hamburger et al (96). Upon alanine substitution, the tyrosine side chain is reduced to a 
single methyl group, removing the hydrogen-bonds and hydrophobic interactions 
normally mediated by this residue, while minimally disturbing the native structure as 
alanines are highly represented in both alpha helix and beta sheet secondary structure 
elements. If a given tyrosine residue contributes significant free energy to stabilize the 
invasin-integrin binding interaction, we would expect to see a decrease in affinity or 
cellular invasion for the corresponding alanine variant. Regions adjacent to or 
encompassing these key residues would then be targets for mutagenesis to optimize the 
local interaction. 
First, to measure invasin-integrin binding activity and to validate our work with 
existing data for the D911A variant (68), we developed an ELISA using recombinant 
soluble α5β1 integrin as a coat protein and a soluble fusion protein of maltose binding 
protein (MBP) and the invasin D4-D5 domains (MBP-D4D5; Figure 2.1C). In this assay, 
wild-type invasin gave a strong response, while the D911A variant showed no response, 
consistent with prior reports. However, ELISA analysis requires time-consuming 
expression and purification of the soluble MBP-invasin fusion protein. In order to rapidly 
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screen large number of invasin variants, we developed two complementary assays based 
on bacterial display of invasin, followed by flow cytometry analysis or eukaryotic cell 
invasion. Full-length invasin was expressed in E. coli using an arabinose inducible 
promoter, resulting in translocation to and anchoring in the outer membrane. To confirm 
invasin presence on the cell surface, induced (+0.2% arabinose) cells were incubated with 
the invasin-specific monoclonal antibody 3A2 (65), followed by a fluorescent secondary 
antibody and analysis with flow cytometry. Bacteria expressing invasin exhibited a 
median fluorescence intensity (MFI) shift of several orders of magnitude (from ~0 to 
~8000), compared to bacteria not expressing invasin (Figure 2.2A).  
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Figure 2.2: Alanine invasin variants exhibit a spectrum of integrin binding abilities. (A) 
Flow cytometry of E. coli displaying wild-type invasin as a histogram plot. Incubation 
with the 3A2 anti-invasin antibody and Cy5-labeled goat anti-mouse IgG results in a 
fluorescence shift for bacteria expressing invasin (solid line, MFI ~8,000) as compared to 
bacteria not expressing invasin (dashed line, MFI ~0). (B) Normalized MFI for the eight 
alanine variants and controls after incubation with the 3A2 anti-invasin antibody to assess 
differences in surface display levels. The Y976A variant appears to no longer bind the 
antibody. (C) Flow cytometry of E. coli displaying wild-type invasin after incubation 
with fluorescent, recombinant, soluble α5β1 integrin shows a fluorescence shift for 
bacteria expressing wild-type invasin (solid line, unshaded; MFI ~50) versus the non-
binding D911A variant (dashed line, unshaded; MFI ~10), and bacteria not expressing 
invasin (solid line, shaded; MFI ~10). (D) Normalized MFI for the eight alanine variants 
and controls after incubation with fluorescent, α5β1 integrin demonstrate the effect of 
each residue change on integrin binding.  
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Having confirmed that invasin is present on the cell surface and accessible for 
ligand binding, we replaced the antibody with fluorescent, recombinant, soluble α5β1 
integrin to monitor the protein-protein interaction of interest. The fluorescent integrin was 
prepared by coupling Alexa Fluor 647 to commercial extracellular α5β1, resulting in 5-
15 fluorophores per protein. After incubation of cells with fluorescent integrin results in 
an increase in MFI for those expressing invasin (MFI ~40) versus those not expressing 
invasin or expressing the D911 variant (MFI~ 13; Figure 2.2C). Unfortunately, attempts 
to introduce a peptide tag into invasin to directly monitor the surface levels were 
unsuccessful (data not shown). We can thus only approximate changes in surface 
expression from 3A2 anti-invasin binding (Figure 2.2B).  
Using bacterial FACS, MFI values were normalized such that cells expressing 
wild-type invasin were defined as 100 and cells not expressing invasin were defined as 0. 
(Figure 2.2D) The D911A variant again showed greatly reduced binding to the integrin 
(normalized value of 4), similar to bacteria not expressing invasin. The D811A, Y860A, 
Y863A, Y878A, and R883A variants all exhibit moderate reduction in integrin binding 
(normalized values of 40-55), suggesting these are less important or second-shell residues 
(stabilizing residues directly participating in the binding event), while Y885A and Y976A 
show wild type binding (normalized values between 84-106). Interestingly, the Y976A 
mutant, which is not recognized by the 3A2 antibody, retains wild-type affinity for 
integrin, suggesting that this residue is critical for antibody but not integrin binding.  
Three residues with reduced integrin affinity also exhibit reduced Caco-2 
invasion. The invasin-β1 integrin interaction is not just a simple binding event, but in the 
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context of a live cell, triggers an intracellular signaling cascade and actin reorganization, 
ultimately resulting in internalization of particles presenting invasin. While our primary 
concern is to increase the invasin affinity for α5β1 integrin, in order to enhance M cell 
targeting, it is also critical to retain the internalization abilities. Moreover, the integrin has 
been shown to exist in multiple conformations on the cell surface which may not be 
recapitulated by the soluble, recombinant α5β1 used above (75). Therefore, an 
orthogonal gentamicin protection assay was employed, to assess invasin-integrin binding 
and the resulting cellular internalization (81). Here, bacteria expressing surface displayed 
invasin variants and intracellular GFP were incubated with Caco-2 cells at a multiplicity 
of infection (MOI) of 70 for two hours, washed, then incubated with media containing 
gentamicin to kill extracellular bacteria. The next day, Caco-2 cells were analyzed by 
flow cytometry to monitor internalized bacteria via GFP fluorescence.  
This assay provides a clear distinction between Caco-2 cells incubated with 
bacterial cells expressing invasin versus those lacking invasin. When incubated with 
bacteria harboring empty plasmid, the Caco-2 cells exhibit a single population with low 
fluorescence, while those incubated with bacteria displaying wild-type invasin devolve 
into low- and high-fluorescence populations (Figure 3.3A). Cells falling into the higher 
fluorescence window were defined as positive for invasion.  
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Figure 2.3: Alanine invasin variants confer a spectrum of cellular invasion abilities. (A) 
E. coli bacteria expressing intracellular GFP and displaying invasin are internalized by 
Caco-2 cells. After gentamycin treatment to kill extracellular bacteria following in vitro 
infection, the Caco-2 cells were analyzed for GFP fluorescence by flow cytometry. The 
histogram shows a population of Caco-2 cells with low-fluorescence after incubation 
with bacteria not expressing invasin (solid line, shaded) or those expressing the inactive 
D911A variant (dashed line, unshaded). Both low (27.6% of the total population) and 
high fluorescence populations (72.4% of the total population) are observed after 
incubation with bacteria expressing wild-type invasin (solid line, unshaded). All 
experiments were performed at an MOI of 70. (B) Bacteria expressing invasin alanine 
variants exhibit different Caco-2 invasion abilities. The percent of GFP-positive Caco-2 
cells are presented to compare the effects of various alanine mutations. Percent invasion 
corresponds to the percent of cells in the high fluorescence population versus the total 
size-gated population. 
Under optimized conditions, ~70% of Caco-2 cells incubated with bacteria 
expressing wild-type invasin were positive for invasion, while only ~3% of those 
incubated with bacteria lacking invasin (empty plasmid) or expressing the D911A 
substitution were positive for invasion (Figure 2.3B). Of the alanine variants, bacteria 
expressing the Y976A, Y885A and R883A invasin variants were able to infect Caco-2 
cells at near-wild-type levels (68-73%), while the D811A, Y860A, Y863A, Y878A 
variants conferred reduced infectivity (all statistically significant differences from wild-
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type P<0.001, but Y860A: P<0.01; 1-way ANOVA). This data is consistent with the 
direct binding analysis above, except for the R883A variant which showed moderately 
impaired binding in the FACS assay, but near-wild-type Caco-2 invasion.  
Generation of four site-directed libraries targeting invasin hot spots 
Given this structure-function knowledge of the invasin-integrin binding site, we 
chose to generate four site-saturation mutagenesis libraries surrounding key residues to 
fine-tune these specific interactions. Variants containing Y860A and Y863A were found 
to compromise both integrin-binding and Caco-2 cell invasion and are located on a single 
loop. Therefore, library 1 randomized ten residues: residues 858-865, which form the 
loop including Y860 and Y863 and residues F844 and N847, which are located on an 
adjacent loop with side chains oriented towards the 860-863 loop. Similarly, the Y878A 
and R883A substitutions moderately affect binding; library 2 targets these by 
randomizing the surface exposed residues on the beta sheet between positions 878-883. 
Library 3 surrounds the residue D811, targeting the surface loop between residues 809-
814. Library 4 surrounds the essential residue D911, randomizing the 908-913 loop. Each 
library contained >107 unique transformants, which corresponded to greater than ten-fold 
more non-template sequences than the theoretical library size. 
Identification of invasin variants with enhanced affinity for α5β1 integrin and  
Caco-2 invasion from site-directed libraries 
Bacterial protein display in conjunction with FACS is well documented as a 
protein engineering tool allowing enhanced control over the selection process by 
providing single clone information in real time (100). However, flow cytometry alone is 
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unable to efficiently sort large libraries due to resolution and sorting rate limitations, 
restricting FACS enrichment to library sizes on the order of 107 (101). For larger 
libraries, pre-enrichment techniques, such as magnetic bead capture (102), can be used to 
reduce library sizes feasible for FACS enrichment. We chose a dual Caco-2 adhesion/ 
invasion and bacterial FACS selection platform, in which the Caco-2 step removes 
inactive or poorly active invasin variants while simultaneously rapidly reducing library 
size (Figure 2.4). Libraries were grown, induced and incubated with sub-confluent Caco-
2 cells. After allowing time for bacteria to bind and invade, unbound bacteria removed by 
washing with retained and internalized bacteria recovered. The remaining library 
members were then subjected bacterial FACS with fluorescent integrin until the 
populations were enriched, as measured by a stable population MFI and sequence 
convergence.  
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Figure 2.4: Selection of invasin variants from targeted libraries. (A) Overview of the 
invasin selection process. First, a targeted library is created using a single, degenerate, 
mutagenic primer, plasmid pTAK020 encoding the entire invasin gene with stop codons 
inserted in the mutagenic region, polymerase, and ligase before transformation into E. 
coli. Next, the library is enriched for functional invasin variants capable of mediating 
bacterial adherence to and invasion of bacteria into Caco-2 cells. Only internalized 
bacteria, harboring plasmid corresponding to the expressed invasin variant, are recovered. 
Last, recovered bacteria expressing surface displayed invasin are incubated with 
fluorescently labeled soluble α5β1 integrin and the more highly fluorescent clones 
enriched by multiple rounds of FACS to identify individual clones for more detailed 
characterization. (B) Representative data depicting the changing bacterial population 
during rounds of selection by FACS. Initially, the population as a whole is poorly 
fluorescent, with ~1% of events falling into the fluorescence gate for integrin binding. 
This population increases with each round of bacterial sorting until after three rounds, 
50% of the population falls into this gate. Data shown for library one. 
Each library was subjected to two rounds of Caco-2 selection and four rounds of 
bacterial FACS, followed by sequencing of individual clones (Figure 2.5). Clones are 
named for the library, sort round and isolate, i.e., isolate 2 analyzed from library 1 after 
four enrichment rounds is termed 1R4-2. For library 1, all positions were represented the 
most by the wild type amino acid, except for F844, at which position a tyrosine was 
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observed to be the most prevalent substitution (7 of 10 clones). Similarly, for library 2 
only one position was represented the most by a non-wild type amino acid, S881V (8 of 
10 clones). Library 3 did not exhibit sequence convergence although Y810P was present 
in six clones and the 814 position was restricted to the wild-type phenylanine (7 of 10 
clones) or leucine (3 of 10 clones). Library 4, surrounding the critical D911 residue, 
exhibited sequence convergence more rapidly than the other libraries. All clones 
sequenced after two Caco-2 cell enrichment steps contained the wild-type D911 residue, 
while three of those sequenced after the first FACS sort further modified the D911 
environment to include a RGD motif. Further rounds of enrichment and sequence 
analysis revealed the RGD to correlate with M912L and/or S913A substitutions. 
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Figure 2.5: Sequence convergence observed in libraries after selection. The distribution 
of observed amino acid residues are shown as WebLogo frequency plots. Underneath, the 
residue’s number, wild-type amino acid identity and the degenerate codon used for 
library generation. Six positions converged to a non-wild-type residue and are highlighted 
in yellow (F844Y, S881V, G909R, S910G, M912L, S913A).  
Individual clones from each library were analyzed for increased integrin affinity 
by bacterial flow cytometry with fluorescent α5β1. The post-sort libraries 1, 2, and 4 
each resulted in clones exhibiting increased MFI compared to bacteria expressing wild-
type invasin (151, 179, and 132 normalized MFI values, respectively)(Figure 2.6A). 
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Based on the three variants analyzed from library 2, the S881V substitution was observed 
in both variants yielding increased MFI and was further suggested to be important by 
sequence homology in following the next round of FACS enrichment. The post-sort 
library 3, which did not exhibit sequence convergence, also did not exhibit an MFI 
greater than wild-type invasin. Library 3 was abandoned for further analysis due to the 
lack of clear sequence convergence and isolation of clones with poor performance in the 
bacterial flow cytometry assay.  
 
Figure 2.6: Invasin variants show enhanced integrin binding and cellular invasion. Non-
homologous clones recovered from the last round of selection were analyzed by surface 
expression on E. coli cells followed by (A) incubation with fluorescent integrin prior to 
analysis with flow cytometry and (B) ability to invade Caco-2 cells. 
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Clone Name Substitutions 
1R5-2 F844A, N847H, I858V, Y863F, S864Y 
1R6-1 F844Y 
2R5-2 S879A, S881V 
2R5-3 Y885S 
2R5-4 S881V, R883K, Y885S 
2R6-7 S881V 
3R5-2 A809P, T810P, D811S, K812G, F814L 
3R5-4 A809T, T810P, K812H, F814L 
4R3-3 G909R, S910G, M912L, S913A 
RGD G909R, S910G 
DLA M912L, S913A 
RGD844 F844Y, G909R, S910G 
 
Table 2.2: Amino acid substitutions present in each clone, relative to c-terminal wild-type 
sequence. Clone nomenclature includes library, selection round and clone number, such 
that 1R5-2 is clone 2 from library 1 after round five.  
Bacterial clones exhibiting a MFI higher than bacteria expressing wild-type 
invasin in the bacterial flow cytometry assay (Figure 2.6A), along with clones exhibiting 
sequence homology different from wild type were analyzed for Caco-2 cell invasion 
capability. Clones 1R6-1, 2R5-2, 2R5-4, and 2R6-7 all exhibited statistically significant 
improvements (P<0.001; 1-way ANOVA) for Caco-2 cell invasion, 52%, 69%, 64%, 
67% respectively compared to 52% for wild type (Figure 6B and Table 2.2). Clone 1R6-
1, including a single F844Y mutation, was selected for further characterization from 
library 1. All clones from library 2 shared a S881V mutation; for clone 2R6-7 this is the 
only change from wild-type sequence, leading to its selection as a lead from this library. 
While the 4R3-3 variant exhibited improved invasion, it was not statistically significant. 
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However, given its performance in both assays, along with the intriguing presence of an 
RGD epitope, it was also selected for further analysis.  
The combination of three amino acid substitutions produces a nine-fold 
improvement in affinity to α5β1 integrin 
Three lead candidates, based on bacterial flow cytometry and Caco-2 invasion 
screening (Figure 2.6), were sub-cloned into pTAK039 for expression as a soluble MBP-
D4D5 fusion protein followed by ELISA to assess relative binding affinities for integrin. 
After cytoplasmic expression, amylose affinity and size exclusion chromatographic steps 
resulted in highly pure protein at the expected 62kDa size, based on amino acid sequence 
(Figure 2.7A). Purified protein yields were approximately 100 mg per liter culture 
volume for all variants. The 2R6-7 variant (S881V) from library 2 exhibited a higher 
EC50 than wild-type, indicating weaker binding (data not shown). This substitution may 
result in increased expression rather than increased integrin affinity. The lead candidates 
from libraries 1 (1R6-1) and 4 (4R3-3) exhibited statistically significant EC50 shifts, 
compared to wild-type (95% confidence intervals for EC50 shifts relative to wild-type: 
(1.8-2.4) and (3.2-4.1), respectively (Figure 2.7B).  
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Figure 2.7: Contributions of individual amino acid substitutions in selected variants to 
integrin binding. Two lead candidates (4R3-3 and 1R6-1) were selected for further 
analysis on the basis of high fluorescence in the flow cytometry assay and high Caco-2 
invasivity. As 4R3-3 contains multiple substitutions (GSDMS to RGDLA at positions 
909-913), two additional variants were constructed to determine the contributions of the 
RGD and DLA motifs surrounding the essential D911 residue. The D4-D5 domains for 
all four variants were expressed and purified as MBP-D4D5 proteins from pTAK039. (A) 
Non-reducing SDS-PAGE depicts purified protein of the expected molecular weight (62 
kDa). Lanes contain 1: Spectra Multicolor Broad Range Protein Ladder, 2: wild-type 
invasin, 3: clone 4R3-3, 4: clone 1R6-1, 5: variant with RGD, 6: variant with DLA. (B) 
ELISA comparing binding of clones 4R3-3 () and 1R6-1 () with wild-type invasin 
() to α5β1 integrin. (C) ELISA comparing binding of clone 4R3-3 () with the RGD 
(), DLA () variants and wild-type () invasin to α5β1 integrin. ELISA plates were 
coated with soluble α5β1 integrin and bound invasin detected with anti-MBP-HRP.  
While the both invasin and fibronectin both bind integrin, invasin has a much 
higher affinity for α5β1integrin: invasin Kd = 5 nM, while the fibronectin Kd = 800 
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nM)(73). Interestingly, while invasin also presents an aspartic acid residue essential for 
binding (D911), it lacks the classic RGD epitope found in fibronectin, which is necessary 
and sufficient to support integrin binding (67, 73, 74). From library 4, we isolated a 
variant (4R3-3) containing an RGD sequence surrounding D911, which bound α5β1 
more tightly than wild-type invasin (~four-fold decrease in EC50). This 4R3-3 variant is 
composed of four substitutions between C-terminal residues 909-913 (GSDMS to 
RGDLA). To assess whether the GSD  RGD and DMS  DLA changes each 
contribute to increased affinity, we made a series of site-directed variants to assess the 
specific contributions of each set of changes. We found the DMS  DLA substitutions to 
actually decrease binding while the GSD  RGD substitution increase binding (Figure 
2.7C).  
Given that both the F844Y substitution and the RGD epitope individually confer 
increased affinity, we constructed a variant containing both sets of substitutions and 
analyzed its behavior as a bacterial cell surface displayed protein and as a soluble MBP-
D4-D5 fusion protein. This protein, along with wild-type and the individual site mutation 
variants were expressed and purified as before to produce highly pure protein (Figure 
2.8A). After ELISA analysis against α5β1, we found our optimized invasin variant, 
RGD844, to have a lower EC50 than variants with either F844Y or the RGD epitope alone 
(Figure 2.8B). This resulted in a nine-fold increase in affinity, compared to wild-type 
invasin (Figure 2.8C). We then compared these variants on their ability to bind α3β1 
(Figure 2.8D). We found the variants containing the RGD epitope to also exhibit 
increased affinity [95% confidence intervals for EC50 shifts relative to wild-type: RGD 
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(1.39-2.73) and RGD844 (1.31-2.56)]. However, the F844Y substitution had little effect 
on affinity to α3β1 (95% confidence intervals for EC50 shifts (0.516-1.01), relative to 
wild-type).  
 
Figure 2.8: Lead invasin variant, RGD844 shows enhanced affinity and specificity for 
α5β1 integrin. To determine whether the RGD motif and F844Y synergistically enhance 
invasin binding to integrin, they were introduced into invasin in the pTAK035 and 
pTAK039 plasmids for purification as MBP-D1D5 and MBP-D4D5 fusion proteins, 
respectively. (A) Non-reducing SDS-PAGE depicts purified protein of the expected 
molecular weights (94 kDa). Lane 1: Spectra Multicolor Broad Range Protein Ladder, 2: 
wild-type invasin, 3: RGD844, 4: RGD, 5: 1R6-1. (B) ELISA comparing binding of wild-
type invasin () and the 1R6-1 clone () with the RGD () and RGD844 () variants 
to α5β1 integrin. (C) Table detailing the changes in binding to α5β1 integrin as changes 
in the relative EC50. (D) ELISA comparing binding of wild-type () invasin and the 1R6-
1 () clone with the RGD () and RGD844 () variants to α3β1.  
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RGD844 variant exhibits improved affinity as MBP-D1D5 construct 
Binding of soluble invasin to both integrin and eukaryotic cells is enhanced by 
inclusion of the D2 domain, responsible for increased avidity through self-association 
(Figure 2.1C)(62, 96, 97). Therefore, we introduced the substitutions identified in our 
optimized invasin variant RGD844 (F844Y, G909R, and S910G) into an MBP-invasin 
fusion protein encompassing all five extracellular invasin domains (MBP-D1D5) in 
vector pTAK035. The purified proteins (Figure 2.9A) were analyzed by ELISA with 
soluble integrin as described above (Figure 2.9B). As expected, invasin variant RGD844 
in this construct exhibited a decreased EC50 compared to the monomeric MBP-D4D5 
version (95% confidence intervals for EC50 shifts (1.84-3.05), relative to wild-type). Also, 
the optimized invasin in the MBP-D4D5 construct demonstrated a lower EC50 than the 
wild type sequence in MBP-D4D5, showing the beneficial substitutions outweigh the 
effect of incorporating the D2 domain (95% confidence interval for EC50 shift (3.32-
5.67), relative to wild-type).  
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Figure 2.9: Comparison of wild-type and RGD844 invasin binding to integrin as MBP-
D1D5 and MBP-D4D5 constructs. (A) Non-reducing SDS-PAGE depicts purified protein 
of the expected molecular weights (62 and 93 kDa). Lane 1: Spectra Multicolor Broad 
Range Protein Ladder, 2: wild-type (MBP-D4D5), 3: RGD844 (MBP-D4D5), 7: wild-
type (MBP-D1D5), 8: RGD844 (MBP-D1D5). (B) ELISA comparison of wild-type     
(, ) and RGD844 (, ) invasin binding to α5β1 integrin as MBP-D4D5 and *MBP-
D1D5 constructs. (C) Structural characterization of three variants (MBP-D1D5 format) 
with notable binding differences for integrin: wild-type, D911A, and RGD844 by circular 
dichroism and thermal melting temperature.  
To determine whether the key amino acid substitutions affect invasin structure, 
we measured the apparent thermal unfolding transition temperature (Tm) and circular 
dichroism (CD) spectra using the MBP-D1D5 constructs. The Tm for the wild type, 
D911A, and RGD844 variants, determined with a high-throughput fluorescent assay, 
were all within error, near 54°C (Figure 2.9B). The secondary structure of these variants, 
from CD spectra, also exhibited similar features between variants (51-55% alpha helix, 
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23-37% beta sheets, 6% turns, and 16-20% unordered), suggesting an absence of major 
structural changes (Figure 2.9C).  
The Y. psuedotuberculosis invasin protein has received considerable attention and 
has been proposed as a targeting molecule for oral vaccines (57, 61, 62, 64, 68, 79, 81, 
96). However, its affinity for the α5β1 integrin present on intestinal immune M cells is 
only moderate (Kd ~5 nM) and previous studies have shown that increased affinity of M 
cell ligands translates to enhanced immune responses for oral vaccines (42, 93). Using 
alanine scanning mutagenesis, we identified four previously unidentified surface residues 
involved in integrin binding (Y860A, Y878A, R883A, Y885A). Next, using directed 
evolution and four site-directed libraries, we show for the first time, that the presence of 
an RGD epitope surrounding the essential D911 residue, in conjunction with an F844Y 
substitution, enhances the affinity of invasin nine-fold for the α5β1 integrin and Caco-2 
cell invasivity without compromising specificity. This engineered invasin molecule, 
RGD844, may be valuable to oral vaccines as both an M cell ligand and a natural 
adjuvant (78, 103). 
Invasin RGD sequence is not observed in Yersinia strains  
The template invasin for our library comes from the Y. psuedotuberculosis 
bacteria, as this is the best-characterized variant. Comparing among the available 
sequences, we noticed that two of the three beneficial amino acid substitutions naturally 
occur in other invasin strains (Table 2.3). Both F844Y and G909R are present in the 
invasin expressed by Y. enterocolitica, indicating that the substitutions are well-tolerated 
and that our in vitro evolution process may have mimicked natural evolution. 
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Nevertheless, since the presence of the RGD motif dramatically enhances invasin affinity 
for the α5β1 integrin and thus would be expected to confer an evolutionary advantage, it 
is interesting that it is not present in Y. pseudotuberculosis. Notably, invasin is not the 
only adhesion employed by Yersinia species; it assists the YadA adhesion and thus would 
be expected to be more tolerant to sequence drift (104). However, introduction of the 
RGD motif does require a series of DNA base pairs changes, which may need to occur in 
a specific sequence. Out of 25 sequenced clones from library 4, only two clones had 
amino acids other than serine or glycine position 910. All 12 clones containing the 
S910G change were accompanied by G909R, although clones with G909R did not 
require S910G (3/25 observed). This suggests that Y. psuedotuberculosis invasin can only 
acquire the S910G substitution if it has already acquired a G909R substitution. 
Furthermore, the codon change from serine to glycine requires changing two nucleotides, 
one of which is a T->G substitution, which are believed to occur much less frequently 
than other mutations in bacteria (105).  
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Table 2.3: Invasin amino acid comparison between Yersinia strains 
RGD844 combines fibronectin and invasin binding functions 
When the crystal structure of invasin was first revealed, the integrin D4D5 
binding domains were compared to the endogenous human α5β1 integrin ligand, 
fibronectin (70, 96). Fibronectin type III repeats 9-10 interact with α3β1, α4β1, α5β1, 
α8β1, αVβ1. αVβ3, and αVβ6 integrins (106), while invasin binds α3β1, α4β1, and 
α5β1, suggesting functional if not structural homology (69). Moreover, invasin and 
fibronectin bind the same region of α5β1, based on competitive binding and integrin 
mutational studies (70, 73). Notably, in the absence of sequence homology, the structural 
comparison identified a remarkable structural similarity between fibronection’s RGD 
epitope and synergy site and invasin’s essential D911 and key D811/ R883 residues, 
respectively (Figure 2.10). The D811 position also seems to behave in a manner 
suggesting it lies in synergy site, like that observed in fibronectin type III repeats 9 and 
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10 (67, 70). In spite of this structural homology, fibronectin binds with a Kd over two 
orders of magnitude lower (73) and is a poor facilitator of inducing internalization of 
particulates (62, 98). 
 
Figure 2.10: Structural comparison of wild-type invasin (D1-D5) with fibronectin III 
repeats 7-10. The critical aspartic acid residues (D911 in invasin and the RGD motif for 
fibronectin) and synergy sites are highlighted for comparison with the color code Asp 
(red), Arg(yellow), Gly(blue), Tyr(green), invasin F844Y (purple).  
Considerable work with the fibronectin with α5β1 integrin interaction has 
revealed the complexity and difficulties in studying α5β1 binding (75, 107, 108). These 
difficulties lie in the fact that α5β1 is a membrane bound protein, difficult to express and 
purify, and both molecules convert between multiple physical states. Since the initial 
invasin protein structure/function work by Isberg and others, it has been shown that α5β1 
integrin is a highly dynamic heterodimeric molecule that exists in at least three different 
conformations: relaxed, extended, and tensioned (75). The switch of an integrin complex 
from its relaxed to extended state is necessary for ligand recognition and integrin 
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clustering (109), and is linked to the enhanced cellular uptake of particulates coated with 
α5β1 ligands (62).  
From the current work and others, it is apparent that a broad surface of invasin in 
the D4-D5 domains interacts with α5β1 integrin. Comparisons between the D911 of 
invasin with the RGD epitope found in fibronectin are further supported by our data (70, 
96). The RGD epitope, especially the aspartic acid residue(110), of fibronectin is 
believed to primarily engage the β1 subunit of the integrin receptor, while the synergy 
site is thought to engage the α5 subunit (75). When we compared binding of our RGD 
invasin variant to the α5β1 and α3β1 integrins, we observed increased binding to both 
receptors compared to wild-type invasin, suggesting the RGD substitution enhances 
binding to the shared b1 subunit. In contrast, the additional F844Y substitution located 
near invasin’s proposed synergy site (R883), exhibits increases affinity towards α5β1, 
but not α3β1, suggesting this change affects interactions with the α5 subunit.  
The engagement of the fibronectin synergy site in the tensioned state of α5β1 has 
been shown to provide up to 90% of the adhesion strength in cell binding assays (75). We 
find invasin’s synergy site to play a role in role in integrin binding, but not significantly, 
compared to D911, in our bacterial flow cytometric analysis. This suggests that the 
recombinant α5β1 in our work behaves more similar to the extended state, rather than 
either the relaxed or tensioned states. The tensioning of α5β1 is easily understood in the 
context of mechanical stress-strain interactions between mammalian cells and their 
extracellular matrix (ECM)(111-114). From an evolutionary standpoint, the incredible 
structural similarity of the synergy site of invasin to that of fibronectin might suggest that 
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pathogens expressing invasin also undergo a stress-strain relationship with mammalian 
cells upon infection. It is hard to imagine systemically infected bacterial cells partaking in 
shear forces similar to those involved with the ECM. However, invasin expressing 
pathogens gain systemic entry through M cells via the luminal surface of the GI tract 
(58). Also, Y. pestis encodes a disrupted invasin gene and does not invade its host as an 
enteropathogen, suggesting invasin’s primary role is along the GI tract (115). It is 
believed that the peristaltic motion of the GI tract results in tissue stresses and strains 
within the small intestine (116-118). These mechanical forces may have provided the 
selective pressure to produce the unique structure similarity between invasin and 
fibronectin.  
CONCLUSIONS 
The invasin protein from Y. psuedotuberculosis has been studied in great depth 
and has been lauded as a potential targeting molecule for oral vaccines (57, 61, 62, 64, 
68, 79, 81, 96). Here we show, for the first time, that the presence of an RGD epitope 
along with another mutation further enhances the affinity of invasin for α5β1 integrin. By 
incorporating three substitutions in the D4-D5 region, we decreased the EC50 value by 
nine-fold, measured by ELISA against α5β1 integrin. This affinity maturation may aid 
vaccines systems beyond simple targeting, by also potentially increasing the adjuvanticity 
by signaling intracellular pathways and increasing the number of M cells, mediated 
through β1 integrins (78, 103). In this report, we furthered the understanding of how 
invasin engages α5β1 integrin and applied this knowledge to engineer invasin for higher 
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affinity, which may yield improvements in oral vaccines using invasin as a targeting 
agent.  
MATERIALS AND METHODS 
Display of invasin on E. coli surface  
To facilitate rapid screening and analysis of invasion variants, a vector was 
constructed in which the intact invasion gene is presented on E. coli outer membrane, 
where it is accessible for ligand (integrin or anti-invasin antibody) binding and able to 
mediate invasion of cells expressing the α5β1 integrin. The full-length invasin gene was 
PCR amplified from plasmid pRI203 (61) using primers TAK43 and TAK45 (Table 2.4), 
digested with restriction enzymes XbaI and SphI (NEB) and ligated into similarly 
digested pBAD30 vector (119) to create plasmid pTAK020 (Figure 2.1B). Individual 
alanine substitutions at positions D881, Y860, Y863, Y878, R883, Y885, D911 and Y976 
were introduced using a modified QuickChange procedure. Off-set complementary 
primers annealing to pTAK020 and introducing a single alanine substitution were used in 
a PCR reaction with high fidelity polymerase PFU Ultra II (Agilent). The PCR product 
was digested with DpnI and transformed into E. coli MC1061 cells. DNA sequencing 
confirmed the presence of only the desired mutation.  
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Primer Name Nucleotide Sequence 
TAK43 taactgacgatctagaactttaagaaggagatataccatgatggttttccagcc 
TAK45 tacgatgtctaatgtatgcatgctcaattattcattatattgacagcgcacag 
TAK46 agctatcgagctcgaactcattcacattgagcgtc 
TAK47 cgtcattataccatggctagttaatcattatattgacagcgcacagag 
TAK139(Library 1) gccgtcacagccacwtcadmadmgsywtkadmgkwaancgtcacctgaccctgatcgttaaccgatacmtbgggtgtadmtgacgacgaccactc 
TAK140(Library 2) cgccatcgtatatccacykstkcggadmaankykakaadmaanadmadmacttgggaattttttacttttcgc 
TAK141(Library 3) gcgtttttaaagatcgttttcggaangccsnnsnnsnnsnngaaattttgcccgttaacc 
TAK142(Library 4) gcacgtgaggattcaagaaccgcakmsnnadmgnngnnwwngcattgtctgctggcctcgag 
Table 2.4: Primer sequences 
Fluorescent labeling of soluble α5β1 integrin 
In order to monitor the ability of cells displaying invasin variants to bind the α5β1 
integrin ligand in a high-throughput manner, we employed a FACS-based assay with 
fluorescently labeled integrin. To label the integrin, Alexa Fluor 647 (Invitrogen A20006) 
was dissolved in acetonitrile at 1mg/ml, aliquoted in 50ul fractions, dried and stored at -
20°C. A 50 ug aliquot of α5β1 integrin (R&D Systems, Inc 3230-A5 Lot OOJ2510121), 
was adjusted to 100 mM sodium bicarbonate and combined with 20 ul dye solution 
(prepared from 50 ug Alexa Fluor 647 dissolved in 5 ul of dimethylformamide plus 45 ul 
of 1 M sodium bicarbonate). The reaction was allowed to proceed for 1.5 hours with 
rotation at room temperature, after which the solution was dialyzed against integrin 
buffer (50 mM HEPES, 200 mM NaCl, 2 mM MnCl2 pH 7.5) using a 20K MWCO 
dialysis cassette (Pierce 66005) to remove unreacted dye. To prevent photobleaching, all 
steps proceeded in the dark.  
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Analysis of single invasin variants via flow cytometry 
Bacterial strains with plasmids encoding full-length invasin variants for surface 
display were grown overnight in LB with ampicillin (150 ug/ml) at 37°C, then diluted 
into fresh media at an OD600 =0.05. Cells were allowed to grow for two hours (OD600 
~0.4-0.8) at 37°C, at which point arabinose was added to 0.2% and expression proceeded 
for an additional two hours. Samples for FACS analysis (1 x 108 cells) were pelleted, 
media removed and cells resuspended in 25 ul integrin buffer (50 mM HEPES, 200 mM 
NaCl 2 mM MnCl2 pH 7.5) with 4% BSA. Next, 25 ul of a 200 nM Alexa Fluor labeled 
α5β1 solution in integrin buffer, was added to each cell sample and allowed to equilibrate 
for 30 minutes at room temperature with periodic gentle agitation, placed on ice for 5-15 
minutes and centrifuged as above. The cell pellets were stored on ice until just prior to 
flow cytometric analysis when they were resuspended in 1 ml of integrin buffer and 
diluted 1:10. For labeling with the 3A2 anti-invasin antibody (65), cells were resuspended 
in 100ul of PBS with 1ul of a 1mg/ml stock antibody solution after the initial harvest. 
After 30 minutes equilibration, cells were pelleted and incubated in 100 ul PBS with 1 ul 
of Cy5-labeled goat anti-mouse IgG (H+L) (Invitrogen A10524) for an additional 30 
minutes, prior to a final resuspension in PBS prior to analysis. Cells expressing alanine 
variants were scanned on a FACSCalibur (Becton-Dickinson), while cells expressing 
variants selected from libraries were analyzed on an LSRFortessa (Becton-Dickinson). 
Data was analyzed using FlowJo software, in which a size gate including ~90% of the 
collected events was determined and the median fluorescence intensity (MFI) within this 
gate reported. 
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Analysis of invasin variant activity by Caco-2 invasion  
The Caco-2 invasion assays were performed similarly to those described by 
Critchley-Thorne et al. (81). Briefly, BL21(DE3) cells were co-transformed with two 
plasmids: (1) pTAK020 encoding full-length invasin variants for surface-display and (2) 
a pET28 plasmid encoding green fluorescent protein (GFP) as a reporter molecule to 
track bacterial internalization. Bacterial cultures were grown as for FACS analysis, but 
diluted to an OD600=0.1 with kanamycin (50 ug/ml) and 1 mM IPTG to support the pET28 
plasmid and a 4-hour expression period, induced upon dilution. Simultaneously, Caco-2 
cells (P23-P33, 5-10 passages after receipt from ATCC) were seeded at a density of 5 x 
104/cm2 in complete media [DMEM (Mediatech, Inc 15-013) supplemented with MEM 
nonessential amino acids (Mediatech, Inc 25-025-CL), penicillin/streptomycin (Gibco 
15140-122), GlutaMAX (Gibco 35050-061), and 10% serum (Gibco 26140-079)] and 
placed in a CO2 incubator (5%) at 37C overnight.  
Immediately prior to infection, the Caco-2 cells were washed twice with DMEM 
without supplements, then provided complete infection media without 
penicillin/streptomycin or serum, but with ampicillin, kanamycin, arabinose, and IPTG at 
the concentrations listed above. Bacteria were added to the cultures at a multiplicity of 
infection of 70, based on seeded Caco-2 cell numbers, using the relationship 1 OD600=1 x 
109 cells/ml and allowed to incubate for two hours at 5% CO2 and 37°C. At this point, the 
Caco-2 monolayer was washed again and placed in complete infection media without 
penicillin/streptomycin and with gentamicin (20 ug/ml) to kill extracellular bacteria. The 
next day, the Caco-2 cells were trypsinized, washed in PBS and stored on ice in PBS + 
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1%FBS prior to scanning with an LSRFortessa (Becton-Dickinson) and analysis as 
above. The populations clearly divided into a bimodal distribution. The percentage of the 
higher fluorescence population, compared to the size-gated total, is reported as the 
percent of Caco-2 cells with high fluorescence, indicating the presence of internalized 
GFP-expressing bacteria. 
Generation of site-directed libraries 
Four libraries were created each with a theoretical library size of ≤3-6x106 in 
order to allow for complete experimental sampling of the library. This was achieved by 
randomizing a small number of residues in each library (ten or fewer) and by using a soft 
randomization procedure to preserve physicochemical properties, which may be 
important for folding or stability. For example, F884 has a hydrophobic side chains and 
faces towards the center of the D4-D5 domains, likely contributing to hydrophobic 
interactions. This residue was mutated using the degenerate codon NTT that encodes 
hydrophobic residues (F, I, L V). Libraries affecting fewer residues utilized degenerate 
codons that sampled larger number of amino acids, such as the NNS codon that samples 
all natural amino acids. All libraries were designed to allow for sampling of the wild-type 
sequence of invasin, using the primers shown in Table 2.4. Library 1, with a theoretical 
library size of 3.98x106, was created using the following degenerate codons 
corresponding to their c-terminal amino acids: 844(KHT), 847(VAK), 858(NTT), 
859(WMC), 860(KHT), 861(MAW), 862(RSC), 863(KHT), 864(KHT), and 865(GAW). 
Library 2, with a theoretical library size of 5.31x106, was created using the following 
degenerate codons: 878(KHT), 870(KHT), 880(NTT), 881(KHT), 882(TMT), 
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883(MRM), 884(NTT), 885(KHT), 887(MAS), and 888(MRG). Library 3, with a 
theoretical library size of 4.19x106, was created using the following degenerate codons: 
809(NNS), 810(NNS), 811(NNS), 812(NNS), and 814(NTT). Library 4, with a 
theoretical library size of 3.15x106, was created using the following degenerate codons: 
908(NWW), 909(NNC), 910(NNC), 911(KHT), 912(NNS), and 913(KMT). The number 
of actual transformants was at least 10-fold greater than the theoretical size for each 
library. 
Libraries were generated using a modification of the protocol described by Sidhu 
and Weiss (120). Briefly, we created inactive invasin templates by introducing stop 
codons or frame shift mutations into the regions targeted for mutagenesis. The templates 
were transformed into E. coli strain CJ236 and infected with M13KO7 helper phage in 
media with uridine to isolate uracil-containing single-stranded plasmid DNA (dU-
ssDNA). Four separate libraries were created with mutagenic primers (Supplementary 
Figure 1). The primers were added to dU-ssDNA templates with T4 ligase and T7 
polymerase to generate a double-stranded heteroduplex with a complementary strand 
containing the mutagenic primer and dTTP. Libraries were generated by transforming 
heteroduplex DNA into electrocompetent MC1061 cells. In all cases, the number of 
transformants was 10-fold greater than their predicted library sizes of 3-6 x 106. Colonies 
were scraped from plates, the cell concentration was measured by absorbance at 600 nm 
and recorded, adjusted to 15% glycerol and frozen at -80°C.  
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Caco-2 based selection of invasin variants 
In order to select for invasin variants able to both target and invade M cells, we 
employed a dual selection approach using bacterial cells with surface-displayed invasin: 
first, a cell-based invasion protocol similar to that described above, followed by a FACS-
based selection employing fluorescent α5β1 integrin. Each library underwent two rounds 
of Caco-2 cell panning, followed by 2-4 rounds of FACS based selection with fluorescent 
integrin, using sequence convergence based on analysis of 6-10 clones per round to 
assess the enrichment process. 
For the two rounds of Caco-2 based cell panning, the first recovers bacterial cells 
adhering or internalized by Caco-2 cells, while the more stringent second round uses 
gentamycin to kill extracellular bacteria, and only propagate clones which have been 
internalized. Caco-2 cells (P23-P33) were seeded into two T-75 flasks using the complete 
media described before, one at 5 x 104 cells/cm2 and one at 1 x 104 cells/cm2, and allowed 
to adhere overnight. Bacterial cultures were grown as above, using a 100 ul aliquot of 
frozen library cells to seed a starter culture, followed by growth and expression in a 20 ml 
culture (101). The Caco-2 cells seeded at 5 x 104 cells/cm2 were washed and prepared as 
described earlier, with complete media containing ampicillin and arabinose, before 3 x 
109 bacteria (MOI ~800) were added for a two hour incubation at 5% CO2, 37°C. Next, 
the Caco-2 cells were washed several times with DMEM base media to remove 
extracellular bacteria. To lyse Caco-2 cells and recover internalized bacteria, ~6 ml of LB 
with ampicillin (150 ug/ml) and 1% Triton X100 was added to the flask for 10 minutes. 
The flasks were then scraped and the contents transferred to microfuge tubes, pelleted 
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and resuspended to remove Triton X-100, and transferred to 20 ml of TB with ampicillin 
and 2% glucose for overnight growth at 37°C.  
The following day, 1 x 109 bacterial cells from the overnight culture were 
inoculated into 20 ml of fresh LB with ampicillin, for expression and infection as above 
using the other T-75 flask seeded at 1 x 104 cells/cm2 two days prior. After 2 hours of 
infection at an MOI ~800, the flask of infected Caco-2 cells, were washed with DMEM 
base, followed by DMEM supplemented with MEM nonessential amino acids, 
GlutaMAX, 10% serum, ampicillin, arabinose, and gentamycin for overnight incubation. 
Bacterial cells were recovered as described above and fractions (<1%) of the recovered 
cells were plated for sequence analysis. Overnight cultures were either subcultured or 
frozen for subsequent FAC-based selection rounds.  
FACS-based selection of invasin variants 
After Caco-2 cell panning, libraries were grown and expressed as previously 
described for Caco-2 panning. After expression, cells (~1 x 108) were labeled with 
fluorescent α5β1 (100nM-250nM) as described earlier and stored on ice. The 
concentration of the label was reduced during subsequent rounds of sorting. Cells were 
diluted in integrin buffer such that they could be sorted at rates between 1,000-5,000 
events per second. The forward scatter and side-scatter thresholds were adjusted to 
remove debris in the FACS buffer, which improved the electronic abort rate. A size gate 
was set to encompass ~90% of events. Initial sorting rounds were less stringent and 
sorted 3-5% of the most fluorescent events, while later sorting rounds became more 
restrictive, collecting only the top 0.5-1%. Sorted cells were collected in 15 ml conical 
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tubes holding ~2 ml of cold LB with ampicillin and glucose. Fractions of collected cells 
were plated after each round to analyze cell viability and sequence convergence. The 
remaining collected cells were grown overnight for subsequent rounds of sorting and 
freezing of aliquots from each round.  
Expression & purification of soluble invasin variants 
To compare the integrin binding abilities of different invasin variants, a soluble 
version of invasin consisting of the minimal receptor binding domains (D4-D5, residues 
795-986) was expressed in the E. coli cytoplasm. To enhance expression levels and 
solubility, these domains are expressed as a c-terminal MBP fusion, as performed 
previously (68). To generate this construct, the D1-D5 domains were first amplified from 
plasmid pRI203 using primers TAK46 and 47 and cloned into vector pMAL-c5x (NEB) 
using SacI/NcoI restriction sites to generate plasmid pTAK035 (MBP-D1D5)(Figure 
2.1B). Domains D1-D3 were deleted using PCR-based plasmid mutagenesis, as above, to 
create plasmid pTAK039 (MBP-D4D5)(Figure 2.1B). Invasin variants selected from 
mutagenic libraries were either sub-cloned into pMAL-c5x or generated by site-directed 
mutagenesis of pTAK039.  
The pTAK035 plasmid was transformed into E. coli strain Origami B to support 
formation of the lone di-sulfide bond in the D4-D5 region during cytoplasmic expression 
(EMD Chemicals). To further enhance expression levels, the 17 kilodalton (Skp) 
chaperone was co-expressed from a compatible expression vector, pAR3-Skp without its 
native periplasmic leader sequence (121). Starter cultures grown in LB with ampicillin 
(150 ug/ml), chloramphenicol (34 ug/ml), kanamycin (15 ug/ml), tetracycline (12.5 
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ug/ml), 0.2% glucose were sub-cultured into 250 ml of Terrific Broth (TB) containing the 
same additives. After ~16 hours growth at 37°C, the cells were harvested and 
resuspended in fresh TB with antibiotics, but without glucose, and shaken at 25°C and 
225 RPM. After 30 minutes, arabinose was added to a final concentration of 0.2%, after 
another 30 minutes, IPTG was adjusted to 1 mM, and expression continued for ~4-5 
hours. Cells were then harvested and frozen at -80°C, resuspended and lysed via French 
Press with a standard cell (Thermo Electron). To minimize degradation, complete 
protease inhibitor tablets (Roche Diagnostics) were immediately added and the cell lysate 
clarified via centrifugation at 4°C for 45-60 minutes at 20,000 RPM and syringe filtered 
through 45 μm PVDF filter (Millipore). The protein were purified using an MBPTrap HP 
(5 ml) column on an ÄKTA FPLC system followed by size exclusion chromatography 
using a HiLoad 16/600 Superdex 200pg column (GE Healthcare). Protein purity was 
analyzed by non-reducing SDS-PAGE, in which samples were heated in loading buffer 
without DTT and run on a Mini-PROTEAN electrophoresis cell (Bio-Rad) using a 4-15% 
TGX Gel (Bio-Rad).  
ELISA analysis integrin binding by soluble MBP-INV  
ELISAs were used to assess the relative affinity of different invasin variants for 
relevant integrins. ELISA plates (96 well high-binding plates; Costar) were coated with 
recombinant, soluble versions of the extracellular α5β1 or α3β1 integrin domains (R&D 
systems 2840-A3-050 and 3230-A5-050) in PBS at ~3 ug/ml overnight at 4°C. Coated 
plates were blocked with 5% milk in PBS and washed with binding buffer (50 mM 
HEPES, 200 nM NaCl, 2 mM MnCl2, 0.05% Tween20). Purified MBP-invasin variants 
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were added to the plates in a 1:3 dilution scheme from 1000 nM in blocking buffer (50 
mM HEPES, 200 nM NaCl, 2 mM MnCl2, 1% milk) and allowed to equilibrate for 1.5 
hours. The addition of 2 mM MnCl2 was found to enhance invasin-integrin binding (data 
not shown)(67). Plates were washed again, followed by anti-MBP antibody-HRP 
conjugate (New England BioLabs E8038S) at a 1:3333 dilution in blocking buffer for 1 
hour. All incubation steps were performed at room temperature with shaking. The plates 
were washed a final time prior to the addition of TMB substrate (Pierce 34021), 
quenching with 1N HCL and the absorbance measured at 450 nm. All statistical analysis 
was performed using Prism 5 (GraphPad Software, Inc.). ELISA data was fit using a 3-
parameter nonlinear curve fit with the bottom parameter shared between curves.  
Melting Temperature and Circular Dichroism Measurements 
The melting temperature of purified protein was assessed using protein solutions 
(3.2 mg/ml) and Sypro Orange (1:6,000 dilution). The solution temperature was gradually 
increased (1 degree C per minute) and fluorescence was recorded using a ABI 7900HT 
Fast Real-Time PCR System. As the protein denatures, the Sypro Orange is able to access 
hydrophobic regions of the protein, resulting in fluorescence activation. The inflection 
point of temperature, fluorescence plots is reported as the derivative Tm. Circular 
Dichroism (CD) measurements were made using a Jasco-J815 CD Spectrometer from 
260 nm to 185 nm (1 nm increments) in a 5 mM phosphate buffer. 
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Chapter 3: Polymeric Antigen Delivery System Formulation and 
Characterization 
INTRODUCTION 
Oral administration is the preferred route for any therapeutic agent. Beyond 
simple administration benefits, vaccination via the oral route can lead to the induction of 
mucosal immune responses, such as secretory IgA (122). Antigen specific IgA in 
mucosal compartments can prevent pathogens from gaining entry into systemic 
circulation. Unfortunately, oral delivery of subunit vaccines is extremely challenging due 
to the proteolytic environment of the GI tract and the small number of intestinal cells 
capable of transporting antigenic material to lymphoid tissue in the lamina propria (9, 
88). The cells that are responsible for transporting particulate matter for immune 
processing are termed M cells. These M cells have become the primary target for oral 
vaccine delivery systems (9, 88, 90). 
Researchers have improved immune responses to oral subunit vaccines by 
targeting M cells using a variety of targeting molecules (40, 42, 71, 92, 93). The methods 
used to target M cells have relied on identifying ligand-receptor pairs that preferentially 
target M cells, including the NKM 16-2-4 antibody, CKS9 peptide, UEA-1 lectin, and 
cholera toxin B subunit, with varying effects on the ultimate immune responses (91). For 
instance, while UEA-1 effectively targets M cells in the mouse model, in humans, goblet 
cells also express the targeted receptor, reducing the specificity of that molecule (123). 
Several studies have demonstrated protein engineering techniques that yielded ligands 
targeting M cells (91, 93). Nochi et al. generated a rat IgG2c that specifically recognizes 
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mouse M cells and when utilized in an oral vaccine formulation results in a protective 
immune response. However, it was determined that the receptor recognized is α(1,2) 
fucose, which is also present on mouse goblet cells (123). The specificity of this antibody 
to murine M cells over goblet cells may be due to glycosylation differences between 
α(1,2) fucose on these two cell types, a difference which may not be preserved in 
humans. Last, a phage displayed peptide library was used to identify a nonameric peptide 
binding a human in vitro M cell model (124). While this was identified with human cells 
and targeting validated in the rat intestine, peptides typically exhibit weak affinity due to 
their small size and may not be as useful.  
Given the expression variations across species, developing vaccines using ligands 
binding known markers on the M cell surface of multiple species (including humans), 
such as α5β1 integrin would be advantageous (32, 57, 59). Using such ligands may show 
better correlations between preclinical and clinical studies. Reports targeting α5β1 
integrin using RGD peptides improved immune responses, compared to particles without 
ligand (42). The invasin ligand discussed in depth in Chapter Two is another potential 
ligand for targeted oral vaccines. 
In addition to its adhesion activities, invasin also possesses adjuvant activity, 
rendering it more attractive as targeting ligand for oral vaccine formulations (74, 90). 
Invasin can directly stimulate T cells when immobilized on a plate (76). Incubation of 
HeLa cells with 1μm polystyrene beads coated with an ovalbumin-invasin fusion protein 
resulted in increased IL-8 secretion, which is an innate immune system chemoattractant 
(80). After intraperitoneal injection of the same beads, systemic increases in CD4 and 
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CD8 T cells and splenocyte production of IL-4 and INF-γ was observed (80). When E. 
coli co-expressing invasin, ovalbumin, and listeriolysin O were orally administered to 
mice prior to challenge with an ovalbumin-expressing tumor, final tumor volumes were 
~25% the size of unvaccinated mice, indicating the presence of a strong anti-ovalbumin 
immune response (81). 
In order to facilitate efficient oral vaccination, polymeric microparticles were 
designed to entrap antigen and be decorated with the invasin targeting protein. These 
microparticles should transit through the stomach and small intestine, upon which they 
will encounter rare M cells. The targeting protein, invasin, should then specifically 
engage α5β1 integrins on the apical M cell surface and trigger phagocytosis. The 
microparticles should then be transcytosed through the M cells, being released in Peyer’s 
patches where they would encounter lymphocytes that initiate immune responses directed 
against the entrapped antigen. This mechanism is shown in the schematic below (Figure 
3.1). 
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Figure 3.1: M cell targeting and particle uptake schematic 
 Poly(lactic-co-gycolic acid) (PLGA) is a biodegradable and biocompatible 
polymer that can be used to entrap water soluble molecules by forming a water-in-oil-in-
water emulsion, followed by solvent evaporation (Figure 3.2). PLGA particles have been 
used in numerous oral vaccine studies, providing a good base to build upon for testing the 
benefits of targeting M cells using the invasin variants generated and discussed in 
Chapter Two (9, 87). During particle synthesis, soluble antigens can be loaded by 
incorporating them in the inner aqueous phase. This inner aqueous phase is emulsified 
with an organic phase, which is used to solubilize the PLGA polymer. This primary 
emulsion is then added to a secondary aqueous phase and emulsified again. This double 
emulsion has an aqueous continuous phase, suspending droplets of the organic solvent. 
The organic solvent droplets contain smaller droplets of the inner aqueous phase. This 
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double emulsion is allowed to stir for several hours, causing evaporation of the organic 
phase. This solvent evaporation step precipitates the PLGA polymer, generating particles 
entrapping the protein in the inner aqueous phase.  
  
Figure 3.2: Water-In-Oil-In-Water emulsion process for encapsulation and release of 
proteins (modified and reproduced with permission)(24) Primary emulsion: water phase 
with solubilized protein is dispersed in oil phase with solubilized PLGA. Some protein is 
denatured at the interface, where hydrophic regions lie in the oil phase and hydrophilic 
regions are maintained in the water phase. Secondary emulsion: droplets from the 
primary emulsion are dispsersed in a second water phase. Some protein is leaked from 
the inner water phase through channels formed during emulsification. Freeze drying: 
during freezing and lyophilization, proteins can become denatured and aggregated. 
Release: once rehydrated, protein diffuses through pores in the PLGA particles. Over 
time the PLGA is hydrolyzed, causing bulk erosion, which expands the porosity of the 
particles. 
RESULTS AND DISCUSSION 
Particle Morphology Effects Due to Antigen/Excipient Loading 
 The designed oral vaccine delivery system relies on encapsulation of antigen in 
the PLGA microparticles by incorporating antigen, ovalbumin, as a soluble molecule 
within the inner water phase of the double emulsion. PLGA microparticles were initially 
synthesized using a previously described protocol to entrap siRNA in the inner water 
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phase (7). The protocol was modified by substituting a different emulsifying surfactant 
(PEMA), shown to increase the amount of protein able to be coupled to the particle 
surface (detailed discussion in the following section). Upon incorporating ovalbumin 
within the inner aqueous phase, we observed changes in particle morphology. At low 
ovalbumin concentrations, there was increased size and polydispersity. At higher 
concentrations, spherical morphology was lost (Figure 3.3). 
No OVA 10 mg/ml OVA 
  
30 mg/ml OVA 60 mg/ml OVA 
  
Figure 3.3: SEM images of particle morphology effects due to antigen loading. 
Lyophilized PLGA preparations were sputter coated with Pt/PD and imaged via SEM. As 
the concentration of ovalbumin is increased in the inner water phase, polydispersity is 
increase and the spherical morphology is lost.     
 While ovalbumin could be encapsulated at low loading concentrations, in order to 
achieve the desired dose (100 ug of antigen) the particle concentration suitable for oral 
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murine trials would be too high for forming a well behaved suspension. Along with 
trying to increase antigen loading, we wanted to ensure high quality antigen is loaded. 
Protein encapsulated within PLGA particles are known to undergo chemical and physical 
changes during the emulsion process as well as release (24). These changes can alter the 
epitopes recognized by B and T cell receptors, potentially producing irrelevant immune 
responses. Emulsification causes the protein to become exposed to oil-water interfaces, 
which can result in protein denaturation. To circumvent this interaction, researchers have 
added protein-stabilizing molecules to formulations. Trehalose has been shown to result 
in more complete protein release and recognition by antibodies in ELISA assays (24, 125, 
126). Mg(OH)2 has also been able to improve release profile and neutralize the acid 
environment generated during PLGA hydrolysis (24, 126, 127). However, the addition of 
these agents result in increased osmotic pressure, producing particles with large pores and 
poor encapsulation efficiency. 
An alternative method to stabilizing proteins in PLGA particles is to avoid the 
inner oil-water interface by adding the protein directly to the oil phase, being termed 
solid/oil/water (S/O/W) emulsion (24, 128). Protein addition directly to the oil phase 
kinetically traps the protein in its native structure, assuming the protein is not soluble in 
the organic solvent used (23). While this method works well to form larger particles (>10 
um), this process relies on the protein to be present in the organic phase at sizes smaller 
than the desired polymeric particle size. The ovalbumin we used to create particles is 
commercially provided as a lyophilized powder with large particle sizes. Therefore, the 
protein was micronized by solubilizing with the trehalose at a 1:2 mass ratio, frozen by 
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the spiral-wound in-situ freezing technique (SWIFT) method described in Chapter Five, 
and lyophilized. A powder was generated, with features much smaller than the 
commercially provided material (Figure 3.4). 
Commercial OVA SWIFT Prepared OVA 
  
Figure 3.4: SEM images of micronized of ovalbumin powder. Protein powder were 
sputter coated with Pt/PD and imaged via SEM. Commercial Sigma Grade V ovalbumin 
powder (left) has particle sizes much larger than 10 um, while SWIFT prepared 
ovalbumin has characteristic lengths less than 5 um. 
The SWIFT prepared OVA was added to oil phase and attempted to be made into a 
dispersion along with Mg(OH)2. However, presence of the SWIFT powder, containing 
OVA, greatly reduced the ability to form spherical particles (Figure 3.5.) 
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S/O/W (No OVA) S/O/W (w/ OVA) 
  
Figure 3.5: SEM images of S/O/W preparation with and without OVA. Lyophilized 
PLGA preparations were sputter coated with Pt/PD and imaged via SEM.PLGA particles 
were synthesized without an inner water phase (left). Micronized OVA was added 
directly to the oil phase, resulting in loss of uniform particle formation (right). Both 
formulations contained the same excipients except for the addition of ovalbumin. 
The S/O/W process was unable to effectively encapsulate ovalbumin to form 
particles smaller than 5 μm. The lack of spherical PLGA particle formation from this 
process is likely due to two factors: protein powder particle size relative to PLGA particle 
size and protein localization at the oil-water interface. The latter factor is likely to be the 
primary concern for ovalbumin. When PLGA particles encapsulating ovalbumin are 
dissolved in DCM and then mixed with an aqueous phase, there is a relatively small 
amount of protein able to be extracted to the aqueous phase (compared to other proteins 
such as BSA and lysozyme) (129). We also observed an inability to efficiently extract 
ovalbumin from DCM into an aqueous phase after extended mixing, measured by size 
exclusion HPLC (data not shown).  
Given the lack of particle formation using the S/O/W process, efforts were 
directed towards stabilizing the particles formed by the W/O/W double emulsion process. 
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Prior literature has shown the inclusion of solute, such as sucrose or NaCl, into the outer 
aqueous phase increases protein encapsulation efficiency (130, 131). This effect may be 
driven by balancing the osmotic pressure between the inner and outer aqueous phases 
and/or altering the electric double layer of the droplets. It is likely that the external phase 
additives stabilize emulsion droplets, preventing coalescence. Therefore, we tested 
several conditions incorporating various solute amounts to the external aqueous phase 
during the W/O/W double emulsion process (figure 3.6).  
No External Phase Additive 5% Sucrose 5% NaCl 
   
Figure 3.6: SEM images comparing morphology effects of external aqueous phase 
additives. Lyophilized PLGA preparations were sputter coated with Pt/PD and imaged 
via SEM. PLGA particles formed without any external phase additives (left) were highly 
porous and lacked spherical morphology. The addition of 5% sucrose w/v to the external 
aqueous phase (center) exhibited an improved morphology, while still showing high 
polydispersity and porosity. Particles formed when 5% NaCl w/v was added to the 
external aqueous phase (right) revealed no observable porosity and showed reduced size 
and polydispersity. 
 While the addition of 5% sucrose exhibited a slight improvement on particle 
morphology, the addition of 5% NaCl had a dramatic effect. Particles formed by the 
addition of NaCl were not porous, considerably smaller, and less polydisperse. All of the 
above formulations were produced with the same amount of Mg(OH)2 added to the 
organic phase, and both trehalose and ovalbumin added to the inner aqueous phase. 
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Adjusting the NaCl concentration from 2.5% to 7.5% had no noticeable changes in 
morphology (data not shown). The final formulation consisted of a 1.25:1.00 
trehalose:ovalbumin mass ratio in the inner aqueous phase and a 2.1% w/w 
Mg(OH)2/PLGA concentration.  
SEM images did observe occasional patches of particles that appeared to exist 
within a continuous phase. By reducing the amount of PEMA in the aqueous phase 
during the solvent evaporation step from 1% to 0.3% w/v particle size and morphology 
was unaffected, but the continuous phase observed by SEM was considerably less. 
Incorporating more rigorous washing steps after solvent evaporation, such as vortexing 
and water bath sonication, further reduced this continuous phase. The optimized 
formulation exhibiting high quality particle morphology is shown below in Table 3.1. 
Phase/Excipient Amount 
Inner Aqueous Phase 
Ovalbumin 
α,α Trehalose 
300 μl 
40 mg/ml 
50 mg/ml 
Oil Phase 
PLGA 
Mg(OH)2 
8 ml 
350 mg 
7.5 mg 
External Aqueous Phase (pH 7.5) 
PEMA 
NaCl 
50 ml 
1% w/v 
5% w/v 
Solvent Evaporation Solution (pH 7.5) 
PEMA 
NaCl 
100 ml 
0.3% w/v 
5% NaCl 
Table 3.1: Optimized PLGA particle formulation recipe 
When this optimized formulation is used with the traditional emulsifying 
surfactant PVA instead of PEMA, a noticeable difference in morphology is observed. 
While the particle size is similar, the surface of PVA prepared particles is considerably 
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more ruffled, shown in Figure 3.7. This ruffling effect in the PVA formulated particles is 
not seen when OVA, Mg(OH)2, trehalose, and NaCl are added to the formulation.  
PEMA PVA 
  
Figure 3.7: SEM images of morphology effects in optimized formulation due to 
surfactant. Lyophilized PLGA preparations were sputter coated with Pt/PD and imaged 
via SEM. Particles formed using PEMA show a smooth surface, while particles formed 
with PVA exhibit a highly ruffled surface.   
Particle Display and Encapsulation of Protein 
The above formulation was used to analyze the ability to display proteins on the 
particle surface. Employing acid end-capped PLGA in the synthesis process results in 
free carboxylic acid groups on the particle surface, which can then be used to generate 
amid bonds with molecules possessing primary amine groups (such as those found on 
lysines and the n-terminus of proteins). However, it has been shown that the emulsifying 
surfactant can become embedded at the particle surface, which may block accessibility to 
the PLGA carboxylic acid groups (132). The synthesis protocol was modified by 
switching the emulsifying surfactant from poly(vinyl alcohol) (PVA) to poly(ethylene-
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alt-maleic acid) (PEMA) used in the outer aqueous phase, previously shown to increase 
the amount of molecules able to be coupled to particle surface (133). PEMA contains 
carboxylic acid groups, which support additional sites for amide bond formation. The 
chemical structures for acid-end capped PLGA, PVA, and PEMA are shown below in 
Figure 3.8. 
 
   
Acid End-Capped PLGA PVA PEMA 
Figure 3.8: Chemical structures of polymers used for particle synthesis  
 
In order to test the effects of emulsifying surfactant substitution, we used 1-Ethyl-
3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (Sulfo-NHS) chemistry to conjugate MBP-497 to the particle 
surface. We then measured coupling efficiency by labeling the particles with a mouse 
anti-invasin antibody, followed by a fluorescent anti-mouse antibody, then analyzed 
particles by flow cytometry. The amount of coupled MBP-497 is greatly influenced by 
the emulsifying surfactant. This surfactant substitution resulted in a ~20 fold increase in 
fluorescence signal for particles coupled to a fusion protein consisting of maltose binding 
protein and the c-terminal 497 amino acids of invasin (MBP-497)(Figure 3.9). 
Lengthening the reaction time, from 2 hrs to 21 hrs, increases the amount of coupled 
protein by ~3 fold when using PVA. However, when PEMA is used the increased time 
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only increases the fluorescence shift by ~1.2 fold. These relative differences in the 
amount of conjugated protein are likely affected by the amount of carboxylic acid groups 
found on the particle surface and the amount of MBP-497 added to the reaction (0.3 
mg/ml).  
  
 
 
Figure 3.9: Flow cytometry histogram plots showing amount of coupled protein can be 
tuned using emulsifying surfactant. PLGA particles were either formed with PVA (blue) 
or PEMA (red). The particles were then labeled with 3A2 mouse anti-invasin mAb, 
followed by a fluorescent anti-mouse antibody. The solid color profiles without a bold 
border correspond to particles not conjugated to MBP-INV. Particles undergoing a 2 hr 
reaction with MBP-INV are shown as profiles with only a bold color border. Overnight 
(21 hrs) reaction coupling reactions are shown as shaded profiles with a bold color 
border.  
 The MBP-497 protein used consists of maltose binding protein genetically fused 
to the extracellular 5 domains of invasin. The D4-D5 domains are responsible for 
receptor binding, while the D2 domain facilitates self-association forming dimers and 
tetramers (96). We compared the ability of an anti-invasin antibody to recognize the D4-
D5 binding domain of particles coupled to MBP-INV fusion proteins containing all 5 
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extracellular domains or just the D4-D5 domain (MBP-192). While the MBP-497 version 
is known to produce increased avidity, MBP-192 has a smaller molecular weight (62 kDa 
vs. 93 kDa). Thus, it was postulated that a smaller molecular weight protein might be able 
to pack more efficiently on the particle surface, increasing effective avidity when 
immobilized to the particle surface. We also compared the use of EDC/Sulfo-NHS and 
EDC alone in the coupling reaction (Figure 3.10). The Sulfo-NHS is able to stabilize the 
activated carboxylic acid groups, but is considerably more costly than EDC. It is 
recommended to increase the activation time when Sulfo-NHS is employed, to increase 
the number of carboxylic acid groups that become activated. In the EDC/Sulfo-NHS 
reaction, the activating molecules were allowed to react for two hours prior to their 
removal and addition of MBP-INV. In the EDC reactions, the amount of EDC utilized 
was doubled and the activation period was terminated after 30 minutes, to reduce the time 
unstable activated carboxylic acids are in solution.  
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Figure 3.10: Conjugation of MBP-INV to PLGA particles effects based on reaction 
conditions. The MFIs of anti-invasin labeled particles are plotted as a function of protein 
concentration in reaction conditions, mass concentration (left), molar concentration 
(right). MBP-INV in with the c-terminal 497 amino acids of invasin (D1-D5) are shown 
in red and purple, while the c-terminal 192 amino acid version (D4-D5) are shown in 
green and blue. Reactions were carried out with either EDC alone (red and blue) or EDC 
and sulfo-NHS (green and purple).  
The MBP-497 version exhibited higher amounts of anti-invasin recognition in 
both EDC only and EDC/Sulfo-NHS reactions, compared to MBP-192. The EDC only 
reactions also displayed higher fluorescence compared to EDC/Sulfo-NHS reactions. 
These results led to future preparations to be formulated in reactions with the MBP-497 
version and without the addition of Sulfo-NHS. The MBP-497 version with EDC only 
begins to show saturation near 10 mg/ml, which is critical for achieving optimal receptor 
binding. Preparing formulations near this saturating concentration is also important for 
reducing batch-to-batch variability, since the relative amount of coupled protein is less 
affected by the protein concentration. 
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During the process of optimizing the reaction conditions for coupling protein to 
the particle surface, we attempted to use ovalbumin in proxy of MBP-INV, due to it 
being readily available and inexpensive. However, we were unable to detect significant 
changes in flow cytometry fluorescence after conjugation, using an anti-ovalbumin 
antibody as a primary label. We found significant amounts of ovalbumin to be present on 
the particle surface after encapsulation, before conjugation (Figure 3.11). Even after 
conjugation of MBP-INV, a large fluorescence shift specific to OVA was observed, 
relative to particles not encapsulating OVA. This shift was much more marked in 
particles formed using PEMA, rather than PVA (while total OVA loading levels were 
similar: 21 and 16 ug OVA/ mg particles, respectively). The reason for higher surface 
displayed OVA in particles formulated with PEMA, compared to PVA, is likely due to 
OVA preferentially interacting with PEMA during the emulsification process.  
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Figure 3.11: Flow cytometry histogram plots of surface displayed OVA after 
encapsulation. Particles were labeled with a mouse anti-OVA mAb, and fluorescent 
secondary anti-mouse antibody, followed by flow cytometry analysis (left). The 
formulation conditions are shown in the legend (right). The MBP-INV used for 
conjugation was wild-type in the D1-D5 construct.  
 In order to claim in vivo immune response differences between particles 
(conjugated to different MBP-INV variants) are due to the affinity, it is important to 
measure the relative amount of protein on the particle surface as well as the activity of the 
variants. We employed the flow cytometric analysis techniques used above to measure 
these properties. The variants of interest are: a version that has greatly reduced binding 
capability via a single amino acid substitution (D911A), the wild-type invasin sequence, 
and the optimized invasin variant engineered in Chapter Two (RGD844). Since the 3A2 
anti-invasin antibody used to stain MBP-INV binds the D4-D5 domain, where the 
variants’ substitutions are located, it was possible the anti-invasin antibody has altered 
affinity towards the MBP-INV variants. Therefore, an anti-MBP antibody was used to 
bind a region of the MBP-INV that is constant between the variants, along with the anti-
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invasin (Figure 3.12). All samples were analyzed after resuspension of a lyophilized 
powder.  
Anti-MBP Anti-INV 
  
Fluorescent α5β1 Legend 
 
 
Figure 3.12: Characterization of MBP-INV variants on particle surface via flow 
cytometry. PLGA particles were conjugated to MBP-INV (D1-D5 version) with either 
the D911A substitution (red), the wild-type sequence (green), or the optimized α5β1 
integrin binding variant RGD844 (black). Unconjugated particles are shown in blue. To 
measure the relative amount of surface conjugated protein, the particles were labeled with 
anti-MBP (top left) or anti-invasin (top right), followed by a fluorescent secondary 
antibody, and analyzed via flow cytometry. The relative activity of the conjugated MBP-
INV variants was measured by labeling particles with fluorescent α5β1 integrin (bottom 
left). Color-coded legend is shown in the bottom right.  
 The fluorescence profiles measuring the presence of different MBP-INV variants 
show no discernible difference and also indicate that the 3A2 anti-invasin antibody 
binding is unaffected by the substitutions in the D911A and RGD844 variants. However, 
there is considerable difference between the fluorescent signatures of particles labeled 
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with the fluorescent α5β1 integrin. The fluorescence shifts due to integrin recognition 
agree with those expected due to binding ability of the variants measured in Chapter Two 
(RGD844 has the highest fluorescence, followed by wild-type, and then D911A). This 
indicates that differences observed by any in vivo immune responses are not due to 
variability in the amount of targeting protein coupled to the particle surface, but rather 
their ability to target M cells and/or increase adjuvanticity.  
In Vitro Costimulation of Antigen Presenting Cells 
 Prior literature has shown invasin derived from Yersinia to have adjuvant 
properties. One study demonstrated a peptide from invasin directly engages integrins on 
the surface of T cells, resulting in proliferation and cytokine release (76). Another study 
has shown IL-8 release from HeLa cells when stimulated by particles with invasin on 
their surface (80). This adjuvanticity is believed to be caused by clustering of integrin 
receptors, leading to activation of the Rac-1 pathway (78). We sought out to test whether 
invasin was capable of upregulating costimulatory molecules on antigen presenting cells 
expressing α5β1 integrin, RAW 264.7 macrophage cells (134). Therefore we added 
particles conjugated to MBP-INV to cultures of RAW 264.7 cells and measured changes 
in the surface costimulatory molecules CD-40 and CD-86 via flow cytometry (Figure 
3.13). The presence of MBP-INV was found to be significantly different from 
unconjugated particles and the relative amounts of D911A and wild-type variants found 
to be similar, measured by anti-invasin and flow cytometry.  
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Figure 3.13: Flow cytometry co-stimulation analysis of RAW 264.7 cells incubated with 
MBP-INV conjugated PLGA particles. RAW 264.7 macrophage cells were incubated 
with PLGA microparticles overnight, stained with fluorescent anti-CD40 and anti-CD86 
antibodies, then analyzed via flow cytometry. Analysis of cells incubated with 100 ng/ml 
LPS (no particles) is shown in the bottom right. 
 Overnight incubation of PLGA particles conjugated to wild-type MBP-INV 
induced significant increases in CD-40 and CD-86 expression on RAW 264.7 cells, 
compared to unconjugated particles. However, the D911A version, which has a 
substantially diminished ability to bind integrin receptors also showed the same marked 
increase in costimulation. This same effect was also observed in our LPS control, which 
is a well known adjuvant that upregulates costimulation via interaction of TLR-4 (135). 
Since the MBP-INV protein was prepared from bacteria the upregulation of 
costimulatory molecules in the RAW 264.7 cells is likely due to LPS contamination. 
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Traditionally, vaccine formulations avoid the presence of endotoxins such as LPS, due to 
the inflammatory responses induced by MyD88 activation. However, responses to LPS 
by intestinal immune cells is muted in order to accommodate colonization of commensal 
bacteria in the GI tract (50). Given that any oral vaccine is likely to become contaminated 
by LPS via transit through the GI tract and the lack of its ability to activate TLR-4 in 
intestinal immune cells, the LPS contamination is not a concern. However, this LPS 
contamination did impede our ability to investigate the ability of invasin to activate RAW 
cells via integrin engagement. Therefore we attempted to remove LPS from the MBP-
INV preparations using an established procedure of washing the protein with a detergent, 
Triton-X114 (136). The RAW activation assay was carried out as above, but using 
particles conjugated to protein washed with Triton-X114 (Figure 3.14). 
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Figure 3.14: Flow cytometry analysis of co-stimulation using particles conjugated to 
protein treated with Triton-X114. RAW 264.7 macrophage cells were incubated with 
PLGA microparticles overnight, stained with fluorescent anti-CD40 and anti-CD86 
antibodies, then analyzed via flow cytometry. The wild-type and D911A MBP-INV 
protein was washed with Triton-X114 prior to conjugation to the PLGA particles. 
Analysis of cells incubated with 100 ng/ml LPS (no particles) is shown in the bottom 
right.  
 After the Triton-X114 treatment both the D911A and wild-type particles produce 
similar responses to the unconjugated microspheres and untreated cells (not shown). The 
presence of MBP-INV was found to be significantly different from unconjugated 
particles and the relative amounts of D911A and wild-type variants found to be similar, 
measured by anti-invasin and flow cytometry (data not shown). While the activity of the 
conjugated wild-type MBP-INV variant was not measured, short invasin peptides have 
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been shown to stimulate T cells through α5β1 integrin (76) and denatured invasin has 
been shown to mediate cell adhesion (68). While our data does not show invasin 
costimulatory activation in RAW 264.7 cells, activation may be observed in more 
representative APCs, such as primary bone marrow derived dendritic cells. 
Protection of Invasin after Conjugation to PLGA Particles 
 In order to demonstrate vaccine efficacy due to M cell targeting, it is important to 
characterize the capacity of invasin to recognize α5β1 integrin after processing, storage, 
and transit through the GI tract. Therefore, we investigated various storage and 
lyophilization excipients on their ability to maintain protein activity and protection from 
proteolytic cleavage. Lyophilization of proteins is known to increase the stability of 
proteins, by maintaining the formulation in a dry kinetically trapped state (137). This 
prevents aggregation caused by collisions between partially denatured proteins. However, 
lyophilized protein can result in activity loss due to the freezing, dehydration, and 
rehydration prior to administration. A major factor contributing to this activity loss is 
believed to be caused by destabilization due to loss of the hydration shell around proteins, 
during drying (137). The addition of trehalose is able to act as a lyoprotectant that 
stabilizes solvent exposed polar amino acids, by replacing water molecules (138). 
Therefore, we added trehalose to the particles prior to lyophilization to evaluate its effect 
on improving α5β1 integrin recognition (Figure 3.15). The particles were resuspended 
and labeled with fluorescent α5β1 integrin and analyzed by flow cytometry. 
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Figure 3.15: Flow cytometry analysis of surface immobilized MBP-INV activity loss due 
to freezing/lyophilization conditions. PLGA microparticles were conjugated to either the 
D911A, wild-type, or RGD844 variant of MBP-INV (D1-D5 version) and subjected to 
either 4-day refrigeration as a suspension (white bars), freezing/lyophilization in 5 mM 
HEPES pH 7.5, or freezing/lyophilization in 5 mM HEPES pH 7.5 plus 10 mg/ml 
trehalose. The particles were then labeled with fluorescent α5β1 integrin and analyzed 
via flow cytometry. MFIs for samples prepared in parallel are shown. 
 The three variants (D911A, wild type, and RGD844) were evaluated for α5β1 
recognition after storage as a liquid at 4°C for 4 days, compared to two 
freezing/lyophilization conditions. All samples were frozen and resuspended, or stored 
(refrigerated sample), in 5 mM HEPES at pH 7.5 at 10 mg/ml. For the trehalose 
condition, the ratio of trehalose to particles prior to freezing in liquid nitrogen was 
adjusted to 1:1 mass ratio. There were only slight differences in variations between 
storage/lyophilization conditions. The total signal variation between the refrigerated 
samples and samples frozen without trehalose was calculated to be 1.1% (Two-way 
ANOVA, P value=0.0137). While this variation is not dramatic, it is expected to increase 
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as storage time lengthens. The refrigerated particles clearly sedimented after storage and 
this condition exhibited the least α5β1 recognition. This sedimentation is likely to lead to 
increased protein denaturation by increasing the probability of collisions between 
partially denatured proteins. The difference between samples frozen with and without 
trehalose was even less, yielding a value of 0.2% (Two-way ANOVA, P value=0.0222). 
Therefore, we concluded the addition of trehalose as a lyoprotectant was unnecessary. 
 Another potential loss of invasin activity is in vivo denaturation and degradation 
during transit along the GI tract. The GI tract is designed to degrade proteins to destroy 
pathogens and promote digestion, which is likely to affect a protein based oral targeting 
vaccine (139). Oral infection of bacteria has shown proteolytic degradation to be concern 
for invasin, primarily mediated by serine proteases (140). Efforts have been made to 
protect proteins during GI tract transit, via formulation with polymers that are insoluble 
or collapsed at low pH, which dissolve or expand at more neutral pH (141). The pH 
increases along the length of the GI tract in humans, ranging from below pH 5 in the 
stomach then increases to 6.5 in the duodenum and becomes neutral in the colon (142). 
These formulations shield proteins from the acidic pH and pepsin found in the stomach, 
then release the encapsulated payload in the small intestine. The invasin-conjugated 
microparticles could be simply granulated and enteric coated using a fluidized bed to 
enable protection during GI tract transit. However, the pellet size of particles needed for 
fluidized bed coating would be too large to pass through pylorus of a rodent, our initial in 
vivo model to measure immune responses.  
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 In order to form enteric coated particles suitable for oral rodent delivery, we 
investigated microencapsulation of the PLGA microparticles with a methacrylic 
copolymer via spray drying. Peyer’s patches, containing M cells, are more prevalent in 
the distal small intestine (143). Therefore, we choose Eudragit S100 as an enteric 
polymer, since it is designed to release in the ileum. A previously published 
microencapsulation spray dying protocol was modified, by substituting the enteric 
polymer S100 in place of L100-55 and the plasticer triethyl citrate (TEC) in place of 
Tween-80 (144). This process relies on the dissolution of the enteric polymer, by the 
addition of NaOH, resulting in a neutral pH solution. Uncoated particles are added to the 
solution, along with plasticer, and the suspension is then spray dried. The drying process 
collapses a film of enteric polymer around the particles. Microparticles formed by this 
process, without the addition of PLGA microparticles, is shown below (Figure 3.16). 
 
Figure 3.16: SEM image of spray dried EUDRAGIT L100. Solubilized EUDRAGIT 
S100 was spray dried with 10% TEC, sputter coated with Pt/Pd and imaged via SEM. 
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 This process was able to form particles in the size range expected to effectively 
coat the PLGA microparticles, while still being small enough to pass through the pylorus 
of a rodent. However, this process relies on the use of dissolved polymer. Since the 
polymer was dissolved by the addition of NaOH prior to spray drying, it is expected that 
the polymer would remain deprotonated in the final dry state. In order to effectively dose 
the particles with an intact enteric film coating, the powder would need to be resuspended 
in a sufficiently buffered acidic solution. This buffered solution may then decrease the pH 
of the fluid in the small intestine, resulting in incomplete dissolution and blocking the 
invasin-integrin interaction. Also, recovery yields from this small batch process was on 
the order of 10%, due to powder coating the glass chambers throughout the spray dryer 
apparatus. Given the lab production scale of MBP-INV, 10% recovery of conjugated 
particles was not acceptable. 
 We then investigated an alternative process to incorporate enteric polymer 
protection. While the S100 polymer is designed for dissolution in the ileum, concerns 
regarding incomplete dissolution led to future preparations with a polymer designed for 
dissolution in the human duodenum, L30D-55. Here, the aqueous dispersion of enteric 
polymer was added directly to the suspension of particles encapsulating OVA, shown to 
be displayed on the particle surface (Figure 3.11). The suspension was then frozen and 
lyophilized as above. The result was a matrix powder where the enteric polymer blocks 
protease access to the particle surface. This powder was resuspended and incubated in the 
USP simulation gastric test fluid, containing pepsin. The volumetric ratio of resuspension 
solution and simulated gastric fluid were scaled to represent our dosage volume relative 
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to the mouse stomach volume (145). The particles were then washed in PBS and 
analyzed for the presence of surface displayed OVA, using anti-OVA mAb and flow 
cytometry (Figure 3.17).  
 
Figure 3.17: EUDGRAGIT L30D-55 protection from simulated gastric digestion 
measured by flow cytometry. Particles were lyophilized with or without L30D-55 (10% 
TEC w/w) and subjected to digestion in simulated gastric fluid, with pepsin. Two mass 
ratios of L30D-55 to particles were used (3:1 and 5:1). Particles were then labeled with a 
mouse anti-OVA mAb, followed by a fluorescent anti-mouse antibody, and analyzed via 
flow cytometry. MFIs for separate digestion reaction are shown. 
 3:1 and 5:1 mass ratios of L30D-55 to PLGA particles were tested. The particles 
lyophilized with the L30D-55 showed a dramatic reduction in pepsin degradation on the 
particle surface. The 3:1 formulation showed slightly higher residual anti-OVA 
recognition compared to the 5:1 formulation, 88% and 74%, respectively. While the 
minimum film forming temperature (MFT) of L30D-55 is 25°C, the addition of 10% 
TEC (acting as a plasticer) is able to reduce the MFT to 0°C. The formulation 
temperature was maintained at or below room temperature during freezing/lyophilization 
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and resuspension. It is likely the addition of 10% TEC to the suspension had a 
pronounced affect on creating a pepsin impermeable matrix powder, protecting the 
particles. This formulation may provide sufficient protection of targeting proteins for oral 
administration in species exhibiting a stomach pH below 5.5 and an intestinal pH above 
5.5. While the rat model has been used as a preclinical model for oral delivery of enteric 
coated formulations, we chose to use the mouse model, given its more characterized 
responses and available reagents for immunological experiments (146). However, the pH 
gradient in the mouse GI tract is not as dramatic as those observed in the rat model and 
humans, further raising concerns for incomplete dissolution and accessibility of invasin 
for integrin recognition (145).  
 In order to ensure the invasin binding domains are able to engage M cells, we 
investigated formulation excipients that would interfere directly with the protease 
activity, rather than shielding the particle surface. First, we examined the ability to inhibit 
intestinal digestion of serine proteases using the USP simulated intestinal test fluid, 
containing pancreatin. Particle suspension volumes and simulated intestinal fluids were 
scaled to match our dose volume and mouse intestinal fluid volume (145). MBP-INV 
conjugated PLGA particles were used for digestion for 75 min at 37°C. Particles were 
then washed, labeled with the 3A2 anti-invasin mAb, followed by a fluorescent anti-
mouse secondary, then analyzed via flow cytometry (Figure 3.18). 
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Figure 3.18: Simulated intestinal fluid digestion of surface immobilized MBP-INV 
analyzed via flow cytometry. Wild-type MBP-INV (D1-D5) PLGA particles were 
resuspended in potential dosage buffers and incubated with simulated intestinal digestion 
fluid, containing pancreatin, for 75 min at 37°C. Samples were then labeled with the 3A2 
anti-invasin mAb, followed by a fluorescent anti-mouse antibody, and analyzed via flow 
cytometry. MFIs are shown on a log10 scale for multiple sample digestions. HEPES 
buffers were 50 mM with 200 mM NaCl, pH 7.5. Sodium bicarbonate buffers were 5% 
w/v. Pefablock, an serine protease inhibitor was used at 12 mM. Dosage buffers with 
BSA were 2% w/v. MFIs are shown on a log10 scale for multiple sample digestions.  
 Pefablock SC Plus (Roche) is advertised as an effective serine protease inhibitor, 
with low toxicity and inhibition of protein-protein interactions. Since this formulation 
was being evaluated for in vivo dosage, the low toxicity was an important factor for its 
consideration. In order to balance efficacy, while maintaining low toxicity, 12 mM was 
chosen as a test concentration, 100-fold below the LD50 and above the concentration 
shown to support strong protease inhibition (4 mM). While Pefablock is not able to 
inhibit pepsin degradation, pH neutralizing dosage buffers (5% sodium bicarbonate) can 
inactivate pepsin. However, pH solutions above 8.0 are known to rapidly hydrolyze 
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Pefablock. Therefore, two buffers were evaluated, 50 mM HEPES (pH 7.5) and 5% 
sodium bicarbonate (pH 8.3). The HEPES solution with only Pefablock resulted in less 
than a 3% improvement on anti-invasin recognition on the particle surface, compared to 
resusupension in ddH2O. Given the potential hazards and side-effects of administering a 
protease inhibitor, this improvement was not sufficient to justify its use for oral 
administration. However, the addition of 2% BSA increased the anti-invasin recognition 
by over 10% in both the HEPES and sodium bicarbonate solutions, compared to water. 
Recently, is has been shown that administration of bystander protein, such as BSA, may 
help protect oral vaccine targeting ligands (147). This effect may be more pronounced in 
the fasted state, when there are fewer targets for gut proteases. Therefore, BSA was 
chosen as the preferential excipient to protect invasin during transit through the small 
intestine. It should be noted that even with 2% BSA, only ~20% residual recognition was 
observed, compared to unconjugated particles. However, our experimental conditions 
simulated particles transiting the entire length of the GI tract before analysis for 
digestion. In reality, some particles will interact with α5β1 integrin during gut transit, so 
the actual percent of invasin available for recognition should be higher than tested in our 
experimental conditions.  
 As mentioned above, pepsin becomes inactive at pH’s above 5 and irreversibly 
inactivated at pH’s above 7 (148). Therefore, we sought to measure the residual presence 
of the D4-D5 domain on the particle surface in simulated gastric conditions, utilizing 5% 
sodium bicarbonate to neutralize the pH of the stomach (Figure 3.19).  
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Figure 3.19: Simulated gastric fluid digestion of surface immobilized MBP-INV analyzed 
via flow cytometry. Wild-type MBP-INV (D1-D5) PLGA particles were resuspended in 
either water of 5% sodium bicarbonate and incubated with simulated intestinal digestion 
fluid, containing pepsin, for 75 min at 37°C. Samples were then labeled with the 3A2 
anti-invasin mAb, followed by a fluorescent anti-mouse antibody, and analyzed via flow 
cytometry. MFIs are shown on a log10 scale for multiple sample digestions.  
 The pH of 5% sodium bicarbonate solutions was measured to be 8.3, which is 
above that needed to inhibit and inactivate pepsin. There was greater than 60% 
improvement in anti-invasin recognition using 5% sodium bicarbonate, compared to 
water. This represents >65% of signal retention, compared to unconjugated particles. 
Given this information, the final dosage buffer was chosen to be 5% sodium bicarbonate 
with 5% BSA, in order to inactivate pepsin and competitively inhibit serine protease 
activity. This dosage formulation does not rely on any polymer-based protection, which 
may preclude accessibility of invasin. 
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In Vivo Formulation Characterization and Antibody Responses 
 In order to test our oral vaccine formulation, we tested our system in the mouse 
model (C57bl/6 strain). In addition to the optimized formulation discussed above, we 
added an adjuvant along with OVA to the inner water phase for several sample groups. 
The adjuvant selected, single-stranded CpG DNA, has been shown to be an effective 
mucosal adjuvant increasing total specific IgG responses, shifting helper T cell responses 
to the Th1 type, as well as boosting CD8 T cell responses (149-151). Historically, TLR9 
activation has been thought to rely on recognition by unmethylated CpG motifs, while 
more recent studies have shown this to only be true when a phosphorothiate (PS) 
modified DNA backbone is used (152). The use of PS DNA was popularized because of 
increased resistance to nucleases, compared to phophodiester (PD) backbones. The PS 
backbone also helps enable endocytosis, where the adjuvant is then able to engage TLR9 
within the endosome. However, once internalized, PD DNA is capable of TLR9 
recognition in a less sequence dependent manner (152). Immune responses from particle-
based vaccines have been shown to be enhanced by the addition of PD DNA (151). 
Therefore, we chose to incorporate a PD DNA sequence as an adjuvant, which has 
considerable less cost than the PS DNA alternative.  
 Particles were synthesized using the optimized formulation described above, with 
or without CpG DNA and used for conjugation to the MBP-INV targeting protein 
variants (D911A, wild-type, and RGD844), all in the D1-D5 format. These particles were 
then characterized via multiple biophysical methods (Table 3.2). Unfortunately, the 
encapsulation efficiency of the PD DNA was extremely low, ~0.01%. There was some 
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detection of ssDNA in the particles not loaded with CpG DNA, which is likely due to 
bacterial DNA associated with the MBP-INV protein used for conjugation. While there 
was over two-fold increase in measured ssDNA in PLGA particles synthesized with CpG 
DNA, the total amount is likely not sufficient to have an effect as an adjuvant. Typical 
murine vaccine studies use 2.5-10 ug of CpG DNA per dose, while our dose would 
contain <50 ng of CpG DNA (151, 153). This low encapsulation efficiency may be 
improved upon in the future by conjugating the CpG DNA to a soluble bulking agent, 
such as the protein antigen. Ovalbumin encapsulation efficiencies for particles loaded and 
not loaded with CpG DNA were 55% and 45%, respectively. The amount of OVA 
encapsulated could not be determined directly after conjugation due to interference of the 
MBP-INV in the micro BCA assay. However, performing “mock” conjugation reactions 
and release studies estimate on the order of 5% or less OVA loss during conjugation (data 
not shown). It is important to note that “mock” conjugation reactions where 
hydroxylamine was used to quench unreacted activated carboxylic groups resulted in a 
saturated micro BCA assay signal, after expedited hydrolysis. This effect may be due to 
the PEMA surfactant forming poly[ethylene-alt-(N-hydroxlmaleimide)](154), which 
could be recognized by the BCA assay. Therefore, the “mock” reaction conditions used 
to determine OVA losses during conjugation underwent the same washing conditions and 
reuspension time as the actual reactions, but did not have EDC or hydroxylamine steps. 
Release studies in 50 mM HEPES 200 mM NaCl 0.005% Trition-X100 also showed ~5% 
release in 6 hours, followed by no release up to one week (data not shown).  
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Sample CpG Loaded 
Hydrodynamic 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
Loading 
(ug OVA/ 
mg particle) 
CpG DNA 
(ng DNA/ 
mg particle) 
Preconjugation Yes 1054 ± 18 -55.02 ± 0.66 24.3 ± 1.3 ND 
D911A Yes 1088 ± 22 -36.18 ± 0.57 ND 11.4 ± 0.13 
Wild Type Yes 1053 ± 17 -38.40 ± 0.63 ND 11.5 ± 0.20 
RGD844 Yes 1097 ± 57 -39.82 ± 0.37 ND 10.4 ± 0.24 
Preconjugation No 759 ± 5.4 -44.16 ± 0.68 20.3 ± 2.3 ND 
RGD844 No 764 ± 11 -38.29 ± 0.46 ND 4.57 ± 0.12 
Table 3.2: Characterization PLGA particles used for in vivo administration. PLGA 
microparticles were characterized by dynamic light scattering (DLS), averages from 
multiple measurements fitted with CONTIN are shown. Zeta potential averages are 
shown for multiple measurements. The amount of OVA encapsulated was determined 
using a micro BCA assay after expedited hydrolysis. The amount of ssDNA 
encapsulating was determined using the Quant-iT RiboGreen assay kit after solvent 
extraction. ND= Not Determined 
 Prior literature has shown that differences in particle size and surface charge can 
lead to variations in the extent and type of immune responses, based on their transport 
and adsorption properties (43, 155-157). Therefore, it was important to determine if there 
were any significant size or charge differences between the samples groups. Multiple 
dynamic light scattering measurements were made for each sample and the correlation 
function for each measurement was fitted with CONTIN. The volume averages for each 
sample shown in Table 3.2 agree with SEM images of dry powder (not shown). The 
polydispersity and hydrodynamic diameter was slightly larger for the samples loaded 
with CpG DNA. This effect mimics the observations made above, showing increasing the 
solute of the inner aqueous phase results in larger and more polydisperse particles (Figure 
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3.3). However, spherical particle morphology was maintained in samples loaded with 
CpG DNA, likely stabilized by the addition of 5% NaCl to the outer aqueous phase. The 
surface charge of unconjugated PLGA microparticles was determined to be -55 and -44 
mV in 0.5 mM KCl for particles loaded and not loaded with CpG DNA, respectively. 
This charge difference may be due to the presence of the negatively charged CpG DNA 
on the particle surface. After conjugation of MBP-INV variants to the particle surface, 
the surface charge becomes less negative. Prior to conjugation the particle surface is 
composed of many carboxylic acid groups, used for coupling to primary amine groups on 
the MBP-INV variants. Many of these carboxylic acid groups are replaced by MBP-INV, 
which have surfaces composed of mixtures of polar side chains with positive, neutral, and 
negative charges. This modification makes the surface more positive. The amount of 
MBP-INV was found to be the same for all samples, measured by flow cytometry using 
anti-MBP and anti-INV mAbs (Figure 3.12, top panels). The particles also exhibited flow 
cytometry offsets when labeled with fluorescent α5β1 integrin, corresponding to their 
affinity (Figure 3.12, bottom left). Particles not loaded with CpG DNA (RGD844) are not 
shown in Figure 3.12, but track identically with the non-CpG loaded (RGD844) sample 
for all labels. 
 The sample groups used for in vivo studies are shown in Table 3.3. Mice were 
dosed on day 0, 14 and 28 days. Serum samples were collected prior to dosing, at 14 
days, 28 days, and at day 47. Serum samples were analyzed by ELISA for total specific 
IgG (Figure 3.20). The OVA specific ELISA (Figure 3.20, left) shows anti-OVA 
responses for the “Free OVA” and “Alum” groups, while the other groups had no serum 
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IgG response to OVA. This indicates the designed targeted oral vaccine system was not 
able to induce a serum specific antibody response directed towards the encapsulated 
antigen, OVA. It is interesting to note that there was a clear response to soluble OVA 
orally administered, comparable to the positive control “Alum” group. This response was 
surprising given the body of literature that supports the need for advanced delivery 
systems needed for oral vaccination. The adjuvant, CpG DNA, was included as a soluble 
agent in the “Free OVA” formulation. However, it is not likely to have played a role, 
given the low dose and nuclease susceptible phosphodiester form used. The other two 
excipients present, sodium bicarbonate and BSA, may have played a strong role in 
protecting the antigen during GI transit. Even with this protection, the lack of adjuvant 
and potential for tolerance induction makes this result notable and surprising.  
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Group Administration Route 
OVA 
(ug) 
Particle 
Based Adjuvant 
MBP-INV 
Variant 
Naïve Oral 0 No None N/A 
Free OVA Oral 100 No CpG N/A 
D911A (CpG) Oral 100 Yes CpG D911A 
Wild-Type (CpG) Oral 100 Yes CpG Wild-Type 
RGD844 (CpG) Oral 100 Yes CpG RGD844 
RGD844 Oral 100 Yes None RGD844 
Alum S.C. 100 No Alum N/A 
Table 3.3: In vivo immunization sample groups. Each sample group is shown by name 
along with distinguishing characteristics between them. Oral dosed samples were 
administered in 5% sodium bicarbonate/ 5% BSA, 250 ul per dose. Alum subcutaneous 
(S.C.) doses were administered by 100 ul injection behind the shoulder blades. Particle 
bases formulations use PLGA microparticles encapsulating OVA and were conjugated to 
the designated MBP-INV variant in the D1-D5 construct. The “Free OVA” group was 
prepared with soluble ovalbumin and 50 ng of CpG DNA. All groups were fasted for 6-8 
hours prior to dosing and boosted at 14 and 28 days with the same formulation. 
 
Anti-OVA Anti-MBP 
  
Figure 3.20: Specific total IgG responses. Total IgG responses were analyzed (1:200 
dilution) at day 47, by coating ELISA plates with ovalbumin (left) or maltose binding 
protein (right). Each individual point represents the average signal from a single mouse 
measured in duplicate. (Significance relative to naïve group ** P<0.01, ***P<0.001, 
calculated using Dunnett’s method of one-way ANOVA) 
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 Serum from sample groups that utilized the MBP-INV targeting protein was 
analyzed for specific IgG responses directed towards MBP. These results showed 
significant differences compared the naïve group. However, the differences in responses 
between test groups were not significant, even at higher dilutions (1:1,000; 1:5,000, and 
1:25,000). The lack of difference between the RGD844 groups with and without CpG 
DNA was not surprising, given the low amounts of CpG DNA loaded. The reason for 
lack of differences between targeted groups (D911A, wild-type, and RGD844) could be 
due to several factors. One potential reason is that the MBP-INV protein is sufficiently 
degraded during transit through the GI tract, leading to inefficient recognition of α5β1 
integrin. This reason would be supported by previous literature demonstrating that 
immune responses to M cell targeting vaccines were greatly enhanced when the particles 
were administered by intraduodenal injection, compared to oral gavage (42). However, in 
the Fievez et al. study there was not a significant difference in responses between free 
OVA and the naïve group. This indicates that the soluble OVA dosed in their “Free 
OVA” group was degraded, while ours was not. The addition of 5% sodium bicarbonate 
and 5% BSA may have also protected the MBP-INV, retaining some α5β1 integrin 
recognition on the apical surface of M cells. Another potential reason for the lack of 
difference in anti-MBP responses between targeted groups could be due to saturation of 
M cell uptake. There is likely a dose response effect, where no response is observed at a 
low enough dose, a response dependent on the ability to target M cells in a mid-range 
dose, and saturation of responses at high doses. A future dose response study, with and 
without BSA, may help elucidate the reasons for the effects observed and determine an 
optimal dose for future studies.  
 The other major notable finding was the discrepancy between the anti-MBP and 
lack of anti-OVA responses for the PLGA particle groups. The presence of the serum IgG 
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response directed at MBP was not surprising, as it was fused to the invasin variants that 
were conjugated to the surface of the particles. The presence of OVA and MBP were both 
found to be present on the particle surface after conjugation, by staining the particles with 
anti-OVA and anti-MBP mAbs, respectively (Figures 3.11 and 3.12, top-left). Also, we 
previously found unconjugated PLGA particles encapsulating OVA to generate serum 
IgG responses when administered orally and subcutaneously, although this was tested as 
n=1 sample sizes and with extended times between boosts. Therefore, the lack of IgG 
responses directed towards OVA was surprising. In order to mount an effective antibody 
response, antigens must be processed, displayed by MHC molecules, and recognized by 
B cell receptors. Rather than being surface displayed after encapsulation (OVA), MBP 
was conjugated to the particles. The chemical conjugation process requires activation of 
carboxylic acid groups on the particle surface, which would include those found on 
ovalbumin. After conjugation the reaction was quenched by the addition of 
hydroxylamine, which could have modified T and B cell epitopes on ovalbumin. It 
appears that at least one B cell epitope recognized by the anti-OVA mAb (Santa Cruz 
Biotech 58820) was preserved after conjugation. It is also possible that the highly 
reactive surface of the particles formed with PEMA became hyper-cross-linked after 
conjugation, preventing efficient degradation and release of OVA. Digestion of surface 
exposed OVA after MBP-INV conjugation, using pancreatin, resulted in background 
levels of anti-OVA mAb recognition in flow cytometry (data not shown). While trypsin is 
not an endoprotease believed to be important for antigen processing in lysosomes, this 
experiment shows the surface displayed OVA can be degraded for subsequent peptide 
presentation on MHC molecules (158). It may also be important to note the MHC class II 
immunodominant T cell epitope for OVA most studied (ISQAVHAAHAEINEAGR) 
contains two glutamic acids, which have carboxylic groups. These groups are solvent 
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exposed in the crystal structure for ovalbumin (pdb file 1OVA) and would be potentially 
reactive for chemical modification during the conjugation of MBP-INV. Modifications to 
important T cell epitopes may diminish their ability to be displayed by MHC molecules, 
decreasing the ability of T cells to respond appropriately. Peptides could also be 
displayed by MHC molecules, but have modified residues interacting with T cell 
receptors (TCR). While an altered responsive TCR repertoire would be a concern for 
generating pathogen specific T cell responses, it should not affect the generation of a 
vaccine based antibody response. This is because the antibody response is indirectly 
linked to the T cell response, which proves useful for conjugate vaccines. The portion of 
the OVA trapped in the PLGA particles (not surface displayed) should be protected from 
chemical modification during coupling. The mechanism for the lack of response to OVA 
in the M cell targeted particle formulations is likely due to one or more of the factors 
discussed above. The simplest method to circumvent this issue is to co-couple OVA and 
MBP-INV on the particle surface. This would remove the processing differences between 
OVA and MBP, which should lead to anti-OVA antibody responses.  
CONCLUSION 
While there is tremendous importance in generating an oral subunit vaccine, many 
challenges prevent such delivery systems from modulating immune responses in a 
manner that will lead to protection from pathogens (9). One solution to improving oral 
vaccine delivery is to target M cells, in order to facilitate increased antigen presence in 
mucosal lymphoid tissue (88, 90). As discussed in Chapter Two, we generated and 
characterized invasin ligands capable of binding an apical M cell receptor, α5β1 integrin, 
with various affinities. In this chapter, we designed a polymeric PLGA microparticle 
delivery system capable of testing the in vivo immune responses produced by using 
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invasin ligands with altered affinities toward α5β1 integrin. We were able to produce 
particles, encapsulating the antigen ovalbumin, and conjugate them to soluble forms of 
the invasin ligand. Substituting the emulsifying surfactant PVA to PEMA resulted in over 
an order of magnitude increase in the amount of protein displayed on the particle surface. 
The optimized microparticle delivery system showed α5β1 integrin recognition that was 
based on the affinity of the invasin ligand coupled to the particle surface. Upon in vivo 
administration, several notable observations were made: 1) soluble oral ovalbumin 
generated a serum ovalbumin specific IgG response; 2) the PLGA particles showed 
specific serum IgG responses to maltose binding protein, but not ovalbumin; 3) there 
were not significant differences in the serum IgG responses based on the invasin ligand 
used. While these results do not demonstrate a clearly effective oral vaccine system, they 
do provide valuable insights as to how the formulation may be modified to achieve 
successful oral vaccination in the future. 
MATERIALS AND METHODS  
Synthesis of Water-in-Oil-in-Water (w/o/w) double emulsion microparticles 
Poly(ethylene-maleic anhydride) was hydrolyzed to poly(ethylene-alt-maleic 
acid) (PEMA) by heating polymer solutions and the addition of NaOH. PEMA solutions 
were cooled to room temperature then adjusted to either 1% or 0.3% (w/v) and 5% NaCl 
(w/v). The pH was then adjusted to 7.5. The inner aqueous phase was prepared with α,α-
Trehalose 50 mg/ml, with or without ovalbumin (OVA) 40 mg/ml, with or without the 
1826 phosphodiester oligonucleotide (TCCATGACGTTCCTGACGTT) 30 mg/ml, and 
filtered using a 0.2um PVDF syringe filter (Millipore). 350mg of Resomer and 7.5mg of 
Mg(OH)2 was weighed out into a 50ml conical. 8ml of methylene chloride was added to 
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the conical and vortexed. 300ul of the inner aqueous solution was added to a conical and 
emulsified using a Silverson SL2 T homogenizer at full speed (~11,000 RPM) for 2 min 
and immediately transferred to 50ml of 1% PEMA-5% NaCl and emulsified again under 
the same conditions as before. The w/o/w emulsion was then added to 100ml of 0.3% 
PEMA-5% NaCl and solvent evaporation was carried out for 3.5 hours with stirring. The 
hardened microparticles were washed three times with ddH2O containing 0.005% Triton 
X-100 with vortexing and bath sonication used for resuspension in between washes. 
Washing was facilitated by centrifuging particles at 2,100xg for 20 min. After the last 
wash a batch was resuspended with wash solution to ~2.5ml, frozen in liquid nitrogen, 
lyophilized on an external manifold, then stored at -20°C. 
MBP-INV Expression 
 The invasin (INV) targeting proteins were expressed as soluble maltose binding 
protein (MBP) fusion proteins (MBP-INV). The INV portion was composed of either the 
c-terminal 497 amino acids (MBP-497) or the c-terminal 192 amino acids (MBP-192) of 
invasin from Yersinia pseudotuberculosis. Three variants of INV were used: wild type 
(WT), a single amino acid substitution variant with greatly reduced binding affinity 
(D911A), and an optimized binding variant (RGD844). pMAL-c5x was used as the 
expression vector, which does not contain the signaling peptide for periplasmic transport. 
These proteins were co-expressed in Origami B cells (EMD chemicals), along with the 
Skp chaperone protein on pAR3-Skp, which lacks the native periplasmic signaling 
peptide. Overnight starter cultures were inoculated into Terrific Broth (TB) media, 
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containing glucose and antibiotics, and grown overnight at 37°C. The following day, cells 
were harvested and media was exchanged with fresh TB, without glucose, and was 
placed on a shaker at room temperature. After 20-30 minutes, arabinose was added to a 
final concentration of 0.2% to induce c-Skp expression. Then 20-30 minutes later, 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to 1mM and MBP-INV 
expression was carried out for 4-5 hours. Cells were then harvested and cell pellets were 
stored at -80°C until purification. 
MBP-INV Purification 
Harvested cell pellets were resuspended and lysed via a French Pressure cell 
(Thermo Electron Corporation). Complete protease inhibitor tablets (Roche Diagnostics) 
were immediately added to the cell lysate. Cell lysate was clarified via centrifugation and 
filtration. MBP-INV was purified using a MBPTrap HP (5ml) column on an ÄKTA 
FPLC system followed by size exclusion chromatography using a HiLoad 16/600 
Superdex 200pg column (GE Healthcare). MBP-INV used for particles in vivo 
preparation was only purified using the MBPTrap columns to increase yields. To assess 
purity, purified protein was heated in loading buffer without DTT and run on a Mini-
PROTEAN electrophoresis cell (Bio-Rad) using a 4-15% TGX Gel (Bio-Rad) at 120V 
until the loading dye ran through the gel.  
Invasin Conjugation to Microparticles 
Particles were washed once in 50mM 2-(N-morpholino)ethanesulfonic acid 
(MES) 50mM NaCl 0.005% Triton X-100 pH 5.5 and resuspended to 25mg/ml. Washing 
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steps for conjugation were facilitated by centrifuging particles at 3,300xg for 5 min. A 
freshly prepared stock solution of 140 mg/ml in cold MES buffer was added to the 
microparticle suspension, adjusting the final suspension concentration to 20 mg/ml and 
an EDC concentration of 28 mg/ml. Carboxylic acid groups on particles were activated 
for 20 minutes at room temperature while being rotated. After activation, particles were 
pelleted, supernatant removed, and resuspended to 20 mg/ml in 200mM HEPES 100mM 
NaCl 0.005% Triton X-100 pH 7.8. Solutions containing the invasin fusion protein (30 
mg/ml) in 200 mM HEPES 100mM NaCl pH 7.8 were added to 1:1 to the particle 
suspensions. The reaction was carried out for 3.5 hours at room temperature while 
samples were rotated. Particles were then pelleted and resuspended to 10mg/ml in 50mM 
HEPES 200mM NaCl 40mM hydroxylamine 0.005% Triton X-100 pH 7.5 and incubated 
with rotation at room temperature for 30 minutes. Samples were then washed once in 
5mM HEPES pH 7.5 and resuspended to 10 mg/ml in the same buffer. Samples were 
frozen in liquid nitrogen and placed on a precooled lyophilizer shelf (-40°C). Samples 
were lyophilized at -40°C 150 mtorr until visually dry (~48 hours). Samples were then 
ramped to 25°C over the course of 60 minutes and continued to be dried under vacuum 
(150 mtorr) until removed (~12 hours). 
Scanning Electron Microscopy  
Lyophilized particles were deposited on carbon discs placed on aluminum stubs 
(SPI Supplies). Samples were sputter coated with a 12-15nm Pt/Pd target using a 
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Cressington 208 Benchtop Sputter Coater. Coated samples were imaged using a Zeiss 
Supra 40 VP Scanning Electron Microscope (3-5kV). 
Dynamic Light Scattering and Zeta Potential 
Dynamic light scattering (DLS) was carried out using a Brookhaven ZetaPALS 
instrument with particle sizing capability. Each sample underwent multiple 
measurements. The correlation function from each measurement was fitted with 
CONTIN and the mean percent volume weighted diameter was reported. Zeta potential 
measurements were made in 0.5 mM KCl using a Brookhaven ZetaPALS instrument. 
Each sample was measured 10 times and the mean charge was reported, after outlier 
removal. 
Protein Loading 
Particles encapsulating ovalbumin were subjected to expedited hydrolysis in 0.1N 
NaOH, 5% sodium dodecyl sulfate (SDS) at particle concentrations 1-2 mg/ml, 
accurately weighed. The hydrolysis was carried out for ~16 hours at room temperature 
with rotation. The protein concentration was measured using a Micro BCA Protein Assay 
(Pierce, Rockford, IL). Protein standards were prepared by dissolving lyophilized 
ovalbumin in the hydrolysis solution. Empty microparticles were not significantly 
different from pure hydrolysis solution.  
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CpG Loading 
After conjugation the amount of CpG DNA was quantified by PLGA particle 
dissolution in DCM (20 mg/ml) followed by extraction into Tris-EDTA (TE) buffer (2x 
DCM volume used). The amount of ssDNA present in solution was quantified by 
generating standards using empty unconjugated particles spiked with known amounts of 
CpG in the DCM, then analyzed by fluorescence with Quant-iT RIboGreen® RNA assay 
kit. Standard curve concentrations were made at 0, 1, 5, 10, 25, 50, 100, and 200 ng/ml, 
based on TE extraction volume. The standard curve was linear and spanned the test 
sample concentrations. A separate experiment was performed without the addition of 
empty unconjugated PLGA particles, to measure the interference of the PLGA particles. 
Fluorescence measurements showed values slightly above 0 ng/ml but below 1 ng/ml 
CpG DNA.  
Flow Cytometry Analysis of Particles 
To assess the accessibility of B cell epitopes and activity of MBP-INV on the 
particle surface flow cytometry was used in conjunction with antibodies (specific for 
ovalbumin, maltose binding protein (MBP), and/or the D4-D5 region of invasin) or 
fluorescent α5β1 integrin. 50 μg of particles were labeled for each analysis in 50 μl. 
Primary antibody labels were incubated for 30 min at room temperature in 50 mM 
HEPES, 200 mM NaCl, 1% bovine serum albumin (BSA), 0.005% Triton X-100, pH 7.5 
at a 1:100 solution: anti-ovalbumin (Santa Cruz Biotechnology, Inc sc-58820), anti-
invasin (3A-2)(65) supplied as cell culture supernatant, and anti-MBP (New England 
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BioLabs, Inc E8032S). Cy5-labeled goat anti-mouse IgG (H+L) (Invitrogen A10524) was 
used as a secondary antibody also at a 1:100 dilution for 30 min at room temperature. To 
label the integrin, Alexa Fluor 647 (Invitrogen A20006) was dissolved in acetonitrile at 
1mg/ml, aliquoted in 50 μl fractions, dried and stored at -20°C. A 50 ug aliquot of α5β1 
integrin (R&D Systems, Inc 3230-A5 Lot OOJ2510121), was adjusted to 1mM sodium 
bicarbonate and combined with 20 ul dye solution (prepared from 50 ug Alexa Fluor 647 
dissolved in 5 μl of dimethylformamide plus 45 μl of 1M sodium bicarbonate). The 
reaction was allowed to proceed for 1.5 hrs with rotation at room temperature, after 
which the solution was dialyzed in 50mM HEPES, 200mM NaCl, 2mM MnCl2 pH 7.5 
using a 20K MWCO dialysis cassette (Pierce 66005. To prevent photobleaching, all steps 
involving a fluorophore were carried out in the dark. Particles were labeled with 100 nM 
concentration of fluorescent α5β1 integrin for 1 hr in 50 mM HEPES, 200mM NaCl, pH 
7.5, 2 mM MnCl2, 2% w/v BSA. Particles were washed in between labeling steps by 
centrifuging at 6,000xg for 2 min. After labeling, particles were resuspended in 1 ml of 
50 mM HEPES, 200 mM NaCl, pH 7.5 (w/ 2 mM MnCl2 for integrin labels) prior to 
analysis on a LSRFortessa (BD Biosciences). Samples were gated by size to isolate the 
main population using FlowJo (Tree Star, Inc) and greater than 9,000 events are reported 
for each plot or median fluorescence intensity (MFI). 
Simulated Digestion 
Simulated gastric and intestinal fluids were prepared as recommended by the U.S. 
Pharmacopeia for test solutions. Simulated gastric fluid was made by the combining 200 
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mg NaCl, 225 mg purified porcine pepsin (2,500-3,500 units/mg, Sigma P7012 ), 700 μl 
HCl and bringing the solution to 100 ml (pH measured to be 1.36). Simulated instestinal 
fluid was prepared by combining 680 mg of monobasic potassium phosphate, 7.7 ml 
0.2N NaOH, 333 mg of 3XUSP pancreatin (MP Biomedicals 0210255825), pH adjusted 
to 6.8 and volume to 100ml. Simulated digestions were carried out to mimic in vivo 
dosing conditions, 25 μl particle suspension (10 mg/ml) added to 17 μl gastric test fluid 
or 33 μl intestinal fluid and incubated at 37°C with shaking for 75 min. After digestion, 
samples were washed with PBS and prepared for flow cytometry analysis described 
above.  
In Vitro Costimulation 
To measure upregulation of activation markers on professional antigen presenting cells, 
PLGA particles were incubated with RAW 264.7 macrophage cells. 1x106 cells/well were 
seeded 6-well plates with 1.5ml Dulbeccco’s Modified Eagles Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and grown at 37°C in 5% CO2. The 
next day, media was exchanged and samples were added to wells for overnight 
incubation. The following day, cells were trypsinized and counted using a 
hemacytometer. 1x106 cells were centrifuged at 500xg for 5 min and media was 
aspirated. Cells were then labeled with 1:100 dilutions of APC rat anti-mouse CD40 (BD 
Biosciences 558695) and FITC rat anti-mouse CD86 (eBiosciences 11-0862-81) in 100 
μl PBS with 1% FBS for 30 min at room temperature in the dark. Cells were then pelleted 
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and resuspended in 1 ml PBS 1% FBS for flow cytometry analysis on a FACSCalibur 
(BD Biosciences), followed by FlowJo analysis (Tree Star, Inc). 
Immunological Animal Studies 
Female C57Bl/6 mice 6-8 weeks of age were purchased from Jackson 
Laboratories and cared for under approved The University of Texas at Austin 
Institutional Animal Care and Use Committee (IACUC AUP-2009-00086). All mice 
were deprived of food for 6-8 hours before dosing. Subcutaneous Alum-adjuvanted 
controls were dosed by injection of 100 μg of OVA mixed with alum in 100 μl. Oral 
dosing carried out by 250 μl oral gavage using a blunt-tip feeding needle. The carrier 
solution was 5% sodium bicarbonate and 5% bovine serum albumin (BSA), which the 
naïve group received. All other doses were adjusted such that 100 μg of OVA was dosed. 
Serum samples were prepared from blood collected from the tail via venipuncture 
technique. 
Serum Sample Analysis 
 Serum samples were analyzed for presence of antigen specific antibodies via 
ELISA. The ELISAs were performed by coating 96 well plates with either ovalbumin (10 
ug/ml) or maltose binding protein (5 ug/ml) by overnight incubation in a 50 mM 
carbonate buffer (pH 9.5) at 4°C. The plates were then washed and blocked in 3% fetal 
bovine serum (FBS), 3% bovine serum albumin (BSA), 0.05% Tween-20 in PBS 
overnight at 4°C. Each wash step consisted of four washes in PBS plus 0.05% Tween-20 
(PBST). Serum samples were diluted as stated in the results section in PBST plus 3% 
FBS, 3% BSA for 1.5 hours at room temperature. Plates were then washed in PBST and 
incubated with a goat anti-mouse IgG (subclasses I+2a+2b+3), Fcγ fragment specific 
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(Jackson ImmunoResearch Laboratories, Inc. 115-035-164) for 1 hour at room 
temperature. Plates were then washed in PBST, followed by a PBS wash. Signal was 
developed using Pierce 1-Step Ultra TMB and was quenched after 15 minutes with 1N 
HCl. Absorbance at 450 nm was measured by a SpectraMax M5 plate reader. 
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Chapter 4: In Vivo Imaging Oral Vaccine Delivery System 
INTRODUCTION 
Semiconductor nanocrystal quantum dots can exhibit bright and stable 
fluorescence that can be tuned over a wide wavelength range by changing size and 
composition from visible to near-infrared (NIR) wavelengths. They have been explored 
for use in light-emitting diodes(159, 160), photovoltaics(161-163), and as fluorescent 
probes for bioimaging (164-166). Nanocrystals with NIR optical properties are especially 
of interest for biological applications, due to the relatively strong light absorption by 
tissue and water outside the 650-900nm spectral window (167). In addition, nanocrystals 
offer a wide excitation band compared to molecular dyes, which can be useful for 
multispectral imaging (168, 169). Recently, Cu2-xSe nanocrystals were synthesized with 
strong NIR absorbance due to a plasmonic resonance and demonstrated their potential for 
photothermal therapy (170). 
We report the synthesis of copper indium sulfide-selenide (CISS; CuInSXSe2-X) 
quantum dots with size-tunable photoluminescence across visible to near-infrared (NIR) 
wavelengths with high quantum yield. NIR-emitting nanocrystals have been made, 
including binary compounds, such as lead chalcogenides(171, 172), CdTe(173), 
InAs(174), and Cd3As2(175), ternary and quaternary nanocrystals of Cu(InXGa1-
X)Se2(162), CuInS2, CuInSe2(176), Cu2ZnSnS4(177) and NIR photoluminescence has 
been reported in I-III-VI ordered vacancy compound nanocrystals (178), and ZnS-coated 
chalcopyrite CuInS2 (179). Tuan and coworkers synthesized CISS nanocrystals in gram 
scale quantities(180), however they did not observe photoluminescence in their study due 
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to the large size (>10 nm) of the particles synthesized in their study. Here, we utilize 
CISS nanocrystals with size-dependent photoluminescence in the visible to NIR and test 
their potential for use as a fluorescent probe for in vivo biological imaging. 2.4 nm 
diameter CISS nanocrystals were encapsulated in poly(lactic-co-glycolic acid) (PLGA) 
microparticles (0.5 - 2.0um) with an invasin protein coating to facilitate mucosal vaccine 
delivery. To our knowledge, this is the first report of cell-targeted optical imaging using 
fluorescent nanocrystals via oral delivery. 
The band gap energy of CISS varies between 1.0 eV for x = 0 and 1.5 eV for x = 
2.25 CISS nanocrystals should have tunable emission peaks from visible to NIR 
wavelengths by changing size and composition. Room-temperature photoluminescence is 
rarely observed from bulk CISS or other ternary I-III-VI compounds due to nonradiative 
recombination at defects (181). CISS is also attractive for in vivo biological imaging 
because it does not have toxic heavy metals (such as Cd, Pb, Hg, or As) and can be tuned 
to emit in the red/NIR transparent window of biological tissue.  
RESULTS AND DISCUSSION 
CISS nanoparticle synthesis and characterization 
CuInSXSe2-X nanocrystals were synthesized by arrested precipitation in hot 
octadecene with dodecanethiol serving as both a capping ligand and sulfur source. 
Tributylphosphine selenide (TBP:Se) was injected at 180°C to induce nucleation. Figure 
4.1 shows TEM images of CISS nanocrystals isolated from the reaction after different 
times. The nanocrystals become progressively larger with increasing reaction time. 
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Particle size measured by small angle x-ray scattering ranged from 1.7 to 2.4 nm for 
reaction times of 5 and 90 minutes, respectively. After about 30 minutes, the particles 
increase in polydispersity, with a polydisperisity of 40% measured by small angle x-ray 
scattering. The lattice spacing in the CISS nanocrystals determined from high resolution 
TEM images are consistent with a sphalerite (cubic) crystal structure and a ~1:1 S:Se 
ratio. XRD (Figure 4.2) is consistent with sphalerite CISS and no other phases are present 
in the reaction product. Typically, CuInSe2 and CuInS2 have a chalcopyrite (tetragonal) 
crystal structure; however, peaks at ~17° and 35° corresponding to the (101) and (211) 
lattice planes are not observed. The sphalerite (111) peak lies between where the (112) 
peaks for chalcopyrite copper indium selenide and copper indium sulfide would be 
(JCPDS #97-006-892, 082-1702). This indicates that the nanocrystals are an alloy of the 
two. The average Cu:In:S:Se composition determined from EDS of fields of nanocrystals 
was 1.0:1.0:1.3.0.7. There was no significant compositional variation between areas on 
the TEM grid within the error of the EDS detector. Additionally, the nanocrystal 
composition did not change as a function of reaction time between 15 and 90 minutes. 
However, when the growth temperature was reduced to 200°C or less, the nanocrystals 
became richer in Se, indicating a lower reactivity of dodecanethiol as a sulfur source 
relative to the TBP:Se. These nanocrystals made at lower temperature exhibited 
significantly lower photoluminescence quantum yield. Overcoating with a thin layer of 
ZnS resulted in a 4x increase of PL quantum yield that was stable in air for several 
months. 
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Figure 4.1: TEM of CISS nanocrystals after (A) 2 min, (B) 10 min, (C) 30 min, and (D) 1 
hour of growth. Inset in (C): high resolution TEM image of a CISS nanocrystal. 
 
Figure 4.2: XRD and EDS Spectrum of CISS Nanocrystals. (A) XRD and (B) EDS 
Spectrum. 
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Absorbance and PL measurements (Figure 4.3) show evidence of quantum 
confinement in the CISS nanocrystals. Nanocrystals isolated immediately after TBP:Se 
injection (0 min) exhibited an absorbance shoulder at approximately 380 nm and weak 
PL at 610 nm (QY < 0.01%). As the reaction proceeds and the CISS nanocrystals grow, 
the absorbance shoulder and PL redshift. After 90 minutes of particle growth, the exciton 
peak occurs at ~650 nm and the PL peak at 765 nm. Bulk CISS with the composition 
calculated by EDS would have band gap of about 1.2 eV (1,030 nm). This indicates that 
even after 90 minutes of growth time, the nanocrystals exhibit quantum confinement 
effects, with a size of 2.4 nm. 
 
Figure 4.3: Absorbance and PL spectra of CISS nanocrystals. For PL measurements, an 
excitation wavelength of 400 nm was used. At 5, 15, 30, and 90 minutes the particle 
diameter measured by small angle x-ray scattering was 1.7±0.5, 1.9±.6, 2.0±.8, and 
2.4±1.0 nm. 
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CISS nanoparticle encapsulation in invasin decorated PLGA microparticles 
CISS nanocrystals were integrated into a microparticle-based oral vaccine system 
to demonstrate biological imaging in deep tissue. Previous work has shown that the 
bacterial protein invasin, from Y. pseudotuberculosis, has the ability to target intestinal M 
cells, which play a critical role in gut immunity (57, 79). These M cells exist as a small 
fraction of cells along the gastrointestinal (GI) tract, occurring on the order of 1 in 
10,000,000 enterocytes (15). M cells act as a gut portal to the immune system by 
sampling material (i.e. protein, bacteria, viruses, food, etc). These cells take material in 
the intestinal lumen and deliver it to lymphocytes residing in the lamina propia. Since a 
major limitation to successful oral subunit vaccines is delivery of key pathogen 
components to lymphocytes, the ability to target these M cells has been shown to play an 
essential role in developing a feasible platform oral vaccine delivery system (40, 42, 90, 
93). A single amino acid substitution on the surface of invasin, D911A, leads to loss in 
binding of invasin for its receptor, α5β1 (68). In this study we tested the targeting ability 
of an invasin-functionalized vaccine delivery system. Fluorescent CISS nanocrystals 
were encapsulated in poly (lactic-co-glycolic) acid microparticles as a label for whole 
animal fluorescent imaging. The nanocrystals were encapsulated in PLGA microparticles 
by addition to the oil phase of a Water-in-Oil-in-Water emulsion used to produce the 
microparticles. Figure 4.4 shows SEM and fluorescence microscopy of the CISS 
nanocrystal-loaded microparticles. The microparticles range in diameter from 500 to 
2,000 nm. The microparticles are fluorescent, confirming that the CISS nanocrystals are 
encapsulated. 
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Figure 4.4: In vitro CISS nanoparticle fluorescence before and after encapsulation in 
PLGA micropartilces. (A) SEM images and (B) Photographs showing dispersions of 
ZnS@CISS nanocrystals in cuvettes before encapsulation in room light (left) and under a 
fluorescent lamp (right). (C) Bright field and (D) fluorescence microscopy images of 
CISS nanocrystal-loaded PLGA microparticles. Fluorescence image taken with excitation 
480-550 nm and emission >590 nm. 
In vivo imaging of CISS loaded invasin decorated PLGA microparticles 
Two sample groups were tested: 1) microparticles conjugated to the extracellular 
portion of wild-type invasin expressed as a fusion protein on the C-terminus of maltose 
binding protein (MBP), 2) microparticles conjugated to the same protein with the D911A 
substitution. A schematic illustrating the experimental process is shown in Figure 4.5. 
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Figure 4.5: Schematic of in vivo fluorescence imaging of CISS loaded targeted PLGA 
microparticles. CISS NCs dispersed in dichloromethane (DCM) (A) are encapsulated in 
PLGA microspheres (B). The microparticles are conjugated to either wild-type invasin or 
the protein with a single amino acid substitution (D911A) (C). After intragastric gavage, 
the in-vivo fluorescence is monitored using an IVIS Spectrum (D). 
The invasin functionalized PLGA microparticles encapsulating the CISS 
nanocrystals (InvaCISS) were orally gavaged to mice and imaged, using a non-invasive 
Caliper Life Sciences IVIS Spectrum, to track the time-dependent fluorescence retention 
in the GI tract. The fluorescence should correlate to M cell uptake, as within the GI tract 
only M cells are known to be capable of transcytosis of particles in the microparticle size 
range. Figure 4.6 shows whole-animal fluorescence images of mice fed InvaCISS. 
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Figure 4.6: In-vivo Fluorescence Imaging. Same subjects tracked at 15 min (A, E), 18 
hours (B, F), 45 hours (C, G) after oral gavage and the intestines after dissection at 48 
hours (D, H). Mice were administered CISS nanocrystal-loaded PLGA microparticles 
conjugated with (E-H) wild type invasin-MBP fusion protein or (A-D) the same protein 
with the D911A substitution abrogating the targeting ability.  
The fluorescent CISS nanocrystals were clearly visible in the whole-animal 
images and identified the location of the microparticles in vivo. At 15 minutes, any 
material orally gavaged would be primarily found in the stomach, as the exponential 
decay constant of stomach emptying in the mouse is 72 minutes (182). The fluorescence 
signal in figures 4.6 (a) and (e) is located where the stomach should be located. At 18 and 
45 hours, the majority of ingested material that is not mucoadhesive or transported across 
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the intestinal wall is expected to be excreted. Figure 4.6 (h) shows the fluorescence signal 
is restricted to the cecum and the colon. In mice, M cells are found along the GI tract in 
Peyer’s patches in the distal small intestine, isolated lymphoid follicles, cecal patches, 
and colonic patches (145). The greatest amount of microparticles appears to associate 
with the cecal M cells. Quantatative analysis was performed by integrating the 
fluorescence intensity over a region of interest (ROI) using multiple filter sets (Figure 
4.7). The ROI encompassed the entire abdomen. For images with weaker signals (18 hrs, 
45 hrs, intestines), the images were spectrally unmixed using Living Image 4.0 to 
distinguish tissue autofluorescence from nanocrystal fluorescence.  
 
Figure 4.7: Comparison of fluorescence signal from the nanocrystals at 15 min, 18 hours, 
45 hours in vivo, and the intestines at 48 hours post-mortem. Error bars correspond to the 
standard deviation of measurements of multiple mice for each experiment. 
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CONCLUSIONS 
CISS nanocrystal quantum dots with size-dependent, bright PL were synthesized. 
The initial PL quantum yield of the as-synthesized CISS particles was around 10% and 
increased to 40% after overgrowth of a ZnS shell. This ZnS shell was also found to be 
very important for stabilizing the PL in aqueous media. These nanocrystals do not contain 
toxic heavy metals and emit in the red/NIR wavelength range, making them attractive for 
medical imaging. We demonstrate in vivo whole animal fluorescence imaging of the 
microparticles loaded with CISS nanocrystals in deep tissue, within the GI tract. The 
CISS nanocrystals are promising new materials as a biocompatible diagnostic agent. 
MATERIALS AND METHODS 
Materials 
All chemicals were used as received. Copper (II) acetylacetonate (Cu(acac)2; 
99.99+%) and indium (III) acetylacetonate (In(acac)3, 99.99+%), 1-octadecene (ODE, 
90%), dodecanethiol (DDT, 98%), selenium powder (99.99%), potassium ethyl 
xanthogenate (96%), zinc (II) oleate (90%) and tributylphosphine (TBP, 98%) were 
purchased from Aldrich Chemical Co. Cu(acac)2, In(acac)3, and DDT were stored in a 
dessicator. Ethanol (absolute), toluene (spectrophotometric grade, 99+%), and 
isopropanol (≥99%) were purchased from Fisher Scientific. TBP was stored in a N2-filled 
glovebox. Stock solution of 1M tributylphosphine selenide (TBP:Se) was prepared by 
dissolving 10 mmol of Se powder (790 mg) in 10 mL TBP inside a N2-filled glovebox. 
Zinc bis(ethylxanthogenate) was prepared by a method described by Li et al (183). Acid 
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end-capped PLGA, Resomer RG502H, was purchased from Boehringer Ingelheim. Poly 
(ethylene-alt-maleic anhydride) was obtained from Polysciences, Inc. α,α-Trehalose, 
Dihydrate was from J.T. Baker. 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) and N-hydroxysulfosuccinimide (Sulfo-NHS) were from Thermo 
Scientific Pierce. LB broth (Miller), terrific broth, ampicillin, chloramphenicol, 
kanamycin, tetracycline, D-glucose, HEPES, MES, NaCl, and Isopropyl-b-D-
thiogalactopyranoside (IPTG) were obtained from Fisher Scientific.  
Synthesis of CISS nanocrystals 
In a typical reaction, 5 mmol Cu(acac)2 (1.3g), 5 mmol In(acac)3 (2.5 g), 20 mL 
ODE and 10 mL DDT are placed in a 100 mL 3-neck round bottom flask equipped with a 
magnetic stir bar. The flask is connected to a condenser and sealed with rubber septa. A 
thermocouple is inserted through one septum to measure the solution temperature. The 
flask is attached to a Schlenk line and is heated with a heating mantle. The contents are 
first put under vacuum (~300 mTorr) and heated to 110ºC for 1 hr while stirring. The 
dispersion, which is initially blue and opaque, transforms into a transparent yellow, 
viscous solution as it is heated. After 1 hr, the solution ceases to bubble, indicating that 
all moisture is removed and the flask is thoroughly degassed. The flask is then put under 
a N2 atmosphere and the temperature is quickly ramped to 180ºC, where immediately 10 
mL of 1M TBP:Se is injected rapidly. Upon injection the temperature drops to ~160 ºC 
and the flask contents becomes almost colorless. The temperature is then ramped to 
220ºC, and aliquots are taken along the course of the reaction. Reaction temperatures 
over 240ºC lead to uncontrolled growth, with a final product containing mostly large 
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precipitates with no observed photoluminescence. The solution color is initially pale 
yellow, and as time goes on the color progresses from yellow to orange, red, and finally 
dark brown. Aliquots were taken to monitor the photoluminescence peak. The 
photoluminescent quantum yield of these aliquots were typically between 5 and 10%. A 
ZnS shell precursor solution was prepared by combining zinc bis(ethyl xanthogenate) 
(100 mg), zinc (II) oleate (900 mg). ODE (10 mL), trioctylphosphine (3 mL) and 
oleylamine (1 mL). The CISS nanocrystals are coated with ZnS by cooling the reaction 
solution to 190ºC and injecting this solution into the reaction flask. The mixture is stirred 
overnight to allow the shell to form. The heating mantle is removed and the mixture is 
allowed to cool to room temperature. The nanocrystals are precipitated by adding an 
ethanol/toluene (~2:1 vol:vol) mixture and centrifuging at 8,000 rpm for 5 min. Addition 
of only ethanol as an antisolvent is not effective because ethanol is not miscible in 
octadecene, and the mixture phase segregates. The nanocrystals are further purified by 
redispersing in toluene and precipitating with a minimal amount of ethanol or isopropanol 
and centrifuging. 
Nanocrystal Characterization 
The nanocrystals were characterized using a range of analytical techniques, 
including transmission electron microscopy (TEM), energy-dispersive X-ray 
spectroscopy (EDS), X-ray diffraction (XRD), small angle x-ray scattering (SAXS), 
UV−vis−NIR absorbance spectroscopy and photoluminescence (PL) spectroscopy. 
TEM imaging was performed on nanocrystals drop-cast from toluene dispersions on 
carbon-coated 200 mesh copper or nickel TEM grids (Electron Microscopy Sciences). 
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TEM images were acquired on either a FEI Technai G20 TEM with 80 kV accelerating 
voltage or a JEOL 2010F TEM operating at 200 keV. The JEOL 2010F TEM is equipped 
with an Oxford INCA EDS detector, which was used to collect EDS data.  
XRD data was acquired using a Bruker-Nonius D8 Advance θ−2θ Powder 
Diffractometer equipped with a Bruker Sol-X Si(Li) solid-state detector and a rotating 
stage. Cu Kα (λ= 1.54 Å) radiation was used. For XRD, the nanocrystals were evaporated 
from concentrated dispersions onto quartz (0001) substrates as ~0.5 mm thick films. 
Diffraction data was collected by scanning for 4 to 12 hrs with an angle increment of 
0.01° or 0.02° at a scan rate of 6°/min and a rotation speed of 15 rpm. 
UV−vis−NIR absorbance spectra were obtained with a Varian Cary 500 UV−vis−NIR 
spectrophotometer using hexane-dispersed nanocrystals in a quartz cuvette. 
CISS Nanocrystal Encapsulation in PLGA Microparticles 
Poly (ethylene-alt-maleic anhydride) was hydrolyzed to poly (ethylene-alt-maleic 
acid) (PEMA) by slow addition to heated double-distilled H2O (ddH2O) (~80 ºC) with 
the addition of NaOH. The final solution was adjusted to 1% w/v PEMA and pH 7.5, then 
filtered through a 0.22um bottle top filter. Microparticles were prepared using a 
modification of a previously described protocols (7, 133). Briefly, 2 batches of 350mg 
Resomer RG502H and 55mg of CISS nanocrystals were solubilized/dispersed in 8ml of 
methylene chloride. 300ul of ddH2O was added and the emulsion was homogenized at 
~10,500 RPM for 2 minutes using a Silverson SL2T Homogenizer. This emulsion was 
immediately added to 50ml of a 1% w/v solution of PEMA and homogenized again for 2 
minutes at ~10,500 RPM. The Water-in-Oil-in-Water emulsion was then added to 100ml 
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of 1% w/v PEMA solution and stirred for 3 hrs. The hardened microparticles were 
washed 3x in ddH2O. During the last wash step the 2 batches were combined then 
resuspended in ~3ml ddH2O, frozen in liquid nitrogen, and lyophilized on an external 
manifold of a VirTis Advantage Plus Benchtop Freeze Dryer for ~48 hrs. 
Production/Purification of Soluble Invasin 
Maltose Binding Protein/Invasin (MBP-INV) fusion proteins were expressed 
using the pMAL-c5x (New England Biolabs) vector, similar to one used previously 
(Leong, 1995). The C-terminal 497 amino acids of invasin from Yersinia 
pseudotuberculosis was PCR amplified using the primers TAK046 
(agctatcgagctcgaactcattcacattgagcgtc) and TAK047 
(cgtcattataccatggctagttaatcattatattgacagcgcacagag) and cloned into pMAL-c5x using the 
restriction sites SacI and NcoI. The cytoplasmic fusion protein was co-expressed with a 
cytoplasmic version of the skp chaperone on a separate expression vector, pAR3-Skp in 
Origami B (EMD Chemicals) (121). Starter cultures were grown in 4 ml of LB with 
Ampicillin (150 ug/ml), Chloramphenicol (34 ug/ml), Kanamycin (15 ug/ml), 
Tetracycline (12.5 ug/ml) and shaken at 37°C and 225 RPM. Approximately 16 hours 
later, 3.5 ml of the starter cultures were inoculated into 500ml of Terrific Broth (TB) 
containing the same antibiotics plus 2% D-glucose and shaken at 37ºC and 225 RPM. 
Approximately 16 hrs later, the cells were harvested and resuspended in fresh TB with 
antibiotics, but no glucose and shaken at 25ºC and 225 RPM. 30 minutes after 
resuspension, L-arabinose was added to a final concentration of 0.2% w/v. 30 minutes 
after the addition of L-arabinose, IPTG was added to a final concentration of 1 mM. 
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Expression was carried out at 25ºC for 4 hrs. Cells were then harvested and frozen at -
80ºC. Harvested cell pellets were resuspended and lysed via a French Pressure cell. 
Complete protease inhibitor tablets (Roche Diagnostics) were immediately added to the 
cell lysate. Cell lysate was clarified via centrifugation and filtration. MBP-INV was 
purified using a MBPTrap HP (5ml) column on an ÄKTA FPLC system followed by size 
exclusion chromatography using a Superdex 200 10/300 GL column (GE Healthcare).  
Conjugation of MBP/INV to PLGA Microparticles Encapsulating CISS 
Nanocrystals 
420 mg of PLGA microparticles encapsulating CISS nanocrystals were 
resuspended in 16.8 ml of 0.1 M MES buffer 0.5M NaCl (pH 5.0). 100 ul ddH2O 
containing 280 mg of EDC and 100ul ddH2O containing 320 mg of Sulfo-NHS were 
added to the microparticle suspension. The reaction was rotated for 2 hrs at room 
temperature. After activation, the 2x8ml of the suspension were transferred to new 50 ml 
conicals. 200 mM HEPES 200 mM NaCl pH 7.4 was added to 50 ml and the 
microparticles were pelleted. The activated microparticles were resuspended with 10 ml 
of 200 mM HEPES 200 mM NaCl pH 7.4. 10ml of the same buffer containing 10 mg of 
the respective MBP-INV variant, wild-type or D911A, was added to the microparticles 
and rotated for 2 hrs at room temperature. The microparticles were then washed twice in 
10 mM HEPES 50 mM NaCl pH 7.4 and resuspended in 3 ml ddH2O containing 20 mg 
of α,α-Trehalose. The samples were frozen in liquid nitrogen lyophilized as before.  
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In Vivo Fluorescent Imaging 
6-8 week old female albino (BALB/c) mice were purchased from Jackson 
Laboratories and housed in at the Animal Resource Center, The University of Texas at 
Austin, in accordance with Institutional Animal Care and Use Committee (IACUC) 
Guidelines. The mice received an alfalfa free diet (2019 Tekland Global 19% Protein 
Extruded Rodent Diet) for 7 days prior to commencement of the study in order to reduce 
intestinal autofluorescence, and were maintained on this diet throughout the duration of 
the study. Mice were fasted for 3 hrs prior to dosing. 15 mg of microparticles were dosed 
in 200 ul 5% w/v sodium bicarbonate via intragastric gavage (3 mice per sample group). 
Immediately after dosing, the subjects were anesthetized in an incubation chamber with 
3% isoflurane. The subjects were transferred to an IVIS Spectrum (Caliper Life Sciences) 
and anesthesia was maintained using 1% isoflurane during imaging. Imaging was carried 
out using epifluorescence with 14 filter sets for subsequent autofluorescence subtraction. 
After imaging, the subjects were placed back into conventional housing with food and 
water ad libitum. Mice were imaged again at 18 hours post-dose under the same 
conditions. After 45 hrs post-dose, the mice were sacrificed, imaged, then the intestines 
were removed for further imaging.  
Analysis of Fluorescence Imaging Data 
For the 15 min time point, the signal-to-noise ratio was sufficiently intense 
enough that autofluorescence subtraction was unnecessary and the samples were analyzed 
with the highest contrast filter set (640nm/760nm). For all subsequent time points 
spectral unmixing was carried out to extract the nanocrystal fluorescence from tissue 
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autofluorescence using Living Image 4.0 (Caliper Life Science). For whole animal 
images, the following excitation/emission filter sets were used: 570nm/700nm, 
605nm/720nm, 605nm/740nm, 605nm/760nm, 605nm/780nm, 605nm/800nm, 
640nm/700nm, 640nm/720nm, 640nm/740nm, 640nm/760nm, 640nm/780nm, and 
640nm/800nm. The samples were unmixed using a two fluorophore setting: tissue 
autofluorescence set to “Auto” and Fixed, nanocrystal fluorescence set to “AF750Ex”, an 
internal spectrum standard which matched well with our nanocrystal fluorescence 
spectrum. Regions of Interest (ROIs) were drawn around the abdominal area (supporting 
info). Total Radiant Efficiency [p/sµW-1cm²] was reported. For intestinal images a three 
fluorophore setting was used to additionally subtract the stage fluorescence. The previous 
filter sets were used plus the addition of 570nm/800nm. Note: the D911A sample 3 was 
not used for analysis as the initial image showed substantial fluorescence around the 
mouth, relative to the stomach, that may have been slowly ingested, thereby altering later 
relative fluorescence comparisons.  
 The PL quantum yield (QY) of the CISS nanocrystals was calculated by 
comparing the PL spectra to that of fluorescein (QY = 1). The nanocrystal quantum yield 
(QYNC) was calculated by the following formula:  
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values, respectively. The CISS nanocrystals, PL quantum yields of up to 40% were 
recorded. 
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Chapter 5: High Dose Subcutaneous Delivery of a Protein Therapeutics 
INTRODUCTION 
Monoclonal antibodies have generated considerable interest as therapeutics 
because they specifically target distinct antigens with favorable pharmacokinetic, 
production, and safety profiles. Currently, 29 monoclonal antibodies have received FDA 
approval for treatment of a wide variety of diseases, commanding an annual market size 
of over $20 billion dollars (184, 185). Despite advances in protein drug development 
which allow tailoring of key biophysical properties, such as solubility(186), 
stability(187), and binding affinity(188) via recombinant DNA techniques, few options 
have been developed to deliver these macromolecules at desired dosages (>2 mg 
antibody/ kg body weight). Typically, large volumes of dilute protein solutions are 
delivered intravenously to avoid the chemical and physical destabilization and resulting 
loss in protein activity commonly associated with high concentration formulations (189, 
190). For instance, Rituxan doses of 100-500 mg are currently administered by 
intravenous infusion of a 10 mg/ml solution (191). Self-administered subcutaneous 
injections offer several major advantages over intravenous infusion, including increased 
accessibility and patient compliance, along with reduced pain and cost. However, the 
required therapeutic dosages indicate protein concentrations in excess of 100 mg/ml, 
given the maximum subcutaneous injection volume of 1.5 ml (192, 193).  
Formulation of therapeutic proteins at these high concentrations is intrinsically 
difficult, demanding solutions customized for each new product. Frequently, it is not 
possible due to low protein solubility (186, 194), protein instability(195-197), and high 
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solution viscosity(190, 198, 199) resulting from short-range attractive protein-protein 
interactions. These interactions, which include hydrophobic interactions, hydrogen bonds 
and fluctuating charge dipoles (199), act over distances up to ~1 nm (200). At high 
protein concentrations (over 150 mg/ml), the average separation distance between 
individual antibody molecules is reduced to less than 10 nm (201). Thus, the probability 
that two protein molecules will be less than 1 nm apart is high and the effect of the short-
range attractive interactions between protein molecules becomes significant (201). This 
leads to concentration-dependent formation of reversible and irreversible aggregates with 
potential adverse effects on protein activity, pharmacokinetics and immunogenicity. Most 
troubling are irreversible aggregates, high molecular weight aggregates comprised of 
monomers with altered structure and reduced activity, which can lead to a turbid solution 
or even protein precipitation. The formation of these aggregates is protein specific(202) 
and can form through physical mechanisms, such as partially unfolded monomers with 
exposed hydrophobic residues(203) or chemical mechanisms, such as formation of 
intermolecular bonds mediated by reactive thiols on cysteine or methionine residues 
(204). 
Protein structure and activity in low viscosity formulations can be preserved at 
high protein concentrations by minimizing the effects of these short-range interactions. 
For example, concentrated suspensions of protein microparticles in water-insoluble 
organic solvents(205) and aqueous suspensions of protein crystals(190) with low 
viscosity have been reported. These formulations succeed by using micron-sized (5-20 
μm) particles of proteins as opposed to protein monomers, thus increasing the average 
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distance between protein particles for a given protein concentration. However, 
formulations of proteins in organic solvents are not desirable as they require large-bore 
needles and can result in inflammation at the injection site (206). In addition, while 
highly concentrated aqueous suspensions of crystalline insulin have a history of clinical 
use (206), it is challenging to routinely crystallize large protein molecules such as 
immunoglobulins due to their high molecular weight, surface oligosaccharides, and 
segmental flexibility (190, 207). Similarly, controlled release formulations in which 
proteins are encapsulated in polymeric matrices with non-aqueous(208) or aqueous 
media(209-212) have also been explored. In these cases, the low levels of protein within 
the particle (~15-20 mass%) result in a low deliverable dose even at high particle volume 
fractions (127). Moreover, most polymeric delivery systems suffer from challenges 
related to sterility, protein stability, incomplete protein release, and increased 
immunogenicity (6, 24, 213).  
We recently reported a novel approach to preserve protein activity at high 
concentrations with low viscosity, via concentrated dispersions of nanoclusters, readily 
reversible particles (30-500 nm) composed of amorphous antibody molecules (201). In 
that work, lyophilized monoclonal murine or polyclonal sheep antibody was resuspended 
in buffer containing trehalose as a “crowder” molecule that occupies a large volume and 
increases the short-range protein-protein attractive interactions (201). Consequently, most 
of the protein molecules are concentrated into densely packed equilibrium nanoclusters, 
~80-300 nm in diameter, depending on the trehalose concentration used (201). A possible 
mechanism of nanocluster formation and stabilization was explained in terms of specific 
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short-ranged attraction, van der Waals and depletion attraction forces balanced against 
weak electrostatic repulsion to result in a colloidally stable protein nanocluster dispersion 
of discrete size and low viscosity (201). This hierarchy of attractive and repulsive 
interactions provides one possible explanation for the colloidally stable protein 
nanocluster dispersions with low viscosity that were observed experimentally (201). In 
addition, it was hypothesized that the high volume fraction of protein within the 
nanoclusters, much higher than is possible with a uniform protein solution, helped to 
maintain the native protein structure due to a self-crowding, entropic stabilizing 
mechanism (214, 215). Remarkably, nanocluster formation did not detectably alter the 
structure, antigen binding activity or in vivo pharmacokinetics of a monoclonal antibody.  
While promising, formation of therapeutic protein nanoclusters has only been 
reported using standard bulk freezing prior to lyophilization followed by resuspension in 
dispersion buffer with a single extrinisic crowder, trehalose (201). It is unclear whether a 
single extrinisic crowder will be sufficient to optimize protein formulations for the 
desired therapeutic properties for wide classes of proteins with varying stabilities, 
solubilities and molecular shapes. Additionally, more sophisticated freezing techniques 
than standard lyophilization may be required to preserve protein activity and engineer 
nanocluster particle morphology. In this study, we demonstrate that a multicomponent 
mixture of three crowding agents can be used to create stable dispersions of highly 
concentrated, active monoclonal antibody particles that retain high activity and 
bioavailability upon subcutaneous administration in mice.  
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The murine IgG2a monoclonal antibody 1B7, which binds and neutralizes the 
pertussis toxin (PTx) associated with whooping cough infection (216, 217), was selected 
to demonstrate applicability to a therapeutically relevant molecule and allow comparisons 
with previously described trehalose-only dispersion formulations. First, amorphous 
protein particles were generated via a new freezing method, spiral-wound in-situ freezing 
technique (SWIFT). Next, these particles were dispersed in the presence of three 
pharmaceutically acceptable crowding agents(218): water-soluble organic n-methyl-2-
pyrrolidone (NMP), polyethylene glycol (PEG), and trehalose to yield a formulation with 
low viscosity (<50 cP), high antibody concentration (~200 mg/ml) and ~430 nm 1B7 
nanoparticles. Importantly, the native 1B7 protein activity was preserved, as measured by 
in vitro biochemical methods and pharmacokinetics unaltered. Dispersions are a 
promising approach to generate highly concentrated, low viscosity antibody formulations. 
They can achieve dosages at least 10-fold higher than can be attained via solutions and 
can be formulated with a variety of pharmaceutically acceptable agents. 
RESULTS AND DISCUSSION 
Here, we report formation of highly concentrated, low viscosity dispersions of 
antibody nanoclusters, in which the antibody retains native size and binding activity upon 
dilution and in vivo sub-cutaneous administration. In contrast to our prior work (201), we 
used a novel freezing technique to form amorphous particles and multiple crowding 
agents to tune particle size. The combination of these innovations allowed us to 
administer subcutaneous antibody dispersions to mice at typical therapeutic doses (5.6-
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7.3 mg/kg) as well as an ultra-high dose, more than 10-fold higher than current practice 
(51.6 mg/kg). The measured pharmacokinetic parameters were similar for solution and 
dispersion formulations and antibody present in serum at the terminal timepoint retained 
antigen binding and neutralizing activities expected for 1B7. 
Stable Protein Particles made by SWIFT freezing 
The first step in preparation of concentrated aqueous dispersions is formation of a 
dried powder of protein particles. The choice of freezing method can be critical to both 
protect antibody structure and activity during freezing, as well as to produce particles of 
the appropriate size and morphology to yield a colloidally stable dispersion. To address 
these concerns, we developed a novel freezing technique, SWIFT, which rapidly freezes 
an antibody solution directly in the final packaging vial prior to lyophilization (Figure 
5.1A). The rationale in developing this technique is that two major sources of protein 
denaturation during freezing are exposure to liquid-gas interfaces during spray-freeze 
drying and the slow rate of freezing in larger volumes which can result in freeze 
concentration and subsequent concentration-dependent aggregation (219, 220). By 
rotating the vial of protein solution while in contact with liquid nitrogen, each concentric 
layer freezes in less than a second. The remaining liquid is gently mixed due to rotation, 
normalizing any concentration gradients.  
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Figure 5.1: Schematic of SWIFT freezing process and dry powder SEM. (A) The 
unfrozen protein solution in a cylindrical vial is placed on its side and rolled while 
exposed to liquid nitrogen. This causes a thin film of the protein solution to freeze on the 
inside edge of the vial followed by subsequent films towards the center of the vial 
resulting in a frozen annulus of protein solution which is placed in the lyophilizer to 
remove water. (B) Morphology of SWIFT powder after lyophilization by SEM. Scale 
bars indicate 2 microns, 1 micron and 200 nm. 
We used SWIFT followed by lyophilization to form micron-sized particles of the 
1B7 antibody used in the dispersions. These small particles may aid in minimizing any 
gel formation during the resuspension process that would adversely affect antibody 
activity and formulation viscosity versus tray lyophilization, which is also compatible 
with dispersion formulations18. To prevent protein aggregation during freezing, the 
protein solution was adjusted to contain a 1:1 weight ratio of trehalose as a cryoprotectant 
(219). The buffer selected, 20 mM histidine pH 5.5, is commonly used during 
lyophilization steps44. An SEM analysis of the frozen and lyophilized 1B7 indicates the 
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presence of micron-sized particles (Figure 5.1B). Importantly, antibody processed in this 
manner retained native size and activity upon reconstitution with PBS at 5 mg/ml. At this 
concentration, DLS detected a single species with a ~10nm hydrodynamic diameter, as 
expected for an antibody monomer (Figure 5.2A)(196).  
 
Figure 5.2: Size distribution of antibody particles. (A) Comparison of unprocessed, 
lyophilized and dispersed 1B7 by DLS. All samples were diluted to 5 mg/ml in PBS.   
(B) Effect of antibody concentration on particle size in dispersion buffer. At high 
concentration (200 mg/ml) in dispersion buffer, dynamic light scattering (DLS) detects 
only large particles of ~430 nm. Upon dilution below the threshold concentration for 
cluster formation in the dispersion buffer, concentrations of 2.5 and 1.25 mg/ml detect 
only particles of ~10 nm size, the expected size for monomeric IgG antibody. DLS data 
was analyzed by CONTIN. 
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The absence of larger particles indicated that the antibody did not form irreversible 
aggregates during SWIFT and lyophilization. In addition, an ELISA to monitor the 
specific PTx-binding activity of the reconstituted antibody revealed no significant change 
in activity due to SWIFT versus the untreated control (Table 5.1; Figure 5.3A), whereas 
ELISA after heat treatment (70°C for 60 minutes with 1 mM DTT) did detect a 
significant activity loss (data not shown).  
Dispersion 
buffer 
Protein 
concentration 
(mg/ml) 
Solubility 
(mg/ml) 
Colloid 
diameter 
(nm) 
Apparent 
viscosity 
(cP) 
Relative 
binding 
activity* 
20% NMP 
10% PEG300 190 ± 10 >2.5 196 ± 14 24 ± 7 1.50 ± 0.32 
Table 5.1: Biophysical characterization of 1B7 dispersions.                                                
* Calculated as (EC50, test/EC50, control) 
 
 
Figure 5.3: Characterization of antibody recovered from dispersion. (A) Comparison of 
unprocessed, lyophilized and dispersed 1B7 by PTx ELISA to monitor antibody activity. 
(B) SDS-PAGE gel comparing antibody 1B7 that is unprocessed, purified (lane 1), 
lyophilized, resuspended (lane 2) and a dispersion diluted from 200 to 1 mg/ml in PBS 
(lane 3). Arrows indicate the 175 and 140 kDa molecular weight markers. 
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The SWIFT process was designed to protect protein structure and activity. This is 
achieved via rapid freezing with minimal liquid-air interface, goals inspired by related 
process, thin film freezing (TFF)(221). In SWIFT, each film layer, corresponding to a 
single vial revolution, is ~200 nm thick (data not shown), Indirect contact with liquid 
nitrogen as a heat sink confers cooling rates of ~102 K/s. In TFF, a small volume of 
protein solution is deposited on a cryogenically cooled surface, where it spreads to ~210 
nm thickness, freezing within a single second (221). Scaling-up to compare freezing 
times for equal volumes, TFF freezes at a rate of ~5.1 seconds per ml of protein solution, 
while SWIFT results in a similar rate, ~7.5 seconds/ml (Figure 5.4).  
 
Figure 5.4: SWIFT freezing temperature profiles of lysozyme solutions (10 mg/ml) inside 
vials. The solutions were frozen in different film thicknesses 2.6 mm and 0.6 mm 
corresponding to the total liquid volume of 4 ml and 2.6 ml in vials with 15 mm diameter. 
The coolant temperature was 80 K and the vial rotation speed was 30 rpm. 
As a result of the similarities in freezing rates and film thicknesses, TFF and 
SWIFT processing of similar protein solutions yields dry particles with similar 
morphologies (Figure 5.1B)(221). For TFF, and by extension, SWIFT, the rapid cooling 
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and freezing rates generate a large number of ice nuclei, which exclude solute molecules 
due to freezing point depression effects. The remaining liquid is present in thin channels 
between ice nuclei, becomes supersaturated with dissolved crowder molecules and 
protein. The rapid freezing and consequent rapid vitrification of these liquid channels 
inhibits solute diffusion; as these molecules precipitate, the reduced collision frequency 
inhibits coagulation of these small insoluble particles to generate larger particles. In 
addition, as the concentrations of dissolved solutes rise in the unfrozen liquid, the 
associated viscosity increase further reduces the mobility of the growing particle nuclei. 
During the dehydration step, water present in these channels is removed, leaving small 
particles of dry protein and crowder. In contrast, traditional tray freezing lyophilization 
with its slower freezing rate yields larger liquid channels and larger final particles after 
drying (221). Thus smaller submicron protein particles, as shown in Figure 5.1B, are 
formed during SWIFT freezing versus standard tray freezing lyophilization. 
With both SWIFT and traditional tray lyophilization, low levels of protein 
denaturation and aggregation are achieved by kinetic and thermodynamic stabilization of 
the native protein structure during freezing and lyophilization. The native protein state is 
stabilized during lyophilization by kinetically trapping protein molecules in an 
amorphous solid (137, 204, 222), thereby reducing protein mobility that can lead to 
aggregation. Addition of the lyoprotectant trehalose during lyophilization further 
thermodynamically stabilizes the protein native state during freezing by entropically 
favoring the native folded state(204, 222, 223) and during dehydration by forming 
hydrogen bonds with proteins(224, 225). However, processes to rapidly freeze proteins 
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such as spray freeze drying (SFD), have been shown to increase protein aggregation 
versus standard tray freezing lyophilization due to the large gas-liquid interface in the 
spraying step (226, 227). The large area/volume of the gas-liquid interface of ~6000 cm-1 
in SFD for 10 mm sprayed droplets can lead to protein adsorption at the interface, 
denaturation and aggregation (137, 226, 228-230). In the case of SWIFT, the gas-liquid 
interface is minimized as the only exposure of the liquid protein solution to the air is the 
liquid interface inside the glass vial. As a result, the estimated gas-liquid interface 
decreases 3 orders of magnitude when compared to SFD to ~4 cm-1. Thus 1B7 was 
anticipated and found to remain active upon reconstitution to monomer from the dry 
powder form after SWIFT freezing and lyophilization.  
One practical advantage of SWIFT freezing is the ability to freeze directly in the 
final dosage vial when compared to other rapid freezing techniques such as TFF and SFD 
(221, 230, 231). This approach avoids the need for costly, solid transfer steps while 
maintaining aseptic conditions. In this case, if a dosage of 80 mg of the protein is 
required at a concentration of 20 mg/ml, the 8 ml vial used in the study can serve as both 
the freezing and reconstitution vial. However, since the cooling rate of SWIFT freezing is 
governed by the liquid cryogen used and the thickness of the glass vial, as well as the 
heat transfer coefficients of the materials used, the vial can be readily scaled-up or down 
to meet dosage requirements. In addition, by removing the transfer step to the final vial, 
all of the protein can be recovered after lyophilization and utilized in the formation of the 
final dosage. 
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Colloidal Characterization of 1B7 particles in dispersion 
To form the colloidally stable, translucent nanocluster dispersion, the dry, sub-
micron particles of antibody and trehalose produced via SWIFT were combined (Figure 
5.5A) with a 50 mM phosphate buffer adjusted to the antibody pI (pH 7.2) containing two 
additional crowding agents: 20% n-methyl-2-pyrrolidone (NMP) and 10% polyethylene 
glycol 300 (PEG300) by volume. After combining the SWIFT particles and dispersion 
buffer, the trehalose contained in the dry powder dissolves. A fraction of the trehalose 
will diffuse into the solution, increasing the volume fraction of crowding agents as 
observed previously for sheep IgG (201). Sufficient dispersion buffer was added to the 
dry powder to yield a final antibody concentration of 190 mg/ml with a final 0.34 volume 
fraction (Φ) of crowding agents.  
Under these conditions, DLS with CONTIN analysis of the dispersion using a low 
volume (60 μL) cell identified a single population of particles with a ~432 +/- 16 nm 
diameter. This colloid size was reproduced in three separate experiments, measured each 
time in triplicate, with a representative curve shown in Figure 5.2B. This particle size was 
further confirmed by SEM images of the dispersion after dilution to 100 mg/ml in the 
dispersion buffer, rapid freezing and lyophilization onto an SEM stage (Figure 5.5B).  
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Figure 5.5: Visual appearance of dispersion. (A) Digital image of suspended particles. 
(B) SEM image of antibody dispersion (200 mg/ml) when diluted to 100 mg/ml in the 
dispersion buffer, rapidly frozen and the water removed by lyophilization. Scale bar 
corresponds to 200 nm. 
This image shows nanoparticles of a size consistent with DLS measurements, but 
a different shape due to coating with crystallized trehalose. Previously, SEM and STEM 
images of dispersed sheep IgG and 1B7 particles at lower trehalose concentrations, 
visualized the dispersed particles as clusters of smaller particles (201). To confirm that 
these results are not affected by dissociation of the 1B7 nanoparticles, we determined the 
conditions where 1B7 nanoclusters dissociate to monomer in dispersion buffer, using 
methods reported previously (201). Starting with the 190 mg/ml dispersion, we 
progressively added dispersion buffer to reduce the protein concentration and measured 
the resulting particle sizes by DLS (Figure 5.2B). We observed a single peak at ~430 nm 
until the protein concentration was reduced to 2.5 mg/ml or less. At this concentration, 
only a single ~10 nm peak is present, corresponding to the hydrodynamic diameter of a 
single monoclonal antibody molecule (196). From these data, we conclude that 1B7 
nanoclusters in this dispersion buffer completely dissociate to monomer at ~2.5 mg/ml 
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and that 1B7 nanoparticles formed with trehalose, PEG and NMP are fully reversible 
(Table 5.1). 
The dispersed particles were formed and exhibited colloidal stability, possibly due 
to a previously proposed balancing of the intermolecular attractive and repulsive 
interactions at the protein molecular and colloidal levels, respectively (201). Briefly, 
individual protein molecules are subject to highly attractive depletion and specific short-
ranged interactions such as hydrophobic interactions, hydrogen bonding and charge-
dipole interactions (201, 232, 233). Near the 1B7 pI, longer-range electrostatic repulsion 
is relatively weak and thus the attraction force dominates between isolated pairs of 
protein molecules. However, once these molecules assemble into nanoclusters of 
sufficient size, the cumulative electrostatic interactions between particles in the cluster 
balance the attractions, stabilizing the dominant size (201). Between clusters, short-range 
attractive interactions are expected to be negligible relative to electrostatic repulsion 
resulting in a colloidally-stable dispersion of protein nanoclusters, as has been discussed 
previously (201). 
The strength of depletion-attraction forces can be tuned by varying the 
concentrations of the crowding agents (234, 235). As observed here and previously (201), 
an increase in crowder concentrations favors 1B7 nanocluster formation. While 1B7 and 
the sheep IgG dispersions could both be formulated with a single crowding agent, 
trehalose, the ternary crowder system used here may provide additional flexibility to 
formulate dispersions with highly soluble proteins or to further control the nanocluster 
size, protein stability, dispersion viscosity and nanocluster degradation during delivery. 
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The low apparent viscosity, 24 cP, of the 190 mg/ml 1B7 dispersion was 
measured as the viscosity through a 25 gauge 1.5 inch needle (Table 5.1). This viscosity 
measurement was previously characterized for subcutaneous injections of highly 
concentrated solutions of monoclonal antibodies and non-aqueous suspensions of 
lyosyzme (205). Due to our very small sample volumes (~100 ul), we were concerned 
that evaporation would rapidly affect values measured with a traditional viscometer. The 
apparent dispersion viscosity is commonly described as a function of the intrinsic 
viscosity, [η], maximum volume fraction of particles, φmax, and the solvent viscosity, η0, 
using the Krieger-Dougherty equation (Eq. 1)(205, 236). 
Eq. 1     
The η may be reduced by lowering η0, or [η], which has a minimum of 2.5 for hard 
sphere colloids, and increasing φmax. For protein molecules in solution at high 
concentrations, for example f = 0.1 to 0.3, strong short-range specific attractive 
interactions(233, 237), often produce viscosities 5 to 100 times the hard sphere value 
(198, 238). For monoclonal antibody solutions with concentrations of 150 mg/mL, 
viscosities greater than 100 cP have been attributed to reversible self-association of 
protein molecules, on the basis of measurements by analytical ultracentrifugation (198, 
239). In contrast, the low viscosities observed in the present study for the nanocluster 
dispersions may be consistent with the weak interactions between the nanoclusters, as 
suggested previously (201).  
[ ] max
max
1
φη
φ
φ
η
η
−
⎥
⎦
⎤
⎢
⎣
⎡
⎟⎟
⎠
⎞
⎜⎜
⎝
⎛
−=
o
152  
In vitro molecular stability of 1B7 dispersion 
As processing steps can adversely affect protein structure and activity, we 
monitored the antibody size within the dispersion and after dilution using several 
techniques, including DLS, non-reducing SDS-PAGE and ELISA (Table 5.1). After a 10-
fold dilution from the 190 mg/ml dispersion into PBS, DLS measured a single species 
with a ~10 nm hydrodynamic diameter, as expected for a single antibody monomer 
(Figure 5.2A)(196). The absence of larger particles indicates the dispersion formulation 
does not induce irreversible aggregates and that the antibody can readily recover its 
monomeric size upon dilution. This is further confirmed by non-reducing SDS-PAGE 
(Figure 5.3B), in which a single band of the expected antibody monomer size ~150 kDa 
is observed, indicating an absence of irreversible thiol-linked and SDS-resistant 
aggregates (240). Finally, an ELISA to monitor the specific PTx-binding activity of the 
antibody reveals no significant change in activity due to the formation or dilution of the 
dispersion versus untreated control based on EC50 comparisons (Figure 5.3A; Table 5.1).  
For antibody formulated as a dispersion to maintain therapeutic efficacy upon in 
vivo injection(241, 242), the native antibody activity must be maintained through every 
processing and delivery step: from (1) freezing and lyophilizing the antibody solution, (2) 
nanocluster formation via dispersion, and (3) delivery through a syringe, to (4) 
nanocluster dissociation and diffusion from the injection site. While loss of protein 
conformational stability can result from chemical degradation as well as physical 
denaturation processes, physical denaturation is expected to be the larger challenge to 
successful development of high protein concentration formulations due to its strong 
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dependence on protein concentration (192, 241). As discussed above, the protein powder 
formed by SWIFT freezing and lyophilization exhibited no detectable loss in antigen-
binding activity or development of aggregates after reconstitution in buffer.  
It has been speculated that the use of in vitro self-crowding to stabilize native 
protein might mimic the in vivo intracellular environment, in which folded proteins are 
stabilized by a high concentration of diverse molecular crowding agents (300-400 mg/ml) 
(214, 243). In that model, the high protein volume fraction within a nanocluster allows 
the protein to act as its own crowding agent, entropically favoring the lowest surface area 
conformation of the protein, which is typically the native state (201, 214, 215). This 
result was originally predicted theoretically(214), but the first indirect experimental 
validation awaited development of dispersions(201) as protein solutions cannot achieve 
the high protein volume fractions (>0.15) necessary. Unfolding and irreversible 
aggregation of protein molecules in the nanocluster is thought to be further reduced by 
decreased protein mobility within the highly concentrated nanocluster versus a solution 
(189, 244, 245). Since molecule collisions can lead to the formation of aggregates, a 
reduced collision frequency among protein molecules at the nanocluster-buffer interface 
kinetically stabilizes these molecules (195, 201, 246).  
The retention of protein activity and the lack of detectable aggregates upon in 
vitro dilution from the concentrated dispersion is an important indication of in vivo 
protein stability. At the high concentrations of the dispersion formulation, we speculate 
that the 1B7 antibody is stabilized within the nanoclusters by self-crowding, at the 
nanocluster boundary layer and in the aqueous phase by crowders present in the 
154  
dispersion buffer (247). Similarly, the diluted 1B7 is stable at final solution 
concentrations (~10 mg/ml) in PBS buffer due to the inherent stability of the 
immunoglobulin fold, which has evolved to persist for ~23 days in serum containing 60-
85 mg/ml total protein. The most aggregation-prone step will occur at intermediate 
concentrations, when the protein is no longer at a sufficiently high concentration for self-
crowding to inhibit partial unfolding, but high enough for transiently unfolded 
intermediates to aggregate via concentration-dependent aggregation. Using the Noyes-
Whitney equation for high surface area to volume particles, we predicted a nanocluster 
dissociation time, to provide an estimate of the duration the protein spends in this 
intermediate concentration regime. Dilution of ~430 nm antibody nanoclusters into PBS, 
in which 1B7 nanocluster threshold concentration is >50 mg/ml, is expected to result in 
particle dissociation in less than one second.  
Experimentally, dilution of 1B7 protein nanoclusters with dispersion buffer to 
maintain a constant crowder concentration resulted in recovery of monomeric, active 
protein, as measured by DLS and ELISA (201). For a trehalose-induced polyclonal sheep 
IgG dispersion at a constant protein concentration, a steady decrease in nanoparticle size 
was achieved by diluting the crowder to weaken the attractive forces between 
immunoglobulin molecules (201). At each step, the clusters were fully diluted and 
characterized, and found to have expected activity as measured by ELISA (201). The 
protein molecules on the cluster surface are expected to be crowded by protein molecules 
on the cluster side and sugar molecules at the cluster-buffer interface. As protein 
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molecules diffuse away from the cluster surface into the PBS media, they retain activity 
as shown by the DLS and ELISA experiments.  
In vivo bioavailability of stable 1B7 from dispersions 
No reliable in vitro models exist to mimic in vivo dissociation of the dispersion 
after subcutaneous injection. Thus, we proceeded to a mouse model to measure the 
pharmacokinetic parameters as well as the specific activity of in vivo dissolved antibody 
material. The five treatment groups included three control groups to allow direct 
pharmacokinetic comparison of low volume, high concentration and large volume, high 
concentration dispersion test groups. The control groups 1 and 2 received a standard 
antibody dose (4.6-5.6 mg/kg in 100 μl) to allow for a direct comparison of the 
subcutaneous dispersion injection pharmacokinetics to intravenous and sub-cutaneous 
delivery of an antibody solution. A third control, group 3, assessed the effect of 
dispersion formulation on antibody pharmacokinetics, in which the dispersion was 
diluted to 1.4 mg/ml with dispersion buffer, a concentration below the cluster limit and 
comprised of antibody monomers. Two test groups were designed to assess the combined 
effects of dispersion concentration and delivered volume on in vivo dissociation rates and 
the resulting pharmacokinetics. In group 4, mice received a standard dose (7.3 mg/kg) 
administered as a high concentration dispersion (190 mg/ml) in a small 1 μl volume. 
Group 5 received an ultra-high antibody dose, which can only be achieved with high 
concentration, low viscosity formulations such as a dispersion. These mice received a 
ten-fold higher dose than the other groups (51.6 mg/kg in 100 μl). For all groups, serum 
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samples were collected from the tail vein over 14 days, with the concentrations of total 
and active 1B7 antibody in each sample measured by streptavidin and PTx capture 
ELISAs, respectively. The efficacy of antibody present at the terminal time point was 
also assessed using an in vitro activity assay, based on antibody-mediated inhibition of 
toxin activity. 
Overall, the 1B7 pharmacokinetic profile is quite similar for all groups, with 
distribution and elimination kinetics all within error. The primary differences result from 
the injection site and injection volume, affecting the time to reach the maximum 
concentration (tmax) and the value of the maximum concentration (Cmax/ dose). Looking 
first at the three control groups, delivery via subcutaneous dispersion resulted in a lower 
Cmax/dose and delayed tmax, as compared to IV and subcutaneous delivery of solutions 
(Table 5.2; Figure 5.6).  
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Group 
1: IV 
Solution * 
2: SQ  
Solution * 
3: SQ 
Diluted 
Dispersion 
4: SQ 
Dispersion, 
Standard Dose 
5: SQ 
Dispersion, 
High Dose 
N 6 4 5 5 6 
Injection Volume 
(µl) 100 100 100 1 100 
Dose 
(mg/kg) 5.6 5.6 4.6 7.3 51.6 
Cmax/dose 
(μg/ml)/(mg/kg) 25.5 ± 3.8 18.8 ± 4.4 9.1 ± 3.2 7.3 ± 1.3 7.6 ± 2.6 
AUC 0-∞/ dose 
(μg·hr/ml)/(mg/kg) 3582 ± 990 2699 ± 583 1790 ± 630 1345 ± 467 1919 ± 566 
tmax 
(hours) 15.1 ± 0.7 18.9 ± 3.1 28.8 ± 12.0 20.1 ± 3.2 20.2 ± 5.2 
t1/2,α 
(hours) 45.7 ± 22.8 43.4 ± 17.3 54 ± 21 * 49 ± 29* 51 ± 23 * 
t1/2,β 
(hours) 227.1 ± 24.9 210.0 ± 17.4 219 ± 25 180± 16 250± 24 
Relative 
Neutralization 
Activity 
2.3 ± 1.7 1.0 ± 1.8 0.4 ± 0.2 0.5 ± 0.2 2.1 ± 1.0 
Table 5.2: Pharmacokinetic parameters for antibody 1B7 formulations.                                
* t1/2,α determined from 2 points for some mice. Data reported(201) 
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Figure 5.6: Serum concentrations of antibody 1B7 after delivery. The 1B7 antibody was 
formulated and administered to mice with the indicated volumes and doses. At the 
indicated times, tail vein samples were collected and the concentration of active antibody 
present measured by PTx ELISA, normalized by the administered dose and plotted. (A) 
Comparison of antibody 1B7 pharmacokinetics when delivered as a 100 μl solution. 
Group 1 mice received an IV administration at 5.6 mg/kg, while Group 2 mice received a 
subcutaneous delivery at 5.6 mg/kg. (B) Comparison of 1B7 pharmacokinetics when 
delivered via subcutaneous dispersion with varying concentrations and injection volumes. 
Groups 3 mice received a standard dose as a diluted dispersion at 4.6 mg/kg in a 100 µl 
injection volume, Group 4 mice received a standard dose dispersion at 7.3 mg/kg in a 1 
µl injection volume, while Group 5 mice received high-dose dispersion at 51.6 mg/kg 
dose in a 100 µl injection volume. Curve fits by spline fitting. 
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The group 1 control IV solution reached a maximum serum concentration at the 
first measured time point (12 hours), followed by a rapid decrease as the antibody is 
distributed throughout the tissues (201). In comparison, the subcutaneous solution group 
displayed a slightly reduced Cmax/dose (25.5 versus 18.8 ug/ml/ mg/kg) and statistically 
significant delayed tmax (15 versus 19 hrs; p<0.05). While IV-administered material is 
instantly diluted in the blood volume, material administered subcutaneously must diffuse 
from the injection site through interstitial fluid to reach the lymphatic and blood vessels 
before distribution in the blood volume, delaying these pharmacokinetic parameters 
(Figure 5.6A)(201, 248). The subcutaneous dispersion injections, groups 3 and 5, exhibit 
similar trends as the subcutaneous solution but with a slightly lower Cmax and delayed tmax 
when compared to the subcutaneous solution (Figure 5.6B). This may reflect the effects 
of the dispersion buffer on antibody diffusion, as the effect is minimized with group 4, 
standard dose subcutaneous dispersion, which was injected as a ~1 ul volume instead of a 
100 ul volume using a positive displacement microvolume syringe. For this sample, the 
tmax was similar (within error) to that of the subcutaneous solution.  
Once the maximum serum concentration is attained, all groups show similar 1B7 
distribution and elimination pharmacokinetics. As seen in Figure 5.6, these data fit a 
biphasic exponential profile, with α distribution and β elimination time constants that are 
within experimental error for all groups, based on 1B7 concentrations measured by the 
PTx ELISA (Table 5.2). The β elimination half-life was also within error for all groups 
when measured using a total 1B7 ELISA assay, based on streptavidin detection of the 
biotinylated antibody (data not shown). The distribution phase represents passive 
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antibody diffusion from the well-mixed blood volume into other tissues, driven by the 
1B7 concentration gradient and the elevated vascular pressure, while antibody 
elimination rates are controlled by interactions with specific receptors such as the FcRn 
(248, 249). Notably, both rates will vary with antibody aggregation and misfolding. A 
soluble aggregate will have a larger size and consequently larger diffusion constant and 
slower t1/2α, while a misfolded monomer or soluble aggregate will exhibit different 
binding kinetics for the FcRn and a different t1/2β. The similar kinetics observed for all 
groups indicate that the antibody delivered as a subcutaneous dispersion is able to 
dissociate from the nanocluster and diffuse away from the injection site while retaining 
an active, monomeric form, similar to our in vitro observation in which active 1B7 
monomer is rapidly recovered upon dispersion dilution. 
These experiments were performed in mice, where the large permissible injection 
volume per body mass (100 μl/ 25g) allows for direct comparisons between solutions and 
dispersions formulated at the same concentration. A similar comparison is not possible in 
humans, as subcutaneous injections are restricted to ~1.5 ml volume. To demonstrate that 
dispersions can achieve dosages relevant for humans, we prepared group 4 as a scaled-
down version of a human dose (Figure 5.6B). Here, a ~1 μl volume of highly 
concentrated dispersion (190 mg/ml) was administered subcutaneously, for a final 7.6 
mg/kg murine dosage. Scaling-up to calculate the human dosage, in which a 190 mg/ml 
dispersion could be administered in a 1.5 ml volume, this is equivalent to a 4.3 mg/kg 
human dose, exceeding current typical dosing guidelines (2 mg/kg). To evaluate the 
potential for dispersions to result in less-frequent administration of ultra-high antibody 
161  
dosages, which are not currently achievable with solutions, group 5 mice received a large, 
100 μl injection volume of highly concentrated dispersion (190 mg/ml), for a 51.6 mg/kg 
dose. In spite of the large error inherent to administering a 1 μl injection of a viscous 
solution, this group also exhibited similar pharmacokinetics (similar tmax, t1/2,α, t1/2,β) 
and 1B7 bioavailability indicating concentration and dose-independent pharmacokinetics. 
Reduced absolute bioavailability of 50-100% is expected for a subcutaneous 
administration and was observed in this study as 75.4% +/- 26.4 for the sub-cutaneous 
solution control. The relative bioavailability of the dispersion formulations were further 
reduced (66.3% +/- 27.4 for the diluted dispersion, 49.8% +/- 20.4 for the standard dose 
dispersion, and 71.1% +/- 26.0 for the high-dose dispersion), possibly due to incomplete 
cluster dissociation and/or increased lymphatic processing. This decrease in relative 
bioavailability is likely related to the use of crowder agents employed in this study, as 
previous work using only trehalose resulted in relative bioavailability within error of 
subcutaneous solution injections (201).  
To provide an orthogonal measurement of antibody quality to complement 
antigen ELISA, we measured 1B7 biological activity with an in vitro CHO cell 
neutralization assay using sera from the terminal time point. Free PTx will bind cell-
surface receptors, undergo receptor-mediated endocytosis and eventually ADP-
ribosylation of Gi/o coupled receptors; phenotypically, the cells lose contact inhibition and 
grow in a clustered morphology. Antibody-mediated neutralization of PTx blocks toxin 
entry into cells, protecting the normal growth phenotype. Sera were diluted in the 
presence of a fixed PTx concentration, CHO cells added and, after 24 hrs growth, scored 
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for normal or clustered morphology. The highest sera dilution completely preventing 
CHO cell clustering was recorded and compared versus purified control 1B7 antibody. 
This assay resulted in no statistically significant differences between groups on titre per 
μg antibody basis. Based on this assay, there is no evidence for a loss in antibody efficacy 
as a result of injection site (subcutaneous vs. IV) or formulation (Table 5.2). Western blot 
analysis was used to demonstrate the absence of gross physical changes in serum 
antibody due to formulation and administration route, such as formation of insoluble or 
disulfide bonded aggregates (data not shown). This in vivo data is consistent with our in 
vitro observations, that the protein within the dispersion shows no detectable loss of 
native size or activity during processing or in vivo administration.  
CONCLUSIONS 
Nanocluster dispersions allow monoclonal antibody formulation at high 
concentration and low viscosity, with no detectable loss in antibody size or activity in 
vitro or in vivo and similar pharmacokinetics when administered subcutaneously to mice. 
Highly concentrated ~190 mg/ml aqueous-based dispersions of a therapeutically relevant 
antibody, 1B7(217), were formed from stable, submicron protein particles containing a 
1:1 weight ratio of trehalose in an aqueous buffer with multiple crowding agents, 
including trehalose, PEG and NMP. These particles were produced by rapid freezing in a 
dosage vial using SWIFT to minimize protein denaturation and aggregation, followed by 
lyophilization. A nanocluster dispersion was formed in the aqueous-based solvent near 
1B7’s pI by adding pharmaceutically acceptable crowding agents, PEG300 and NMP, 
163  
along with the trehalose from the dry powder. Additional analyses, ELISA, DLS and 
SDS-PAGE, indicate that the protein rapidly recovers a fully active monomeric form 
upon dilution of the dispersion with PBS. The apparent viscosity of the 190 mg/ml IgG 
dispersion with NMP and PEG through a 25 g 1.5” needle was only 24 cP, reflecting the 
low initial solution viscosity and the low intrinsic viscosity. The measured in vivo 
distribution and elimination half-lives were similar for control solution and dispersion 
formulations administered at similar doses. The time to peak serum concentration (tmax) 
was delayed for the subcutaneous injections, consistent with the expected slower 
diffusion kinetics from this injection site. Remarkably, analysis of terminal serum 
samples was unable to detect a loss in 1B7 activity over the 14-day study period. This 
formulation strategy, in which crowding agents drive formation and stabilization of 
protein nanoclusters, has been shown to be applicable for both monoclonal and 
polyclonal antibodies. In this work, we demonstrate formulation with multiple crowding 
agents, which will provide flexibility in formulating additional therapeutic proteins. The 
ability to form stable, highly concentrated dispersions of a protein therapeutic with low 
viscosities and favorable bioavailability will increase the potential use of subcutaneous 
injection, possibly for treatment of many chronic diseases. 
MATERIALS AND METHODS 
Antibody expression and, purification  
Murine hybridoma cells producing the IgG2a antibody 1B7 were grown in 1 liter 
shaker flasks in Hybridoma-SFM serum-free media (Gibco) at 37˚C with 5% CO2, as 
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reported previously (201, 217). Briefly, antibody purification consisted of media 
clarification by centrifugation at 3,000 rpm for 20 minutes, followed by filter sterilization 
using a 0.2 µm filter, 1:1 dilution with binding buffer (20 mM pH 7.0 sodium phosphate) 
and loading onto a pre-equilibrated Protein-A column with an Akta FPLC system (GE 
Healthcare). After baseline stabilization, 1B7 was eluted into collection tubes containing 
1 M Tris pH 8.0 using a low-pH elution buffer (0.1M glycine pH 2.7), concentrated and 
buffer exchanged with centrifugal micro-dialysis units (Centricon). Protein concentration 
was measured with micro-bicinchonoinic acid (BCA) assay (Pierce, Rockford, IL), while 
non-reducing SDS-PAGE verified protein preparation homogeneity and purity. Purified 
1B7 was labeled with biotin using EZ-link® Sulfo-NHS-LC-Biotin (Pierce, Rockford, 
IL) to provide an orthogonal detection handle to track the murine antibody in murine 
serum samples. A 5 mM solution of the biotin reagent was added at a 5:1 molar ratio to a 
1 mg/ml solution of the 1B7 in PBS at room temperature and allowed to react for 30 
minutes. Excess biotin was removed by buffer exchange using 50,000 MWCO Centricon 
concentrators with PBS. Protein was >95% pure, as judged by SDS-PAGE, SEC and 
isoelectric focusing gel. 
Amorphous particle formation by spiral wound in-situ freezing technology (SWIFT) 
Purified and biotinylated 1B7 was buffer exchanged into 20 mM pH 5.5 histidine 
buffer using Centricons, as above. The protein concentration was measured, solid α-α 
trehalose (JT Baker) was added to a 1:1 wt ratio as a cryoprotectant and gently mixed to 
dissolve. The resulting solution was filter sterilized (0.22 µm), diluted to 20 mg/ml 
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protein and transferred to a sterile 8ml (1.9 cm x 4.8 cm) glass vial for SWIFT freezing. 
During SWIFT, the base of the vial was contacted with liquid nitrogen while rotating the 
vial on its side (~1 revolution/second), resulting in a thin film of frozen solution on the 
inside edge of the vial, with subsequent thin films freezing in a spiral towards the center 
of the vial (Figure 5.1A). After the entire volume was frozen (~10-40 seconds), the 
samples were placed upright on a pre-cooled lyophilizer shelf at -40°C. The samples were 
then lyophilized for 12 hours at -40°C at 100mTorr, followed by a 6 hour ramp to 25°C at 
50 mTorr, and maintained for secondary drying at 25°C at 50 mTorr for at least an 
additional 6 hours. To assess protein activity after freezing, powder was reconstituted at 5 
mg/ml in PBS for analysis by dynamic light scattering (DLS) and enzyme-linked 
immunosorbent assay (ELISA) as described below. Samples of the dry powders after 
lyophilization for scanning electron microscopy (SEM) analysis were placed on adhesive 
carbon tape to fix the sample to the SEM stub. Each sample for SEM was platinum-
palladium sputter coated using a Cressington 208 bench top sputter coater to a thickness 
of 10nm. Micrographs were taken using a Zeiss Supra 40 VP scanning electron 
microscope with an accelerating voltage of 5 kV. 
Dispersion formation 
To form the dispersion, SWIFT frozen and lyophilized 1B7 protein powder was 
compacted into 0.1ml conical vials (Wheaton Science Products No. 986211) such that the 
total powder weight was 0.04 ± 0.001 g. An aqueous-based solvent dispersion buffer, 
containing 10% (v/v) PEG300 (Spectrum Chemical Manufacturing) and 20% (v/v) n-
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methyl-2-pyrrolidone (NMP; Malinckrodt) in a 50 mM phosphate buffer with the pH 
adjusted to match the measured antibody pI (pH 7.2, data not shown), was added to the 
lyophilized protein. Gentle stirring with the tip of a needle removed air pockets, to yield a 
uniform, optically clear dispersion with a final 1B7 concentration of 190 mg/ml. Neither 
sonication nor violent mixing was necessary to form a uniform translucent dispersion. All 
analyses were performed within two hours of dispersion formulation. 
Viscosity measurement 
The apparent viscosity of the 1B7 dispersion was measured as the time to draw 50 
μl of the dispersion into a 25 gauge 1.5” long needle attached to a 1ml tuberculin slip tip 
syringe, as reported previously for sheep IgG dispersions (201). Briefly, videos of the 
conical vial containing the dispersion were taken and the time to draw from a height 0.4” 
from the bottom of the cone to a height 0.1” from the bottom of the cone was measured 
using Image J software. A standard curve using known solutions with various viscosities 
provided a linear correlation between the time to draw 50 μl from the conical vial to the 
viscosity with an R2 value greater than 0.9918. These results are consistent with previous 
work with suspensions of model proteins and protein solutions which found that the time 
to draw up a specified amount of the sample in a syringe was correlated linearly to 
viscosity (198, 201, 205). 
Colloidal size determination/ characterization 
Dynamic light scattering (DLS) was used to measure the sizes of particles present 
in the purified 1B7 preparation, concentrated 1B7 dispersion and dilutions of the 
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dispersion using a custom-built DLS apparatus39 modified to include backscattering 
angles up to 165°(201). Particle sizes in the concentrated dispersion were measured with 
a small volume cell (60 μl, Beckman Coulter #A54094) at ~23°C and a 160° scattering 
angle, while all other measurements were made in a standard 1 ml cell at ~23°C and 
scattering angles optimized to detect the relevant particle size, as analyzed with 
CONTIN. To estimate the concentration below which only 1B7 monomers are present in 
the dispersion buffer, the 190 mg/ml dispersion was diluted 1:40, 1:80 and 1:160 in 
dispersion buffer and particle sizes measured at a 90° scattering angle. We define the 
concentration of 1B7 at which the protein monomer peak is observed by DLS as the 
threshold concentration for cluster formation. To mimic the effects of dilution on particle 
size and detect formation of aggregates, the dispersion was diluted 1:40 in PBS to give a 
final 5 mg/ml 1B7 concentration and the resulting particle sizes measured at a scattering 
angle of 30°. The size of purified 1B7 monomeric antibody in PBS was measured at 5 
mg/ml and a scattering angle of 30°.  
In vitro antibody activity and aggregation assays 
All assays of protein activity and structural stability were conducted on 1B7 
dispersion diluted to 1 mg/ml in PBS. Controls included lyophilized 1B7 and purified, 
untreated 1B7, both adjusted to 1 mg/ml in PBS. The formation of insoluble and di-
sulfide linked aggregates was monitored by non-reducing SDS-PAGE. Here, 3 μg 1B7 
sample was combined with loading buffer, separated on a 4-20% precast linear gradient 
polyacrylamide gel (Bio-Rad) and stained with Gel-Code Blue (Bio-Rad). 
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To monitor ligand-binding activity, an indirect PTx ELISA was employed as 
reported previously (201, 217). High-binding ELISA plates (Costar) were coated with 
pertussis toxin (PTx, List Biological Laboratories) at 0.75 μg/ml in PBS and incubated at 
4°C overnight. Wells were blocked with assay buffer (PBS-1% milk) for 1 hour, prior to 
addition of 1B7 samples in a √10 serial dilution scheme from 50 μg/ml in assay buffer. 
After a one hour incubation at room temperature and triplicate washes with PBS-0.05% 
Tween-20, goat anti-mouse IgG-horseradish peroxidase conjugate (1:2,000 dilution in 
assay buffer, Sigma) was incubated for one hour at room temperature. Plates were 
washed in triplicate and signal developed with tetramethylbenzidine dihydrochloride 
(TMB) substrate (Pierce), quenched with 1N HCl and the resulting absorbance at 450 nm 
recorded using a SpectraMax M5 instrument. The EC50 value was calculated from the 
linear range of the dose-response curve as the antibody concentration corresponding to 
50% of the maximum absorbance, based on a four-parameter fit. For comparison between 
samples, the relative EC50 was calculated as the ratio of the sample EC50 to unprocessed 
control antibody EC50. All samples were run in triplicate. 
In vivo bioavailability in BALB/c mice 
An in vivo pharmacokinetic study of the 1B7 dispersion and control solution was 
performed over a 14 day period using four to six healthy 24-27g, female BALB/c mice 
per group. Mice were administered a single 1 or 100 μl subcutaneous injection of 1B7 at 
standard (4.6-7.3 mg 1B7/kg body weight) or high (~51.6 mg/kg) doses. The five sample 
groups compared in this study included two solution control groups receiving (1) IV and 
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(2) subcutaneous injections of 100 µl 1B7 solution (1.4 mg/ml solution for a final 5.6 
mg/kg dose),(201) as well as three test groups, receiving subcutaneous injections of (3) 
100 µl of a diluted PEG-NMP dispersion at standard dose (4.6 mg/kg), (4) 1 µl dispersion 
at a standard (7.3 mg/kg) dose; and (5) 100 µl of dispersion at high dose (51.6 mg/kg) 
(see Table 5.2). The previously reported solution controls (groups 1 and 2) were prepared 
from a 20 mg/ml 1B7 solution in PBS diluted to 1.4 mg/ml in PBS(201) while the 
dispersion samples were diluted from a 190 mg/ml 1B7 dispersion to a concentration of 
1.2 mg/ml for group 3 (at this concentration, below the threshold for nanocluster 
formation, the antibodies are recovered as monomers), 12.9 mg/ml for group 4, and 190 
mg/ml for group 5 with dispersion buffer immediately prior to injection.  
 
Prior to the injection and at eight additional timepoints between 12 and 336 hours, 
mice were weighed and a blood sample (~20 μl) collected from the tail vein. After 
collection, the samples were allowed to clot, centrifuged at 5,000 rpm for 10 minutes and 
serum transferred to a new tube. At the terminal timepoint (336 hours), mice were 
anaesthetized and between 0.2 and 1 ml serum collected by cardiac puncture. These 
samples were used in ELISA assays, to measure the total and active concentrations of 
1B7 in the serum and, for the terminal time point, to measure antibody activity via an in 
vitro neutralization assays and to provide an initial estimate of mouse anti-1B7 responses. 
This study was performed with approval by the Institutional Animal Care and Use 
Committee at the University of Texas at Austin (protocol #AUP-2010-00070) in 
compliance with guidelines from the Office of Laboratory Animal Welfare. To estimate 
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tmax and Cmax, a curve was fit to the pharmacokinetic data for each mouse using natural 
cubic spline interpolation over the entire time interval. The corresponding maximum was 
then determined analytically from the resulting cubic polynomial on the interval of 
interest. To calculate the AUC values, the data were fit to a four-parameter bi-exponential 
model with one termed weighted by time: 𝑐 = 𝐴 exp −𝛼𝑡 + 𝐵  𝑡  exp  (−𝛽𝑡). The AUC 
was defined as the improper integral of this model as time approaches infinity.  
Measurement of 1B7 in serum samples  
To determine the concentration of active 1B7 in serum samples, a standard 
ELISA approach was used with the following modifications as previously reported (201, 
250). ELISA plates were coated with PTx at 1.5 μg/ml in PBS. The assay buffer used as 
diluent in all steps consists of 4% bovine serum albumin, 4% fetal bovine serum (FBS), 
0.05% Tween 20, in PBS, pH 7.4. After blocking with assay buffer, 2.3 μl serum sample 
was serially 1:√10 diluted in 50 μl per well assay buffer. Each plate included mouse 
serum (Sigma) as a negative control and a 1B7 standard curve diluted to an initial 
concentration of 100 μg/ml in mouse serum. Additional samples were analyzed to assess 
total 1B7 protein levels using a streptavidin coating on the ELISA plates to detect the 
biotinylated 1B7.  
After measurement of the resulting absorbance values, SoftMax Pro v5 was used 
to calculate EC50 values based on the serum dilution using a 4-parameter logistic (4PL) 
model for each individual curve. Concentrations of active 1B7 in each serum sample 
were calculated from a linear correlation between the log [(sample EC50)/ (standard 
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EC50)] versus the log of the known 1B7 concentration in the standard curve. A linear 
correlation with a fit > 0.95 from at least 5 independent standard curves were determined. 
Measurement of active antibody by CHO cell neutralization assay 
  As an orthogonal activity measurement to determine the concentration of serum 
1B7 able to neutralize PTx activity in vitro, we employed a CHO cell neutralization assay 
modified from Gillenius et al (217, 251). The concentration of neutralizing antibody was 
measured as the sera dilution that completely inhibited PTx-induced CHO cell clustering 
relative to a standard curve of purified 1B7 with known concentration. Briefly, 50 μl of 
0.5 ng/ml pertussis in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS was 
added directly to each well of a sterile 96 well tissue culture plate. Terminal serum 
samples (23 μl) were serially diluted into the PTx media using a 1:√10 dilution scheme. 
After incubation for 30 minutes at 37°C and 5% carbon dioxide, 100 μl / well of freshly 
trypsinized CHO cells at 105cells/ ml were seeded in each well. After 48 h of incubation 
at 37°C and 5% CO2, wells were scored for CHO clustering using 0-3 scale, with 0 as 
elongated (non-clustered) and 3 as completely clustered. A 5-parameter logistic model 
was used to fit the assay scores against 1B7 concentration and to find the hypothetical 
concentration yielding a CHO score of 1.5. The molar ratio of 1B7 to PTx at this point 
was then calculated relative to that of the standard and reported as the relative activity.  
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Chapter 6: Conclusions and Future Directions 
CONCLUSIONS 
The work described in this dissertation was focused on developing delivery 
systems for vaccines and therapeutic proteins with the overall goal of achieving 
administration by routes previously not possible. Approved vaccines today rely on 
injection (subcutaneous or intradermal) of live-attenuated pathogens or protein antigens 
and glycoconjugates with adjuvant formulations. Such methods have drawbacks; for 
example injectable vaccines use heat-killed or pathogen subunits in order to elicit 
immune responses, without administering live microorganisms or viruses into systemic 
circulation. However, these injectable vaccines bypass the natural infection route, leading 
to a lack of mucosal immunity (253). Live-attenuated pathogens administered via 
mucosal route would result in more complete protection by inducing secretory IgA, 
which plays an important role in preventing physiological entry of pathogens (20, 253). 
However, there are important safety concerns when utilizing “live” vaccines, the major 
concern being their potential to revert to a virulent form (20, 85). Due to practicality of 
administration and the lack of systemic immunity induced by other routes, oral and nasal 
delivery are the only mucosal routes clinically suitable for vaccines (4, 88). While 
researchers are making strides to develop subunit nasal vaccines, clinical success has 
been stunted due to safety concerns (88). This thesis therefore devoted a large portion of 
its efforts towards developing a platform for oral delivery of mucosal vaccines. 
 One of the key challenges facing oral vaccines is an inability to efficiently target 
intestinal sampling cells called M cells (88, 90). In Chapter Two, we describe the 
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molecular engineering of an M cell targeting protein ligand. One potential M cell target, 
not expressed on the apical surface of other enterocytes, is α5β1 integrin (32, 57, 59). We 
used a naturally existing α5β1 integrin found in the pathogen Yersinia 
psuedotuberculosis, called invasin, as a template to engineer a higher affinity M cell 
targeting ligand (69). Since this protein is naturally displayed on the bacterial surface, 
affinity matured variants could be selected using cell adhesion/internalization and FACS 
enrichment (68, 81, 254). We used alanine scanning of solvent exposed tyrosines to map 
the binding interface and elucidate important regions to be targeted for mutagenesis. Four 
site-saturation mutagenesis libraries were generated and subsequently screened to 
identify affinity-matured variants binding α5β1 integrin. Selection was carried out by 
panning for Caco-2 cell adhesion and internalization, which was followed by FACS 
enrichment using fluorescently labeled α5β1 integrin. This process led to the 
identification of three beneficial substitutions. Two of these substitutions introduced an 
RGD epitope in a region of invasin, which has previously been compared to the RGD 
epitope in fibronectin, responsible for β1 integrin recognition (96). Together these three 
substitutions resulted in a nine-fold improvement in EC50 compared to wild-type 
(measured by ELISA against α5β1 integrin). This engineered high-affinity invasin 
mutant termed RGD844, may aid targeted oral vaccine delivery by offering enhanced 
translocation through M cells. 
 Chapter Three sought to generate a polymeric antigen delivery system capable of 
testing the benefits of the RGD844 variant. This delivery system encapsulated antigen 
within poly(lactic-co-glycolic acid) (PLGA) microparticles. The formulation was 
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improved to encapsulate increased amounts of the model protein antigen, ovalbumin, by 
the addition of 5% NaCl to the external aqueous phase during the double emulsion 
process. Substituting the emulsification surfactant from polyvinyl alcohol to 
poly(ethylene-alt-maleic acid) generated particles with an increased capacity for the 
amount of targeting ligand that could be coupled to the particles surface. In parallel, this 
surfactant exchange increased the amount of encapsulated ovalbumin displayed on the 
particle surface. Invasin variants with different affinities toward α5β1 integrin were 
recombinantly expressed as a fusion protein to maltose binding protein (MBP) and 
conjugated to the particle surface. We showed, via flow cytometry, that with similar 
levels of ligand on the particle surface, recognition for α5β1 integrin was dependent on 
the invasin variant used.  
These particles were then studied in vivo by orally administering the particles in 
suspension to mice. In Chapter Four, the particles were loaded with novel fluorescent 
nanocrystals to serve as a contrast agent for whole animal imaging. These studies suggest 
that the wild-type aids in retention of our microparticles in the gastroinstinal tract. The 
ability of these particles to modulate immune responses was also characterized in Chapter 
Three. Serum samples were collected from mice that received oral doses of particles 
conjugated to different invasin variants, encapsulating ovalbumin. The serum samples 
were then analyzed for specific IgG responses. This study showed that antibody humoral 
immunity was generated to the invasin targeting ligand but not the encapsulated 
ovalbumin antigen. There were not clear distinctions in immune responses between 
sample groups using different invasin variants for targeting. We also found serum IgG 
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responses to be generated by our soluble oral ovalbumin control group. This suggests the 
addition of a bystander protein, in this case 5% BSA, may be an important factor for 
protection of antigens delivered orally. This study has provided valuable information, 
which will lead to future optimizations of oral vaccines. In the future, we can consider 
conjugation and formulation details in order to optimize an oral microparticle vaccine 
delivery system based on M cell targeting. 
In addition to vaccine delivery, we have created formulations of therapeutic 
proteins suitable for subcutaneous administration (Chapter Five). The dose requirements 
for delivery of biologics via the subcutaneous route often require highly concentrated 
formulations (201). These concentrations produce unstable formulations prone to 
aggregation and are too viscous to be passed through the needle of a syringe. We were 
able to create protein nanoclusters, with the addition of crowding agents that revert to 
monomer upon dilution. We showed that these dispersions yielded similar 
pharmacokinetic profiles as solution based formulations.  
FUTURE DIRECTIONS 
 The generation of an affinity-matured invasin variant may lead future 
contributions in two areas: 1) understanding of pathogenicity by Yersinia 
psuedotuberculosis and entericolitica and 2) the employment in targeted oral vaccine 
delivery systems. Invasin has been heavily studied, by Isberg and others, to help 
understand the role it plays in pathogenicity of certain Yersinia strains (61, 103, 255). It 
has often been compared to the endogenous human α5β1 integrin ligand fibronection, in 
particular the D911 residue of invasin and the RGD epitope of fibroectin (96). Here we 
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show, for the first time, that the introduction of an RGD epitope containing D911 
enhances invasin’s affinity toward α5β1 integrin. The fibronectin- α5β1 integrin 
interaction has been shown to be dynamic, acting as a “catch-bond”(75). It would be 
interesting to study the invasin-integrin bond strengths induced in the tensioned states in 
the advanced system used by Friedland et al., along with the incorporations of the three 
substitutions we found through our affinity maturation process. These studies may further 
aid in the understanding of Yersinia pathogenicity. 
 The RGD844 variant created in this work may also to lead to important advances 
in targeted oral vaccination. While our studies were not able to elucidate modulations in 
immune responses based on the invasin variant used, others have shown the ability to 
target M cells plays an important role (42, 93). Incorporating the RGD844 variant into 
these systems may lead to further improvements on current targeting strategies.  
Additionally, the knowledge gained from this work also provides an important 
foundation for optimization of our particle-based delivery system. The lack of response to 
ovalbumin in our oral particle delivery systems indicated that the conjugation process 
used to couple the targeting ligand might alter the ability of the ovalbumin to be 
efficiently processed for MHC presentation. Efforts could be focused on altering the 
conjugation chemistry to allow for efficient antigen processing of encapsulated proteins. 
However, since we did observe serum IgG responses directed at our targeting ligand, the 
delivery system could simply be modified to co-couple the antigen(s) and the targeting 
ligand on the particle surface.     
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Given the inability to discern significant differences in immune responses due to 
our targeting ligand and the presence of a response in our soluble oral ovalbumin control 
group, certain control studies should be carried out to further understand these 
observations. Recently, it has been postulated that the inclusion of bystander proteins in 
oral vaccine delivery systems may protect antigen from proteolytic degradation, by 
competitive inhibition (147). We used this information, along with our simulated 
digestion studies, to include 5% BSA in our oral formulations. This excipient may have 
had pronounced effects on antigen recognition. The lack of distinction between sample 
groups with different invasin variants may have been due to saturation of M cell uptake. 
If saturation was the cause for the similarity between groups, the addition of 5% BSA 
may have contributed to this effect. Various doses of invasin targeted particles with and 
without the addition of BSA, would help elucidate the roles of bystander protein and M 
cell targeting. These further studies will help advance the efficacy of oral vaccines.    
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